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Abstract 
 In this research project, we have synthesized a series of nine dimethyl ether resorcinol 
analogues of NMS-E973 (L-1) 38, a potent Hsp90 inhibitor. These analogues were chosen 
because they share the same pharmacophore with NMS-E973 (L-1) 38 and were thus 
expected to have a similar biological activity. Moreover, it is generally easier to synthesize 
the dimethyl ether resorcinol analogues of NMS-E973 (L-1) 38 as compared to their 
demethylated counterparts. Since other Hsp90 inhibitors such as geldanamycin 19 have 
demonstrated anti-plasmodial activity, we also expected our compounds to be Hsp90 
inhibitors and to possess anti-plasmodial activity. However, our compounds were tested for 
growth inhibitory activity of Plasmodium falciparum and not for P. falciparum Hsp90 
(PfHSP90) inhibitory activity.  
The synthesis involved a series of steps that led to the formation of the ester compound TU-
011 (L-7) 43 that was then used as a precursor for different NMS-E973 (L-1) 38 analogues. 
The choice of analogues to be synthesized was dictated by binding affinity predictions 
obtained from molecular docking. 
 The chosen synthetic analogues were active against chloroquine-sensitive Plasmodium 
falciparum (3D7 strain) in a Plasmodium lactate dehydrogenase assay and they were not 
generally cytotoxic to human cervical adenocarcinoma cell line HeLa. The most active of our 
compounds was TU-018 (L-103) 50 with an IC50 value of approximately 1.830 M as 
compared to the standard, chloroquine, with an IC50 value of 0.01062 M. Some of the 
compounds showed mild cytotoxicity towards HeLa cells with IC50 values higher than 25 M 
as compared to the standard apoptosis inducer drug, emetine that had an IC50 value of 
0.09948 M.  
These results highlight the fact that the synthesized analogues are novel relatively non-toxic 
anti-plasmodial agents.  
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Chapter One:  Introduction 
Different diseases affect the world population and some of these diseases such as malaria are 
infectious while others such as cardiovascular diseases are non-infectious. The health risk 
associated with these diseases and the economic burden imposed by their treatment imply 
that there is a constant need to look for different ways of overcoming these diseases. 
Amongst the methods used in fighting different diseases are treatment with therapeutic drugs 
and the use of preventative methods to combat the infections. In the case of infectious 
diseases such as malaria, the causative agents, for example, Plasmodium falciparum, 
generally develop resistance over the course of time, which implies a permanent need to 
develop new drugs with a novel mode of action to efficiently overcome the rising number of 
cases of multidrug resistance.  
 
1.1. Malaria and Plasmodium falciparum  
1.1.1. Overview of Malaria and Plasmodium falciparum 
Malaria is one of the deadliest infectious diseases.
(1)
 It is estimated that 198 million cases of 
malaria occurred globally and that 584000 lives were lost due to malaria in 2013.
(2)
 The 
disease affects particularly the African continent where 90% of malarial deaths occurred in 
2013. Young children accounted for 78% of all malarial deaths in the same year.
(2)
 In 2013, 
82% of cases that occurred were in the WHO African Region, 12% were in the WHO South-
East Asia Region and 5% were in the WHO Eastern Mediterranean Region.
(2)
 In response to 
these alarming figures, different malaria control programs have been put in place and thus far 
they have yielded impressive results. For example, the global malaria mortality rates 
decreased by 47% between 2000 and 2013.
(2)
 The control programs include vector control 
through the use of insecticide-treated mosquito nets (ITNs) or indoor residual spraying (IRS), 
chemoprevention, and case management which consists of the diagnosis and treatment of 
infections.
(2)
  
Malaria is spread from one person to another through the bite of an infected female 
Anopheles mosquito.
(3,4)
 Infection in humans is caused by five species that belong to the 
genus Plasmodium: P. falciparum, P. vivax, P. malariae, P. ovale and P. knowlesi.
(1,3)
 
Although cases of malaria in humans due to P. knowlesi have been recorded in recent years, it 
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normally causes malaria in monkeys and it is found in some forested areas of South-East 
Asia.
(2)
 The most dangerous malaria causing species is P. falciparum.
(3)
 P. vivax is 
geographically more widespread than P. falciparum due to its ability to resist harsh 
conditions. P. vivax has the capability to develop in Anopheles mosquitoes at lower 
temperatures and to survive at higher altitudes and in cooler climates than the other species.
(3)
 
It has a dormant liver stage called hypnozoite that enables it to survive when Anopheles 
mosquitoes are not present, e.g. during winter.
(3)
  
Although P. vivax occurs throughout Africa, the risk of infection is low due to the absence of 
the Duffy gene in many African populations.
(2)
 The Duffy gene produces the protein 
necessary for P. vivax to invade the red blood cells.
(2)
 While P. falciparum is the most 
prevalent on the African continent, infections due to P. vivax are more common in many 
areas outside Africa.
(2) 
 
1.1.2. The life cycle of Plasmodium 
The life cycle of Plasmodium can be divided into three stages as illustrated in Figure 1. It is 
complex and involves both the female Anopheles mosquito host and the human host. Only 30 
of the 400 different species of Anopheles mosquitoes are considered major vectors.
(2)
 The life 
cycle of Plasmodium can be divided into three stages as illustrated in Figure 1. 
 
1.1.2.1. The liver stage  
After the female Anopheles mosquito has injected the parasites in the form of sporozoites into 
the blood stream of the human host, they migrate into the liver within 30 minutes where they 
replicate.
(1)
 Inside the hepatocyte, the sporozoites develop into schizonts, which in turn 
develop over a period of a week to give tens of thousands of merozoites.
(5)
 In the case of P. 
vivax and P. ovale, the parasite can stay dormant in the liver for many years in the form of 
hypnozoites which can later cause the relapses of infections.
(1,2,5,6)
 In order for the merozoites 
inside the hepatocytes to invade erythrocytes, they first need to escape the host immune 
system.
(7)
 The merozoites escape the macrophages (Kupffer cells) in the sinusoids by hiding 
inside hepatocyte-derived structures called merosomes which bulge into the liver sinusoids 
and release merozoites into the bloodstream.
(7) 
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Figure 1: Plasmodium falciparum life cycle
(4)
 
 
1.1.2.2. The blood stage 
After five to ten days, the hepatocytes burst and release merozoites which invade new red 
blood cells (erythrocytes) and rapidly proliferate, causing malaria symptoms.
(1)
 It is thought 
that the merozoite invasion of red blood cells takes place in steps. First, a random contact 
between any surface of the free merozoite and the human red blood cell is mediated by 
merozoite surface proteins (the apical organelles).
(8)
 The merozoite then re-orientates  itself 
such that the apical end makes a tight junction with the red blood cell surface.
(8)
 
Subsequently, the merozoite invades the cell using an actin-myosin motor and the 
intraerythrocytic development cycle follows.
(8)
 Inside the erythrocytes, the merozoites go 
through various forms (the ring form, the trophozoite form and the schizont form) which lead 
to the formation of about 20 new daughter merozoites.
(1)
 These daughter merozoite are 
released in the blood stream and infect new red blood cells.
 (1)
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Each intraerythrocytic asexual cycle of P. falciparum lasts approximately 48 hours.
(9)
 These 
daughter merozoites are released in the blood stream and infect new red blood cells.
(1)
 After 
several asexual reproductions in the erythrocytes, some of the merozoites differentiate into 
female and male gametocytes, which only contain a half set of chromosomes.
(1)
 Gametocytes 
go through five stages of maturation and only stage V is capable of infecting the 
mosquitoes.
(1) 
 
1.1.2.3. The mosquito stage  
During a blood meal, the gametocytes are taken up by the mosquito and once inside, they 
differentiate into gametes that fuse to give a zygote.
(10)
 Only mature gametocytes survive 
inside the mosquito after being taken up in a blood meal.
(11)
 While gametocytes development 
is arrested for many days in the blood stream of the vertebrate host, they are activated within 
seconds after being taken up by a mosquito in a blood meal.
(12)
 The activation of gametocytes 
inside the mosquito’s gut lumen is stimulated by the change in environmental conditions as 
they pass from the human host into the mosquito host.
(13)
 Inside the mosquito’s gut, the 
gametocytes experience an increase in Ca
2+
 ions concentration, a drop in temperature (from 
37 °C inside the human host to 20 – 25 °C inside the mosquito) and a rise in pH as well as the 
presence of xanthurenic acid.
(12)
 After nuclear fusion in the zygote, DNA replication and 
meiosis ensue and the zygote later changes into an elongated and highly motile form called 
an ookinete that then crosses the midgut epithelium and forms an oocyst on the haemocoel 
side of the midgut wall.
(12,14,15)
  
 
1.1.3. Treatment and prevention of malaria  
Despite decades of research on the development of an efficacious malaria vaccine, providing 
long-term protection, one has not yet been found.
(16)
 Currently, the most advanced vaccine 
that has been developed is RTS,S/AS01, a recombinant protein candidate malaria vaccine 
whose phase III clinical trials were recently published.
(16)
 It was found that RTS,S/AS01 
substantially prevented clinical malaria in young infants and children over a period of 3 - 4 
years with or without a booster dose, with its protective effect enhanced by the administration 
of a booster dose.
(17)
 Thus, malaria chemotherapy remains a viable option for treatment and 
prevention of malarial infections.  
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1.1.3.1. Old and new antimalarial drugs 
There are different anti-malarial drugs that can be grouped according to their chemical 
structures, their targeted stage of the parasite development or their mode of action.  Some of 
the drugs used as anti-malarials are used as prophylactic treatment. They target the liver stage 
of the Plasmodium parasite and prevent the disease from developing.
(1)
 In the case of P. vivax 
and P. ovale which can both switch into an active form after months or years in a dormant 
stage (hypnozoite), the drugs that target the liver provide what is known as a radical cure.
(1)
 
In 2013, primaquine 1 was being used to treat the hypnozoite stage of malaria in more than 
50 countries with transmission of P. vivax malaria.
(2)
 Despite its high cost, the combination of  
atovaquone 2/proguanil 3 (a prodrug for cycloguanil 4), is preferred as prophylactic treatment 
because it is well tolerated.
(1)
  
 
 
Figure 2: Structures of some non-peroxide anti-malarial drugs in use
(1,10,18)
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Most of the currently approved anti-malarial drugs target the blood stage of P. falciparum in 
general in order to help control the symptoms of malaria.
(1,11)
 However, some of these drugs 
also target the gametocytes and help prevent the transmission of the parasite between 
humans.
(1,11)
 Typical examples of gametocytocidal drugs belong to the class of 8-
aminoquinolones with primaquine 1 being the only known drug effective against mature 
gametocytes.
(10)
 However, it is less active against the intraerythrocytic forms of P. falciparum 
and it is generally recommended that it be used in combination with drugs that are active 
against the intraerythrocytic these forms.
(10)
 The other drawback is that primaquine 1 causes 
haemolytic anaemia in people who are deficient in glucose-6-phosphate dehydrogenase.
(19)
 
 
 
Figure 3: Structures of some peroxide-based anti-malarial drugs in use or in 
development
(1,10,18)
 
 
Artemisinin combination therapies (ACTs) are the WHO recommended first line treatment 
for uncomplicated P. falciparum.
(3)
 ACTs have been found to be highly efficacious in treating 
uncomplicated malaria as exemplified by the study done by Bukirwa et al.
(20)
 in Tororo 
(Uganda), an area with very high malaria transmission. In areas where transmission is high, 
severe malaria is treated with quinine 9 or an artemisinin derivative.
(18)
 Artemisinin 13 is 
produced by the plant Artemisia annua.
(1,10)
 Despite their short plasma half-lives, artemisinins 
are good therapeutic options because of their rapid action and safety.
(20-23)
 Due to their active 
uptake by Plasmodium parasites, artemisinins are highly toxic against the parasites at 
nanomolar concentrations while micromolar concentrations are needed for their toxicity to 
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mammal cells.
(21)
 Once most of the parasite mass has been eliminated by an artemisinin 13, 
the remaining parasites are eliminated by a partner drug that has a longer plasma half-life.
(10)
 
Artemisinins are active against gametocytes in the early stages of development which 
contributes to the reduction of the gametocytes that reach the mature stage necessary for 
transmission to the mosquito.
(6)
 The current WHO policy about the use of ACTs recommends 
that the preferred choice of an ACT be dictated by the therapeutic efficacy of that ACT in the 
intended area of use.
(3)
 Artemether 14 should be combined with lumefantrine 5, artesunate 15 
with amodiaquine 6 or mefloquine 7 or sulfadoxine 8-pyrimethamine 10, and 
dihydroartemisinin 16 with piperaquine 11.
(3)
  
 
The success of the currently used artemisinins has prompted interest in the synthesis of more 
structurally diverse artemisinin derivatives and synthetic analogues of artemisinin. Some of 
them have been found in vitro more active than artemisinin 13.
(24)
 For example, some of the 
semi-synthetic artemisinins were tested in vitro against chloroquine-sensitive (3D7) and 
chloroquine-resistant (K1) strains and found to be three times more potent than artemisinin 
13 with high therapeutic indexes.
(24)
 Semi-synthetic artemisinins also completely cured mice 
infected with multidrug resistant P. yoeliinigeriensis.
(24)
 Moreover, the synthetic peroxide 
OZ439 17 cures mice infected with malaria in a single dose of 20 mg/kg, which cannot be 
achieved using artemisinin 13 without a partner drug.
(25)
 In preclinical embryo-foetal 
development studies, the synthetic peroxides OZ439 17 and OZ277 18 were found to have a 
safety margin which was approximately 100 times higher than that of an artemisinin 
derivatives.
(11)
 
 
1.1.3.2. Resistance to existing anti-malarials  
Although the use of a combination of drugs reduces the emergence of resistance, it also 
sometimes fails, which highlights a constant need for new drugs.
(1)
 Ideally, the new drug 
should be rapid acting, amenable to a single dose, well tolerated especially in pregnant 
women and children and also adress the drug resistance problem.
(1)
 Mefloquine 7 is the only 
anti-malarial drug that acts effectively in a single dose when administered as a single agent.
(1)
 
It is preferable that the new molecule be chemically different from the existing drugs as this 
may avert the development of cross-resistance by the parasites.
(18)
 Due to its efficacy, low 
cost and safety, chloroquine 12 was a gold standard treatment for malaria for many years 
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starting from the late 1940s.
(26)
 Its massive use for treatment and prevention led to the 
emergence of chloroquine-resistant strains with resistance associated with the P. falciparum 
chloroquine resistance transporter (PfCRT).
(19)
 To sustain their development, Plasmodium 
parasites degrade approximately 70% of the haemoglobin of the erythrocytes, which results 
in the release of the heme that is highly toxic to the parasites.
(27)
 In order, to survive and 
maintain progress, the parasite detoxifies the heme by crystallizing it into a non-toxic 
structure called hemozoin.
(27)
 Chloroquine 12 acts by binding to the heme and preventing its 
detoxification.
(19)
 PfCRT-associated chloroquine resistance is thought to involve active efflux 
of the drug from the parasite’s food vacuole where it accumulates.(28) However, both 
chloroquine-sensitive and chloroquine-resistant P. falciparum parasites possess chloroquine 
carriers and they only differ by their efficacy, with the chloroquine-resistant parasite having 
the most efficacious carrier.
(28)
  
After emergence of resistance to chloroquine 12, it was replaced in many countries with a 
sulfadoxine 8–pyrimethamine 10 combination as the first line treatment.(19) This combination 
was also very effective, low cost and safe.
(19)
 Sulfadoxine 8 and pyrimethamine 10 act 
synergistically to inhibit two important enzymes of Plasmodium, namely dihydrofolate 
reductase (DHFR) and dihydropteroate synthetase (DHPS).
(23,29)
 Unfortunately, point 
mutations in DHFR and DHPS genes make P. falciparum resistant to pyrimethamine 10 and 
sulfadoxine 8 respectively.
(29)
 After the emergence of resistance to sulfadoxine 8-
pyrimethamine 10 and many other existing antimalarial drugs, artemisinins were 
recommended by the WHO as the first line treatment.
(2,19)
. However, resistance to artemisinin 
13 and its derivatives has been recently observed along the Thai-Cambodian border, which 
highlights the need for antimalarial drugs with a novel mode of action to counteract the rising 
cases of drug resistance.
(2,19)
 It is thought that resistance resulted from the use of artemisinin 
13 derivatives as monotherapy.
(19)
 Some novel drugs are being investigated as possible 
substitutes to artemisinins and these include synthetic peroxides and drugs previously 
developed for other diseases such as heat shock protein 90 (Hsp90) inhibitors previously 
developed for the treatment of cancer.
(1,30,31)
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1.2. Heat shock protein 90 (Hsp90)  
1.2.1. Overview of Hsp90 
Heat shock protein 90 belongs to a superfamily of proteins which also include histidine 
kinases, gyrase and MutL proteins. They all have a novel ATP-binding pocket named the 
Bergerat fold in common.
(32)
 These proteins also share an ATP-lid region which serves as a 
rotatable cover for the ATP-binding pocket and differs in length and tertiary structure as well 
as its predominance of closed or open states from one protein to another.
(32,33)
 The heat shock 
protein 90 family are ubiquitous molecular chaperones that play a key role in protein folding, 
stabilization and activation of a wide range of proteins including those involved in signal 
transduction, cell cycle regulation and steroid hormone responsiveness.
(34,35)
 An in silico 
analysis done by Pavithra et al.
(36)
 suggested that P. falciparum Hsp90 (PfHsp90) might be 
involved in chromatin remodelling and protein translation. 
Hsp90 works closely with the ubiquitin-proteasome machinery to maintain protein 
homeostasis.
(35)
 The 26S proteasome needs the ATP (adenosine triphosphate) activity of 
Hsp90 for its assembly both in vivo and in vitro.
(35)
 The 26S proteasome is involved in the 
degradation of most cellular proteins in eukaryotic cells usually after they have been tagged 
by covalent bonding with polyubiquitin.
(37)
 Hsp90 is the most abundant of all molecular 
chaperones present in the cytosol of eukaryotic cells.
(38)
 Hsp90 molecular chaperones differ 
from other chaperones in that they do not bind to nascent or unfolded polypeptides and that 
they interact with a large number of co-chaperones. In contrast, Hsp90 binds to a limited 
number of partially folded client proteins.
(38)
 These client proteins belong to different protein 
families and do not have any clear structural nor conformational similarity between them. 
However, they all have an intrinsic instability and a need to undergo conformational changes 
in order to achieve their active states in common.
(38)
 
 
The increased ATPase activity of the Hsp90 of cancer cells is very important for their 
increased proliferation and survival.
(39)
 Hsp90 is essential for the survival of a number of 
protozoan parasites in harsh environmental conditions and these parasites include those of the 
genera Plasmodium, Leishmania, Eimeria, Toxoplasma and Trypanosoma.
(31,40-43)
 Hsp90 is 
secreted by normal cells in response to various stressing conditions such as heat, hypoxia and 
UV light.
(38)
 It is also secreted as a response to tissue injury where it stimulates wound 
closure.
(38)
 Its function is regulated by a number of co-chaperones which are classified into 
10 
 
three groups: client recruiter co-chaperones, remodelling co-chaperones and late-acting co-
chaperones.
(38)
 The client recruiter co-chaperones favour the open conformation of the protein 
and, except for the sgt1 co-chaperone, slow down its ATPase activity thus making it ready to 
receive client proteins and other co-chaperones.
(38)
 The most studied client recruiter co-
chaperone is sti1/Hop (stress inducible 1/Hsp70-Hsp90 organizing protein) which delivers 
substrates from Hsp70 to Hsp90.
(38)
 However, the remodelling function of co-chaperones is 
not well understood, but they generally serve to stabilize particular conformations of Hsp90. 
For example, the Aha1 (Activator of heat shock protein 90 ATPase) promotes conformational 
changes that lead to the closed state of Hsp90.
(38)
 The late acting co-chaperones seem to be 
involved in later stages of client maturation as well as its release.
(38)
 
  
1.2.2. Structure of Hsp90  
The Hsp90 molecular chaperone is a dimeric protein with dynamic conformations.
(35)
 Each 
Hsp90 monomer is composed of three domains: the N-terminal domain that accommodates 
the ATP binding pocket and co-chaperone interacting motifs, the middle domain that contains 
binding sites for co-chaperones and client proteins, and the C-terminal domain that contains 
the dimerization domain.
(35)
 Although there is general sequence conservation between human 
Hsp90 and PfHsp90, they differ significantly in their linker region with PfHsp90 having a 
unique 30-amino acid-long stretch adjoining the ATP binding domain.
(31)
 A high homology is 
observed among all Hsp90s.
(34)
 For example, 69% of yeast and human Hsp90 sequences are 
identical. The tertiary structures of their N-terminal domains are also very similar.
(34)
 In both 
cases, the N-terminal domain consists of a highly twisted β sheet with eight strands covered 
on one face with α helices.(34) However, their quaternary structures crystallize differently with 
the yeast N-terminal domain crystallizing as a dimer while the human one crystallizes as a 
monomer.
(34)
 
  
There are three residues substitutions inside the ATP binding pocket when comparing 
PfHsp90 with human Hsp90.
 (33)
 In addition to the Arg-98/Lys-112 substitution, Ala-38 of 
PfHsp90 is substituted with a serine in human Hsp90 and Ile-173 is substituted with a 
valine.
(33)
 Of these three substitutions, only the Arg-98/Lys-112 substitution constitutes a 
potential useful difference for the design of species specific inhibitors.
(33)
 The substitution of 
Ala-38 by a serine does not make any great difference because the residue is also masked by 
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structural water molecules that mediate hydrogen bonds between Asp-79 and Asp-37 and that 
it is also only substituted in human Hsp90 but not in Hsp90.(33,34) In the case of Ile-173, the 
only difference between it and valine is that valine has one extra methyl group, which is 
unlikely to cause any great difference to the structure of the surrounding network of water 
molecules inside the ATP binding pocket.
(33)
  
However, it has been suggested that due to several slight differences between PfHsp90 and 
human Hsp90, it should be possible to design selective PfHsp90 inhibitors.
(44)
 For example, 
Met84 of PfHsp90 adopts a different side chain rotamer than the human counterpart Met98, 
which leads to two different shapes of the ceiling of the binding pocket in PfHsp90 and 
human Hsp90.
(45)
  
Analysis of a geldanamycin 19 bound human Hsp90 showed that the geldanamycin 19 
binding pocket is 15 Å deep and 12 Å wide near its entrance.
(44)
 The pocket is 8 Å in its 
middle and is wide enough to accommodate three molecules of water at its bottom, thus 
giving an overall structure of a flat-bottomed cone.
(44)
 Nevertheless, the size and accessibility 
of the pocket change as the Hsp90 undergoes conformational changes leading to either the 
open or the closed conformation of the chaperone.
(44)
 It is only the open conformation that is 
compatible with geldanamycin 19 binding.
(44)
  
 
1.2.3. Hsp90 function and corresponding inhibitors 
PfHsp90 has the highest ATPase activity of all reported Hsp90 ATPase activities and it is 6 
times higher than that of human Hsp90.
(31)
 17-(allylamino)-17-demethoxygeldanamycin (17-
AAG) 20 or tanespimycin 20, a geldanamycin derivative (Figure 4) is 15 to 25 fold more 
effective against cancer cells where the Hsp90 ATPase activity is higher than in a normal 
healthy cell.
(39)
 Geldanamycin 19 binds PfHsp90 with high affinity robustly inhibits its 
ATPase activity. The whole cell lysate assay of P. falciparum also demonstrated that the in 
vivo activity of geldanamycin 19 is through PfHsp90 inhibition.
(31)
 17-AAG 20 (Figure 4) 
inhibits P. falciparum growth and prolongs the lifespan of a preclinical rodent model of 
malaria. Geldanamycin 19 also specifically binds Trypanosoma evansi Hsp90 (TeHsp90) 
both in its purified form and in its whole cell lysate.
(31)
 Furthermore, 17-AAG 20 inhibited T. 
evansi growth and cured mice infected with T. evansi.
(31)
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Geldanamycin 19 (Figure 4) belongs to a class of natural products called benzoquinone 
ansamycins, which all have an aliphatic chain bonded to an aromatic ring in a 
metacyclophane manner.
(46)
 Different benzoquinone ansamycins have been reported to inhibit 
Hsp90 and some of them such as macbecin I 21 (Figure 4) are more potent than 
geldanamycin 19 in inhibiting the ATPase activity of Hsp90.
(46)
 The respective binding 
affinities are Kd = 0.24 M for macbecin I 21 and Kd = 1.2 M for geldanamycin 19. 
Herbimycins and TAN compounds also belong to this class of compounds.
(46)
  
 
 
Figure 4: Chemical structures of the ansamycin class of Hsp90 inhibitors
(46)
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PfHsp90 and TeHsp90 are potential drug targets and in general there is a possibility to treat 
protozoan infections by inhibiting the protozoan Hsp90s.
(31)
 For example, geldanamycin 19 
blocks the ring to trophozoite stage progression during P. falciparum development.
(40)
 Other 
phases of P. falciparum growth such as the progression from trophozoites to schizont, the 
release of merozoites from schizonts and the reinvasion of erythrocytes by the newly released 
merozoites are not affected by geldanamycin 19. Banumathy et al.
(40)
 The difference might be 
due to the fact that the trophozoite is the most active phase and that the progression from ring 
to trophozoite might depend greatly on PfHsp90, hence its great sensitivity to inhibition by 
geldanamycin 19. In fact, PfHsp90 production is maximal during the progression from ring to 
trophozoite.
(40)
  
 
Geldanamycin 19 acts by binding to the ATP binding site in the N-terminal domain of Hsp90, 
thus blocking the maturation of the client protein and consequently leading to its 
degradation.
(31)
 The anti-tumour activity of macbecin I 21 is due to the degradation of Hsp90 
oncogenic client proteins ErB2 (Estrogen receptor b2) and cRaf1 (CD40 Receptor associated 
factor 1) following the inhibition of Hsp90.
(46)
 The Western blot analysis of protein 
expression in lysates of the prostate cancer cell line DU145 following incubation with 
macbecin shows that Hsp90 proteins are still present when ErB2 and cRaf1 disappear.
(46)
 
These two sets of observations about geldanamycin 19
(31)
 and macbecin I 21
(46)
 lead to the 
conclusion that Hsp90 inhibitors might inhibit cell growth by causing the degradation of its 
client proteins. 
 
A sequence alignment of different Hsp90 from protozoan parasites revealed that the residues 
required for geldanamycin 19 binding are conserved across the parasites.
(31)
 This highlights 
the possibility of using Hsp90 inhibitors to treat different protozoan infections in both 
animals and humans.
(31)
 The sequences of human Hsp90 and PfHsp90 revealed that their 
binding sites complexed with geldanamycin 19 differ only by the substitution of Lys-112 in 
human Hsp90 with Arg-98 in P. falciparum.
(31)
 However, this slight difference cannot be 
linked to the small increase in geldanamycin 19 binding affinity of PfHsp90 as compared to 
human Hsp90.
 (31)
 In spite of PfHsp90 and human Hsp90 having identical sequence 
alignments, PfHsp90 has a distinct extension which differs from its human counterpart 
through its tertiary structure. These structural differences between PfHsp90 and human 
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Hsp90 were exploited to design a new generation of PfHsp90 selective inhibitors based on 
compound IND31119 34 (Figure 5).
(33)
 
 
 
Figure 5: Miscellaneous Hsp90 inhibitors
(47-53)
 
 
Furthermore, the substitution of Arg-98/Lys-112 can potentially be exploited to design 
selective inhibitors of different Hsp90s of various protozoan parasites over the human 
Hsp90.
(33)
  
Due to the flexibility of the Arg-98 side chain, the selective inhibitors of protozoan Hsp90s 
would need to interact with hydrophobic residues surrounding Arg-98 for stronger binding.
(33)
 
The hydrophobic region of the ATP binding pocket of P. falciparum consists of a glycine-
rich hinge loop (G118 to G123) and amino acid residues G100, T101 and F104. Two studies, 
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one with geldanamycin 19 and another with IND31119 34 (Figure 5), that were carried out to 
assess whether the homologous substitution Arg-98/Lys-112 was important for drug-protein 
interactions concluded that this substitution has no significant effect on the binding affinity or 
on the selectivity of the drugs for the Hsp90.
(31,33)
 
 
However, harmine 40 showed selectivity for PfHsp90 while its derivative harmalol 36 
(Figure 5) showed selectivity for human Hsp90.
 (54) 
On one hand, when Arg-98 was 
substituted with Lys in PfHsp90 and Lys-112 in human Hsp90 was replaced with Arg, 
harmine 40 showed better binding for human Hsp90 compared to PfHsp90. On the other 
hand, the analogous harmalol 36 showed better binding for PfHsp90 than for human 
Hsp90.
(54)
 This was also corroborated by docking studies suggesting that the methoxy group 
of harmine 40 interacts with the guanidinium moiety of Arg-98 while the hydroxyl group of 
harmalol 36 mediates polar interactions with Lys-112.
(54)
 Hsp90 inhibitors have the 
advantage that mutations that would render a pathogen resistant by modifying the ATP 
binding pocket would also compromise the pathogen’s viability since ATP binding and 
hydrolysis are essential for the Hsp90 function.
(55)
 
  
Asp-79 is essential for the binding of ATP and ADP (adenosine diphosphate) in the N-
terminal domain of Hsp90.
(55)
 Mutation of Asp-79 to Asn results in the complete loss of 
Hsp90 function.
(55)
 In fact, the side-chain carboxylate of Asp-79 forms a direct hydrogen 
bond with the exocyclic N6 of the adenine moiety and the bonding environment is such that 
when Asp-79 is mutated to Asn, this leads to a strong repulsive interaction with the 
adenine.
(55)
 The mutations of Glu33 to Ala in yeast Hsp90 leads to a significant decrease in 
the Hsp90 ATPase activity. Although the Glu33-Ala mutant retains ATP binding capabilities, 
its Hsp90 ATPase activity is reduced to less than 1% of the wild type’s ATPase activity.(55) 
Thus, Asp79-Asn and Glu33-Ala mutations compromise the yeast’s viability and highlights 
the importance of ATP binding and hydrolysis for the Hsp90 function.
(55)
 A superimposition 
of the bound structures of Hsp90 with the inhibitors geldanamycin 19 and radicicol 33 
revealed that the inhibitors mimic ADP binding in shape and interactions with the protein and 
water molecules, and that in particular they conserve the hydrogen bonding to Asp-79 side 
chain carboxylate.
(56)
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PfHsp90 inhibitors such as geldanamycin 19, 17-AAG 20, PU-H71 39 and harmine 40 act in 
synergy with chloroquine 12 in vitro and in vivo experiments indicating that PfHsp90 
inhibitors might reverse drug resistance of chloroquine-resistant P. falciparum.
(57)
 In fact, 
PfHsp90 is essential for the folding of proteins involved in drug-resistance and virulence in 
the infected cells.
(57)
 In erythrocytes, geldanamycin 19 alone was active against chloroquine-
sensitive and chloroquine-resistant strains of P. falciparum.
(30)
 When it is combined with 
chloroquine 12, the two drugs act in synergy, reducing their IC50 values 5-10 fold.
(30)
 
Harmine 40 inhibits PfHsp90 and has a synergistic effect in vitro with either one of 
chloroquine 12 and artemisinin 13.
(54)
 After the identification of the Hsp90 inhibitors 
geldanamycin 19, 17-AAG 20 and other semi-synthetic ansamycin derivatives, more Hsp90 
inhibitors with new scaffolds have been synthesized. These include for example the 
compounds SST0116CL1 35
(58)
, NVP-AUY922 37
(59)
, CPUY201112 45
(60)
, NMS-E973 (L-1) 
38 
(61)
 and their analogues.  
 
Figure 6 : Crystal structure of NMS-E973 (L-1) 38 bound to human Hsp90 (PDB: 4B7P) 
Some of these synthetic Hsp90 inhibitors such as compound SST0116CL1 35
(50,62)
 have anti-
plasmodial and anti-trypanosomal activity. The anti-tumour activity and the physicochemical 
properties of our lead molecule NMS-E973 (L-1) 38 and its analogues depend on some 
particular moieties.
(61)
  For example, the nitro group maintains their binding to Hsp90 and the 
two hydroxyl groups are also important for Hsp90 affinity. The carboxamide and its side-
chains are important for potency and solubility can be increased by simply adding a 
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hydrophilic moiety to the molecule.
(61)
 Thus, the analysis of structure-activity relationship is 
important in order to identify a suitable inhibitor lead molecule from its analogues.  
 
1.3. Modern approaches to rational drug discovery 
1.3.1. Introduction 
A drug is generally defined as a chemical substance that can change the way a given tissue 
responds to its surroundings.
(63)
 Traditionally, drugs used to be discovered by  trial and error 
by which chemical substances were assessed for their capability to produce the desired effect 
in vitro and/or in vivo.
(63)
 Although those methods were based on the assumption that  
receptors existed, in many cases their presence and locality still remained unknown to 
researchers.
(63)
    
In order to increase our knowledge of protein structure and functions, new techniques such as  
high-throughput protein purification, x-ray crystallography and nuclear magnetic resonance 
spectroscopy have been employed.
(64)
 These techniques coupled to the completion of the 
human genome project have contributed to the amount of biological data available. This 
information, combined with empirical studies, led to the increased use of computer based 
methods to facilitate the study of chemical entities that are capable of influencing the 
molecular interactions that govern life.
(64,65)
 In contrast to classically used random screening 
methods, the modern process of drug discovery typically starts with the identification of a 
suitable drug target such as a receptor or an enzyme.
(66)
 The relevance of the drug target is 
then validated.
(66)
 This is followed by the identification of the modulators (agonists or 
antagonists of the receptor, enzyme inhibitors etc.) of the drug target.
(66)
 The next stage 
comprises the development of an appropriate assay to assess the effect of newly designed 
ligands on the drug target.
(66) 
The lead molecule is then identified based on its relative 
selectivity for the target molecule, and it is optimized for potency, selectivity, 
physicochemical properties as well as pharmacokinetic and toxicity properties.
(66)
 After lead 
optimization, the lead compound is assessed in animal studies and then progress to clinical 
trials.
(66) 
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1.3.2. Virtual screening  
Virtual screening is one of the approaches used in rational drug discovery in order to speed 
up the process of finding the hit compounds. Modern drug discovery methods rely on the 
knowledge of the conformation of the receptor when complexed with the ligand.
(67)
 The 
information obtained from the ligand-receptor complex is used to design and synthesize 
analogues of the ligand. The results of bioassays on the synthesized analogues are then used 
to improve the ligand until a better potency and specificity is obtained.
(67)
 In silico methods 
(virtual screening) used in rational drug design are gaining popularity and can currently be 
used for different purposes such as virtual high throughput screening and even predictive 
toxicology.
(66)
 Virtual screening is performed using docking software such as AutoDock 
Vina, Autodock 4, Dock, FlexX, Fred, Glide, Gold, LigFit, etc.
(64,68,69)
 Docking involves 
prediction of the conformation of the ligand within the binding site, its position and 
orientation as well as the corresponding binding affinity.
(64)
 AutoDock Vina is one of the 
most recently developed docking software packages with a proven accuracy in predicting the 
binding mode of the ligands to their target proteins.
(69)
 Its speed is approximately two orders 
of magnitude higher than that of Autodock 4, another widely used docking program.
(69)
 The 
virtual high throughput screening has the advantage that it is cost-effective.
(66)
 However, it is 
important to remember that the scores assigned by the docking software are simply 
approximation and that increased accuracy also requires expensive computational time.
(70)
   
 
1.3.3. Structure and ligand based drug design  
 Two approaches are followed in rational drug design namely structure-based drug design and 
ligand-based drug design. In the case of structure-based drug design, the bioactive 
conformation of the ligand in complex with its receptor is known. The researcher can modify 
the ligand in such a way that the new ligand keeps key interactions with the receptor but that 
less important interactions are replaced with new interactions that give to the ligand more 
potency and specificity.
(67)
  This gives the researcher the capability to design completely new 
analogue molecules based on the structure activity relationship of the bioactive ligand-
receptor conformation. In some cases when a group of ligands for a protein is known while 
the structure of the target protein is not known, a ligand-based approach is used in order to 
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discover new ligands of the target protein.
(64)
 This approach uses methods such as 
pharmacophore modelling and quantitative structure activity relationship (QSAR).
(64)
   
  
1.3.4. Combinatorial chemistry and high throughput screening  
Combinatorial chemistry and high-throughput screening are of great interest in experimental 
drug design. Typically, combinatorial chemistry involves the synthesis of large-scale libraries 
of compounds based on a few available building blocks.
(65)
 For example, a large number of 
different peptides can be obtained by combining differently 7 of the 20 coded amino acids.
(65)
 
Combinatorial chemistry is used in parallel with high throughput screening. Due to the large 
size of combinatorial libraries, it is impractical to analyse them manually. Scientists therefore 
rely on automated screening systems that can assay up to a 100 000 thousand compounds a 
day.
(66)
 This technique is termed high throughput screening and has gained widespread 
popularity amongst drug discovery scientists in the last two decades.
(66) 
  
 
1. 4. Aims and objective of the project 
The fact that compounds such as geldanamycin 19
(31)
, 17-AAG 20
(31)
 and SST0116CL1 
35
(50,62)
, which manifest anti-tumour activity, also exhibit anti-plasmodial activity, we sought 
to prove that the analogues of the anti-tumour Hsp90 inhibitor NMS-E973 (L-1) 38
(61)
 could 
be ‘switched’ for possible anti-plasmodial activity.  
Our primary aim was to synthesize a series of compounds based on a NMS-E973 (L-1) 38 
template as potential PfHsp90 inhibitors and then evaluate their potential in vitro anti-
malarial activity against a selection of P. falciparum strains. We also aimed to use docking 
studies in order to assess whether these compounds would interact with the PfHsp90 target in 
the same way as known inhibitors such as geldanamycin 19 in order to prioritise compounds 
to be synthesized. Finally, we aimed to show that these compounds were non-toxic.
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Chapter Two: Results and discussion 
2.1. Introduction  
Resorcinol derivatives have been found to inhibit Hsp90, which has applications in treating 
diseases associated with Hsp90 malfunction such as cancer
(59,61,71-73)
 and neurodegenerative 
diseases.
(72,73)
. Resorcinol derivatives are attractive chemical scaffolds that could be 
potentially used as alternative treatment against human parasites such as Tryapanosoma 
brucei rhodesiense and Plasmodium falciparum.
(74)
 Recently, the group of Brasca reported 
the discovery of a potent inhibitor, NMS-E973 (L-1) 38, of Hsp90 protein which showed 
good anticancer activity.
(61)
 Taking into consideration that Hsp90 inhibitors have also been 
shown to exhibit anti-parasitic activity,
(74)
 it was worth resynthesizing analogues of NMS-
E973 (L-1) 38 and repurposing them as potential anti-plasmodial agents. 
Since the synthesis of compounds requires much work and implies a high cost of reagents 
and solvents, we used molecular docking to screen the library of molecules synthesized by 
Brasca et al.
(61)
 in order to select appropriate molecules for synthesis. The molecules were 
assessed based on their calculated binding energies deduced from the predictions of their 
binding affinity.   
1
H NMR (Nuclear magnetic resonance), 
13
C NMR, COSY (Correlation spectroscopy), HSQC 
(Heteronuclear single quantum coherence spectroscopy) and HMBC (Heteronuclear multiple 
bond correlation) data and in some cases also NOESY (Nuclear Overhauser effect 
spectroscopy) and Mass Spectrometry were obtained for most of the molecules that were 
synthesized in order to confirm their structures. In this chapter, we will only give a brief 
description of the collected data. The full spectral assignments of the molecules we 
synthesized can be found in Chapter Three and in the supplementary data.  
 
2.2. Results and discussion 
2.2.1. Docking studies (virtual screening) 
Our molecular docking studies were aimed at selecting molecules from those synthesized by 
Brasca et al.
(61)
 as well as close analogues that would potentially have selective interactions 
with PfHsp90 as compared to human Hsp90. We used the ADP-bound crystal structures of 
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human Hsp90 (PDB (Protein Data Bank) code: 1BYQ) and PfHsp90 (PDB code: 3K60) for 
our docking studies. Based on their inhibition constants (Ki) for human Hsp90 and PfHsp90, 
three molecules L-31 63, L-62 64, and L-63 65 were identified as potential selective 
inhibitors of PfHsp90. The full list of molecules screened by docking and the values of 
binding affinity and inhibition constants obtained can be found in appendix III. The inhibition 
constants were calculated according to the equation: G = -RTln Ki, where G = Gibbs free 
energy of binding, R = the gas constant and T = 298.15 K.  
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Table 1: NMS-E973 (L-1) 38 analogues potential selective inhibitors of PfHsp90 and 
their constants of inhibition 
Code Molecules  Smiles M.W. 1BYQ  
Ki (M) 
3K60  
Ki (M) 
NMS-
E973 (L-
1) 38 
(lead 
molecule) 
 
O=C(C1=NOC
(C2=C(OC3=C
C=C([N+]([O-
])=O)C=C3)C
=C(O)C=C2O)
=C1)NC4CCN
(C)CC4 
454.43 0.1 0.3 
L-31 63 
 
O=C(C1=NOC
(C2=C(OC3=C
C=C([N+]([O-
])=O)C=C3)C
=C(O)C=C2O)
=C1)NC4CCN
(C(C)C)CC4 
482.49 1.1 0.2 
L-62 64 
 
OC1=CC(OC2
=CC=C([N+]([
O-
])=O)C=C2)=
C(C3=CC(C(N
C4CC(C)(C)N
(C)C(C)(C)C4)
=O)=NO3)C(O
)=C1 
510.54 0.8 0.2 
L-63 65 
 
OC1=CC(OC2
=CC=C([N+]([
O-
])=O)C=C2)=
C(C3=CC(C(N
C4CCN(C(C)=
O)CC4)=O)=N
O3)C(O)=C1 
482.44 0.8 0.1 
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The analysis of the docking results of these three molecules L-31 63, L-62 64 and L-63 65 
shows that they all have three particular hydrogen bonds interactions in common with three 
amino acid residues (Ile-96, Thr-101 and Asn-92) of PfHsp90. These H-bonds are not found 
in the docking results of NMS-E973 (L-1) 38 to PfHsp90. However, it should be remembered 
that these molecules do not only interact with PfHsp90 through hydrogen bonds, but other 
interactions such as hydrophobic interactions are also observed. Moreover, our docking 
results do not show any interaction mediated by the water solvent molecules since they were 
all removed from the protein before docking.  
 
       
 
 
 
 
The analysis of the conformations and positions of the ligands NMS-E973 (L-1) 38, L-31 63, 
L-62 64 and L-63 65 (Figure 7 and Figure 8) shows that apart from ligand L-1 (38), the 
other ligands occupy the same position and adopt similar conformations inside the PfHsp90 
binding pocket.  
 
 
 
 
 
 
 
Figure 8: Conformations and positions 
of NMS-E973 (L-1) 38 (red), L-31 63 
(blue), L-62 64 (green) and L-63 65 
(yellow) inside the binding site after 
docking to PfHsp90 
Figure 7: Conformations and positions of 
NMS-E973 (L-1) 38 (red), L-31 63 (blue), 
L-62 64 (green) and L-63 65 (yellow) after 
docking to PfHsp90 
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Table 2: Analysis of the interaction between PfHsp90 and its potential selective 
inhibitors analogues of NMS-E973 (L-1) 38 
 Residues of PfHsp90 
involved in H-bonds with 
the ligand 
Bond length (Å) 
NMS-E973 (L-1) 38 Arg-98 3.09 
Arg-98 3.01 
Asp-37 3.14 
Asp-79 2.78 
Lys-44 2.89 
Thr-171 3.04 
L-31 63 Ile-96 3.17 
Thr-101 3.10 
Asn-92 2.84 
Arg-98 3.19 
Asn-37 3.13 
L-62 64 Ile-96 3.12 
Thr-101 3.19 
Asn-92 2.82 
L-63 65 
Thr-101 3.17 
Ile-96 3.11 
Asn-92 2.87 
Arg-98 6.90 
Asn-37 3.08 
Lys-44 3.12 
 
From our docking results, we identified three potential inhibitors that could preferentially 
select PfHsp90 above human Hsp90. Based on the ease of synthesis, we choose two 
compounds, L-31 63 and L-62 64 and synthesized their respective dimethyl ether resorcinol 
analogues, TU-019 (L-104) 51 and TU-017 (L-102) 61. We also synthesized TU-016 (L-14) 
60, the dimethyl ether resorcinol analogue of our lead molecule, NMS-E973 (L-1) 38 in order 
to use it for comparison. Our docking results (Table 3) for these dimethyl ether resorcinol 
analogues indicate that they do not selectively bind to PfHsp90 in the presence of human 
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Hsp90. In comparison, docking studies clearly predict that their non-methylated analogues 
could be selective for PfHsp90.   
 
Table 3: Dimethyl ether resorcinol analogues of NMS-E973 (L-1) 38 potential inhibitors 
of PfHsp90 and their constants of inhibition 
Code Molecules  Smiles M.W. 1BYQ  
Ki (M) 
3K60  
Ki (M) 
TU-016 
(L-14) 60 
 
O=C(C1=NOC
(C2=C(OC3=C
C=C([N+]([O-
])=O)C=C3)C
=C(OC)C=C2
OC)=C1)NC4
CCN(C)CC4 
482.49 0.7 0.6 
 
TU-017 
(L-102) 
61 
 
COC1=CC(OC
2=CC=C([N+]
([O-
])=O)C=C2)=
C(C3=CC(C(N
([H])C4CC(C)
(C)N(C)C(C)(
C)C4)=O)=NO
3)C(OC)=C1 
538.59 0.2 
 
0.5 
 
TU-019 
(L-104) 
51 
 
COC1=CC(OC
2=CC=C([N+]
([O-
])=O)C=C2)=
C(C3=CC(C(N
([H])C4CCN(
C(C)C)CC4)=
O)=NO3)C(O
C)=C1 
510.54 0.8 
 
0.8 
 
 
Since PfHsp90 has the highest ATPase activity of all known Hsp90 ATPase’s(31) and 17-
AAG 20 inhibits 15 to 25 fold more effectively cancer cells because of their higher ATPase 
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activity as compared to normal healthy cells,
(39)
 we suggest that, based on our docking 
results, dimethyl ether resorcinol analogue compounds are more effective growth inhibitors 
of P. falciparum than HeLa cells because PfHsp90 has higher ATPase activity. This is based 
on the assumption that growth inhibition is mediated by the inhibition of the PfHsp90 
chaperones.   
The analysis of the H-bond interactions between the dimethyl ether resorcinol analogues in 
Table 4 with their counterparts in Table 3 indicates that they do not mediate the same 
interactions, which is likely the source for the observed difference in their selectivity for 
PfHsp90.  
 
Table 4: Analysis of the interaction between PfHsp90 and its potential inhibitors 
dimethyl ether resorcinol analogues of NMS-E973 (L-1) 38  
 Residues of PfHsp90 
involved in H-bonds with 
the ligand 
Bond length (Å) 
TU-016 (L-14) 60 Ala-38 3.17 
Lys-44 3.16 
Asn-92 3.00 
TU-017 (L-102) 61 Arg-98 3.06 
Arg-98 3.22 
Arg-98 5.76 
TU-019 (L-104) 51 Lys-44 3.24 
Phe-124 3.00 
 
A visualization of the docking results (Figure 9 and Figure 10) of the ligands in Table 4 
illustrates that each molecule adopts a different conformation and position inside the binding 
pocket of PfHsp90, which is not the case for the ligands in Table 2.  
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In addition to compounds TU-016 (L-14) 60, TU-017 (L-102) 61 and TU-019 (L-104) 51, we 
also synthesized compounds TU-013 (L-98) 57 and TU-015 (L-100) 59 based on our docking 
studies. They are variations of our series of compounds and based on their docking results, it 
was thought that they would assist in the exploration of the effects of other binding 
fragments. Compounds TU-007 (L-96) 55 was also added to the study as it had the resorcinol 
moiety cyclised into a benzofuran ring which made it unique. Benzofurans are known 
bioactive molecules.
(75)
 All the above compounds and their synthetic intermediates in our 
synthesis which shared the same pharmacophore were submitted for PLDH and cytotoxicity 
assays. 
 
2.2.2. Synthesis of diaryl ethers 
Diaryl ethers constitute an important class of natural bioactive compounds.
(76)
 They have 
therefore attracted the attention of many researchers who have synthesized them for various 
applications such as potential anticancer agents,
(61)
 antiplasmodial and antibacterial agents,
(77)
 
anti-arthropods and anti-helminths.
(78)
 They are also widely used in polymer chemistry.
(76)
 
The synthesis of NMS-E973 (L-1) 38 and its analogues involved a series of steps starting 
from the synthesis of the diaryl ether 41.
(61)
 Different amides that share a common diaryl 
ether isoxazole substructure were then synthesized from this precursor.  
Figure 9: Conformations and positions 
of TU-016 (L-14) 60 (red), TU-017 (L-
102) 61 (blue) and TU-019 (L-104) 51 
(green) 
 
Figure 10: Conformations and positions 
of TU-016 (L-14) 60 (red), TU-017 (L-
102) 61 (blue) and TU-019 (L-104) 51 
(green) inside the binding site after 
docking to PfHsp90 
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Scheme 1: Synthesis of compound NMS-E973 (L-1) 38 
 
The most common way of preparing diaryl ethers involves a reaction of a phenol with an aryl 
halide in the presence of a catalytic amount of copper or iron.
(76,79,80)
 However, ortho-
nitrofluorobenzene and para-nitrofluorobenzene react with phenols without a catalyst in 
DMSO or DMF and in the presence of K2CO3 as a base and temperatures ranging from room 
temperature to 110 °C.
(61,73,81)
 The obtained yields can be as high as 90%.
(81)
 The treatment of 
para-bromonitrobenzene with para-methoxyphenol without a catalyst  gave the desired 
compound in 89% yield with a longer reaction time (18 h).
(79)
  
Taking into consideration that the product TU-003 41 of the first step (scheme 1, page 29) of 
our synthesis was a diaryl ether and that the mechanism involved in its formation is an 
aromatic nucleophilic substitution (scheme 2, page 30), we first tested similar reactions using 
3,5-dimethylphenol with 1-fluoro-4-nitrobenzene and with 1-(4-fluorophenyl)ethanone. In 
nucleophilic aromatic substitution where addition-elimination mechanism is involved, the 
intermediate species is stabilized by electron-withdrawing groups positioned ortho or para to 
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the site of substitution.
(82)
 Such substituents activate the aromatic ring to nucleophilic 
substitution and the strongest effect is observed when the substituent is a nitro group.
(82)
 
Cyano and carbonyl groups also favour nucleophilic aromatic substitution, but are less 
reactive than a nitro group.
(82)
 A fluoride ion is the best leaving group in most aromatic 
nucleophilic substitution reactions.
(83)
 
 
Scheme 2: The most important mechanism for nucleophilic aromatic substitution
(83)
  
 
The reaction between 3,5-dimethylphenol and 1-fluoro-4-nitrobenzene in the presence of 
K2CO3 yielded compound TU-001 46 (Scheme 3, page 31) with a yield of 96% after 
purification. The melting point 68 °C - 70 C was lower than the one of 59 C reported in the 
litarature.
(76)
 We attribute this to different degrees of purity of the product. The yield of 96% 
was obtained without using a catalyst and the best yield (99%) was obtained using a nickel-
based catalyst.
(84)
 This is comparable to the yields (88% - 95%) obtained by using copper-
based catalysts,
(76,80,85,86)
 iron-based catalysts
(76,80)
 or palladium-based catalysts
(87)
 with 
halides (Cl, Br, I) other than fluoro (F) as leaving groups.  
Scheme 3: Synthesis of TU-001 46 and TU-002 47 
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The 
1
H NMR (Figure 11) of compound TU-001 46 has signals representing the protons of 
the two methyl groups at 2.33 ppm (parts per million) and the protons of the nitro substituted 
aromatic ring at 7.00 ppm and 8.17 ppm. The electron density and consequently the shielding 
of a nucleus are affected by inductive and mesomeric effects which also depend on the 
electron shells of that nucleus and its direct neighbours.
(88)
 The protons (3’-H and 5’-H) on 
the para substituted benzene ring that are ortho with respect to the nitro substituent are 
therefore less shielded due to its electron-withdrawing effect and their signals have chemical 
shift values of 8.17 ppm whereas 2’-H and 6’-H have signals at 7.00 ppm. The two sets of 
signals appear as doublets because the protons of each set have only one neighbouring proton 
each. The signals of two equivalent protons ortho to the ether moiety of the tri-substituted 
benzene ring are at 6.71 ppm. They are singlets since each one has no neighbouring proton. 
The signal of the remaining proton on the tri-substituted benzene ring is a singlet at 6.89 ppm.  
 
 
Figure 11: 
1
H NMR spectrum of TU-001 46 in CDCl3 (deuterated chloroform) 
 
The 
13
C NMR spectrum (Figure 12) has nine peaks representing the nine non-equivalent 
carbon nuclei. The signals for the two equivalent methyl groups are at 21.2 ppm and the 
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signals of the carbon nuclei of the aromatic rings are in the region of 110 ppm – 170 ppm as 
expected.  
 
 
Figure 12: 
13
C NMR spectrum of TU-001 46 in CDCl3 
 
An HSQC experiment (Figure 8) was used to assign the signals of carbon nuclei directly 
attached to the protons of TU-001 46. For example, the signals of the protons of the methyl 
groups which appear at 2.33 ppm in the 
1
H NMR spectrum form a cross peak with the signals 
of the carbon nuclei of the methyl groups at 21.2 ppm. The cross-peak (6.89 ppm, 127.04 
ppm) that links 2-H to 2-C is also illustrated in Figure 8. An HMBC experiment was used to 
assign the peaks of non-hydrogen substituted carbon nuclei situated two or three bonds away 
from protons.  
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Figure 13: HSQC spectrum of TU-001 46 in CDCl3 
 
For the synthesis of TU-002 47, while we obtained 60 % of the desired product using 3,5-
dimethylphenol and 1-(4-fluorophenyl)ethanone without a catalyst, better yields (88% - 95%) 
were obtained by Keller et al. 
(89)
 and Xia and Taillefer 
(90)
 who used the less reactive 1-(4-
bromophenyl)ethanone and 1-(4-chlorophenyl)ethanone respectively, but in the presence of 
ligands and copper catalysts. The use of the more active 1-(4-fluorophenyl)ethanone is 
advantageous in that it is not as costly as the other methods that require the catalysts.  
An analysis of the 
1
H NMR of the product TU-002 47 (Figure 14)  shows 6 protons of the 
two equivalent methyl groups at 2.31 ppm and three protons of the acetyl at 2.57 ppm. The 
protons of the aromatic ring substituted with acetyl show up as doublets at 6.99 ppm and 7.93 
ppm. The same as in the case of the nitro substituent, the acetyl group also reduces the 
shielding of the protons close to it due to the inductive and mesomeric effects. Therefore, the 
protons that appear at 7.93 ppm are those close to the acetyl group whereas their close 
neighbours appear at 6.99 ppm. Their corresponding signals show up as doublets because 
each one of the protons has one neighbour. The two equivalent protons of the ring substituted 
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with methyl groups appear as a singlet at 6.68 ppm and the remaining proton (4’’-H) appear 
at 6.83 ppm. 
 
 
Figure 14: 
1
H NMR spectrum of TU-002 47 in CDCl3 
 
The 
13
C NMR spectrum of TU-002 47 shows 11 carbons as expected with the carbons of the 
two equivalent methyl groups and the carbon of the methyl of acetyl appearing between 20 
ppm and 30 ppm. The carbonyl of the acetyl substituent appears at 196.8 ppm and the 
carbons of the aromatic rings appear between 110 ppm and 170 ppm as previously observed 
for TU-001 46.  
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Figure 15: 
13
C NMR spectrum of TU-002 47 in CDCl3 
 
In the HMBC spectrum (Figure 16) the cross peak that links the signals of the three protons 
of the acetyl group to the signal carbonyl carbon of the acetyl substituent assisted in their 
differentiation from the signals of the protons of the methyl groups directly attached to the 
aromatic ring. The protons of the methyl groups directly attached to the aromatic ring are too 
far from the carbonyl carbon of the acetyl substituent to form any significant HMBC cross 
peaks. 
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Figure 16: HMBC spectrum of TU-002 47 in CDCl3 
 
TU-003 41 was synthesized by stirring the reaction mixture for two hours at 110 °C giving 
lower yields than the reported 63%
(61)
. The reaction conditions were changed to stirring the 
reaction mixture for four hours at 45 °C and the yield was improved to 88%. (Scheme 4, 
page 40)  
The 
1
H NMR spectrum of  TU-003 41 (Figure 17) has a signal of the acetyl substituent at 
2.33 ppm and signals for the methoxy groups at 3.78 ppm and 3.86 ppm. Peaks of protons of 
the ring substituted with the nitro group appear as multiplets at 7.00 ppm and 8.19 ppm. As in 
the previous cases, the signals of the protons that are direct neighbours of the nitro substituent 
are at 8.19 ppm due to the deshielding effect of the nitro group whereas the signals of their 
neighbours are at 7.00 ppm.  
 The HMBC spectrum (Figure 19) assisted in the differentiation of the proton peak of the 
acetyl group from proton peaks of the methoxy groups. The protons of the acetyl group 
couple with the carbon nucleus of the carbonyl group through two bonds resulting in a cross-
peak.  
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The protons of the methoxy groups couple to the carbon nuclei of the aromatic ring through 
three bonds forming cross-peaks on the HMBC spectrum. 
 
 
 
Figure 17: 1H NMR spectrum of TU-003 41 in CDCl3 
 
TU-003 41 has sixteen carbon atoms but because there are two groups of equivalent carbon 
atoms (3’’-C and 5’’-C, 2’’-C and 6’’-C) on the nitro-substituted ring, only fourteen carbon 
peaks are observed on the 
13
C NMR spectrum. The peak of the carbonyl carbon of the acetyl 
is at 199.4 ppm and is confirmed by its coupling with the protons of the acetyl group in the 
HMBC spectrum (Figure 19).  
37 
 
 
Figure 18: 
13
C NMR spectrum of TU-003 41 in CDCl3 
 
 
Figure 19: HMBC spectrum of TU-003 41 in CDCl3 
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Scheme 4:  Synthesis of different dimethyl ether resorcinol analogues of NMS-E973 (L-1) 38 
without a coupling agent 
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When we synthesized TU-003 41 at 55 °C, we obtained TU-003 41 (65%) andTU-004 52 
(7%). The formation of TU-004 52 could be the result of the keto-enol tautomerism (Scheme 
5, page 41) of our starting material. The species that reacted to yield TU-004 52 was an 
enolate while in the case of the formation of TU-003 41, the reacting species was a phenolate. 
Normally, in the case of keto-enol tautomerism, the keto form is the predominant form due to 
the fact that it is thermodynamically more stable than the enol form.
(83)
 The melting point of 
TU-004 52 was 124 °C - 126 °C as compared to the reported value of 150 °C. The difference 
in the melting points is very likely due to different degrees of purity of the two samples. 
Another reason for this could be the fact that some compounds crystallize in different forms 
(crystallographic polymorphism) and crystallographic polymorphs normally have different 
physical properties such as melting points.
(91)
  
 
Scheme 5: The formation of TU-003 41 and TU-004 52 from the same starting material 
 
The 
1
H NMR spectrum of TU-004 52 (Figure 20) has two singlets representing the two 
methoxy groups at 3.83 ppm and 3.86 ppm. The signal of the two protons of the methylene 
group is a singlet at 4.43 ppm and the signals of the two protons of the aromatic ring 
substituted with methoxy groups are doublets at 5.94 ppm and 6.09 ppm respectively. The 
peaks representing the two aromatic protons are doublets due to the coupling between them. 
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The protons of the nitro substituted ring appear as multiplets at 7.38 ppm and 8.19 ppm and 
the phenolic proton shows up at 13.65 ppm.  
 
Figure 20: 
1
H NMR spectrum of TU-004 52 in CDCl3 
 
The 
13
C NMR spectrum of TU-004 52 has only 13 carbon peaks because the signals of the 
carbon nuclei of the two methoxy groups overlapp despite the fact that they do not seem to be 
equivalent.  
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Figure 21: 
13
C NMR of TU-004 52 in CDCl3 
 
The main cross peak on the HMBC spectrum of TU-004 52 (Figure 22) is the one (4.43 ppm, 
200.63 ppm) which indicates the coupling between the two protons of the methylene group 
and the adjacent carbon nucleus of the carbonyl group. The phenolic proton also couples with 
three neighbouring carbon nuclei (1’-C, 2’-C and 3’-C). One carbon nucleus (1’-C) is 
immediately assigned due to the fact that it couples with the two protons of the corresponding 
ring in addition to coupling with the phenolic proton. The coupling is observed because it is 
located three bonds away from each of the protons. The peak for  1’-C is at 105.5 ppm on the 
13
C NMR spectrum (Figure 21).  
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Figure 22: HMBC spectrum of TU-004 52 in CDCl3 
 
2.2.3. Synthesis of -diketones 
-diketones are usually prepared from a methylketone and an aliphatic ester in the presence 
of a strong base in an anhydrous medium (Scheme 6, page 45).
(61,92,93)
 Some of the bases 
include sodium hydride,
(93-95)
 sodium amide,
(92,93,96)
 lithium amide,
(93)
 sodium 
ethoxide,
(59,92,97,98)
 sodium methoxide,
(97)
 metallic sodium,
(92,98)
 lithium 
bis(trimethylsilyl)amide,
(61)
 and sodium tert-butoxide.
(61)
 When diesters are used instead of 
monoesters, a di-ketoester is obtained (Scheme 6,  page 45).
(61)
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Scheme 6: General reactions for the preparation of -diketones and -diketoesters 
 
We attempted to synthesize compound 42 by reacting TU-003 41 with sodium (scheme 1, 
page 29) as similar reactions had previously been reported
(98)
 Instead of obtaining the desired 
compound, the starting material was cleaving to give a new compound TU-006 53. The 
cleavage of aryl ethers in the presence of alkali metals has been previously reported
(99)
. It has 
also been reported
(100)
 that a similar reaction takes place when using both an alkaline base and 
a triethylsilane. Based on this information, we suggest that TU-003 41 was also being cleaved 
by the same sodium used to carry out the acylation of TU-003 41 with diethyl oxalate.  
It has been found that these reactions depend on the type and the number of equivalents of the 
base used.
(92)
 For example, acylation with sodium amide is quicker and gives better yields 
than sodium ethoxide and metallic sodium.
(92)
 Lithium amide also gives better yields than 
sodium amide, which in turn gives better yields than sodium hydride.
(93)
 The yields obtained 
using two equivalents of sodium amide for one equivalent of the ketone are twice as high as 
when one equivalent of the base is used, usually yielding less than 50%.
(92)
 However, using 
metallic sodium results in a 95% yield in the formation of a di-ketoester. Excess ester does 
not have any significant effect on the yield.
(92)
 In our study, we did not even detect traces of 
our desired product when metallic sodium was used as the base. 
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The 
1
H NMR spectrum of TU-006 53 has a triplet at 1.39 ppm which corresponds to three 
protons and a quartet corresponding to two protons at 4.37 ppm. The two groups of peaks 
have the same coupling constant (7.09 Hz), which indicates that the two sets of protons are on 
neighbouring carbon atoms and represent the ethyl moiety of the ester in TU-006 53. The 
signals of the methoxy groups of TU-006 53 partially overlap and are singlets at 3.80 ppm 
and 3.81 ppm. The signals of the aromatic protons are coupled doublets at 5.95 ppm and 6.10 
ppm and the signal of the phenolic proton is a singlet at 12.09 ppm.  
 
Figure 23: 1H NMR spectrum of TU-006 53 in CDCl3 
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The 
13
C NMR spectrum of TU-006 53 has eleven peaks representing the 11 non-equivalent 
carbon nuclei. The peak of 2’-C is at 14.2 ppm and the peaks at 55.4 ppm and 56.0 ppm 
correspond to the carbon nuclei of the two methoxy groups. The peak at 61.2 ppm represents 
the methylene carbon nucleus of the ethyl substituent. The rest of the peaks represent the 
aromatic carbon nuclei and carbonyl carbon nucleus of the ester moiety. 
 
 
Figure 24: 
13
C NMR spectrum of TU-006 53 in CDCl3 
 
After observing that sodium was cleaving TU-003 41 instead of giving the desired product, 
we benzylated 1-(2-hydroxy-4,6-dimethoxyphenyl)ethanone with 1-(bromomethyl)-4-
nitrobenzene and obtained compound TU-005 54. The same protecting group has been used 
previously.
(98)
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The peak of the protons of the acetyl group is a singlet at 2.49 ppm, peaks of the protons of 
the methoxy groups are singlets at 3.80 ppm and 3.81 ppm, the peak of the methylene protons 
is a singlet at 5.15 ppm and the peaks of the protons of the ring substituted by methoxy 
groups are doublets at 6.08 ppm and 6.14 ppm. The doublets at 7.56 ppm and 8.23 ppm 
correspond to the protons of the nitro-substituted ring with protons ortho- with respect to the 
nitro group at 8.23 ppm.  
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Figure 25: 
1
H NMR spectrum of TU-005 54 in CDCl3 
 
The 
13
C NMR spectrum of TU-005 54 has fifteen peaks corresponding to fifteen non-
equivalent carbon nuclei. The peak of the carbonyl carbon nucleus of the acetyl substituent is 
at 201.6 ppm and the peak of the methyl group of the acetyl substituent is at 32.7 ppm. The 
peaks of the methoxy groups are at 55.5 ppm and 55.9 ppm and the peak of the methylene 
group of the benzyl moiety is at 69.2 ppm. The peaks between 90 ppm and 170 ppm 
correspond to the carbon nuclei of the aromatic rings.  
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Figure 26: 
13
C NMR spectrum of TU-005 54 in CDCl3 
 
Acetylation of the methyl ketone group of TU-005 54 with diethyl oxalate in the presence of 
sodium, yielded an unexpected product TU-007 (L-96) 55. Upon inspection of the 
1
H and the 
13
C NMR spectra of TU-005 54 and TU-007 (L-96) 55 we noticed that the peak of the 
methylene of TU-005 54 which is at 5.15 ppm in the 
1
H NMR spectrum was not present in 
the 
1
H NMR spectrum of TU-007 (L-96) 55 whereas all other proton peaks were present. 
Moreover, the peak of the carbonyl group of TU-005 54 which is at 201.6 ppm was not 
present in the 
13
C spectrum of TU-007 (L-96) 55 whereas the number of carbons remained 
the same for both compounds. This led us to the conclusion that TU-005 54 had undergone a 
cyclisation and a condensation to give TU-007 (L-96) 55, which was supported by NMR and 
mass spectrometry data.  
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The 
1
H NMR spectrum of TU-007 (L-96) 55 has the peak representing the protons of the 
methyl substituent at 2.65 ppm and the peaks of the protons of the methoxy groups are at 3.86 
ppm and 3.90 ppm. The signals for the two aromatic protons of the ring substituted with 
methoxy groups are at 6.29 ppm and 6.61 ppm and peaks of the protons of the nitro-
substituted ring are at 7.85 ppm and 8.27 ppm. The peaks of 6-H and 8-H appear as doublets 
because of meta-coupling in the aromatic ring. This is supported by the magnitude of the 
coupling constant (J = 1.92 Hz).  
 
Figure 27: 
1
H NMR spectrum of TU-007 (L-96) 55 in CDCl3 
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Three peaks are easily identifiable in the 
13
C NMR of TU-007 (L-96) 55. The peak at 11.6 
ppm corresponds to the methyl group whereas the peaks at 55.5 ppm and 55.8 ppm 
correspond to the methoxy groups. All other peaks between 80 ppm and 170 ppm represent 
the aromatic carbon nuclei.  
 
Figure 28: 
13
C NMR spectrum of TU-007 (L-96) 55 in CDCl3 
 
High resolution mass spectrometry (HRMS) (ESI) of TU-007 (L-96) 55 indicated that the 
calculated mass of [M+H]
+
 is m/z = 314.1028 and the experimentally obtained mass is m/z = 
314.1039. (Figure 29) 
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Figure 29: HRMS (ESI) spectrum of TU-007 (L-96) 55 
 
After realizing that the attempted acylation of TU-005 54 with  diethyl oxalate in the 
presence of sodium did not produce the desired product, we tested whether we would obtain 
the desired product if the hydroxyl of 1-(2-hydroxy-4,6-dimethoxyphenyl)ethanone were 
protected with a methyl. By reacting 1-(2-hydroxy-4,6-dimethoxyphenyl)ethanone with 
iodomethane, we obtained the compound TU-009 56.  
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The 
1
H NMR spectrum of TU-009 56 (Figure 30) has a peak representing the acetyl protons 
at 2.46 ppm, the peak of the two equivalent methoxy groups are at 3.79 ppm, the peak of the 
remaining methoxy is at 3.82 ppm and the peak of the equivalent aromatic protons is at 6.10 
ppm. 
 
Figure 30: 
1
H NMR spectrum of TU-009 56 in CDCl3 
 
The 
13
C of TU-009 56 (Figure 31) has eight peaks as expected. The peak at 32.5 ppm 
represents the methyl carbon of acetyl group and the peak at 201.7 ppm represents the 
cabonyl carbon of the acetyl group. The peaks of the methoxy groups are at 55.4 ppm and 
55.8 ppm and the peaks of the aromatic carbon nuclei are in the interval between 90 ppm to 
170 ppm. An attempt to acylate TU-009 56 with diethyl oxalate in the presence of sodium did 
not yield the desired product.  
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Figure 31: 
13
C NMR spectrum of TU-009 56 in CDCl3 
 
After realizing that using sodium was not yielding the desired product 42, we changed the 
base to lithium bis (trimethylsilyl) amide. Treating TU-003 41 with lithium bis 
(trimethylsilyl) amide, followed by the addition of diethyl oxalate yielded the compound TU-
010 48. Although we had aimed to synthesize compound 42, NMR data suggested that we 
had obtained compound TU-010 48. We continued with the synthesis since the two 
compounds are tautomers. (Scheme 7, page 55) 
 
 
Scheme 7: Synthesis of TU-010 48 from TU-003 41 and diethyl oxalate 
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In the 
1
H NMR spectrum of TU-010 48 (Figure 32), there is a triplet at 1.34 ppm that 
represents the protons of the methyl group of the ethyl substituent while the methylene 
protons of this substituent has its quartet of signals at 4.33 ppm. These two groups of peaks 
have the same coupling constant (J = 7.12 Hz), which confirms that the protons are attached 
to adjacent carbon atoms.  
 
 
 
The singlets at 3.81 ppm and 3.88 ppm represent the protons of the methoxy groups and the 
doublets at 6.18 ppm and 6.40 ppm represent the protons (3’’-H and 5’’-H) of the aromatic 
ring.  Their peaks are doublets because the two protons couple with each other. The singlet at 
6.69 ppm represents the vinylic proton (3-H) and the multiplets at 7.00 ppm and 8.19 ppm 
represent the aromatic protons (2’-H and 6’-H, 3’-H and 5’-H) of the nitro-substituted ring. 
The peak at 14.25 ppm represents the enolic proton (2-OH). Its integral (0.56 instead of 1) is 
low because 2-OH undergoes proton exchange.  
 
55 
 
 
Figure 32: 
1
H NMR spectrum of TU-010 48 in CDCl3 
 
The 
13
C NMR spectrum of TU-010 48 (Figure 33) is more complicated than its 
1
H NMR 
spectrum. However, some of the peaks can be easily assigned. The peak at 14.1 ppm 
represents the carbon nucleus of the methyl group (2’’’-CH3) of the ethyl substituent of the 
ester moiety whereas the signal of the carbon nucleus of the methylene group (1’’’-CH2) is at 
62.5 ppm. The peaks corresponding to the carbon nuclei of the methoxy groups are at 55.8 
ppm and 56.3 ppm and the peak corresponding to the carbonyl carbon nucleus of the ketone 
group (4-C=O) is at 192.2 ppm.  
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Figure 33: 
13
C NMR spectrum of TU-010 48 in CDCl3 
 
The HSQC spectrum (Figure 34) corroborates our assignements of the protons and carbon 
nuclei of the ethyl groups of TU-010 48, but an HMBC experiment would be necessary to 
collectly assign the remaining peaks between 90 ppm and 170 ppm that represent the 
aromatic carbon nuclei.  
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Figure 34: HSQC spectrum of TU-010 48 in CDCl3 
 
2.2.4. Synthesis of isoxazoles 
The third step of our synthesis of analogues of NMS-E973 (L-1) 38 involves the formation of 
the isoxazole TU-011 (L-7) 43. The isoxazole moiety is found in many synthetic Hsp90 
inhibitors which are generally active against cancer cells
(49,50,53)
 and protozoans.
(31,74)
 One of 
the methods of preparation of isoxazoles is the condensation of a -diketone with 
hydroxylamine hydrochloride (Scheme 8, page 59).
(101)
 If the diketone is symmetrical, only 
one product is obtained while unsymmetrical diketones can give one or two products 
depending on the regioselectivity of the reaction.
(101) 
 
 
 
Scheme 8: Synthesis of isoxazoles from -diketones 
 
58 
 
The isoxazoles can also be prepared by condensation of hydroxylamine with ,-unsaturated 
carbonyl compounds such as chalcones.
(101,102)
 In this case, a leaving group in position  of 
the carbonyl is removed.
(101,103)
 An example of this is the synthesis of 5-arylisoxazoles in 
yields of up to 93% in some cases.
(103)
 The same reactions yield pyrazoles or pyrimidines if 
hydroxyl amine is replaced by hydrazines or amidines respectively.
(104)
 Therefore, these 
reagents can be used to synthesize pyrazole or amidine analogues of NMS-E973 (L-1) 38.  
In our study, compound TU-010 48 was reacted with hydroxyl amine hydrochloride in 
ethanol to yield compound TU-011 (L-7) 43, the precursor of different amide analogues of 
NMS-E973 (L-1) 38. The two steps of synthesis of TU-010 48 and TU-011 (L-7) 43 give 
yields of 65% and 77% respectively, with the overall yield of the two reactions being 50%. 
This is much lower than the reported value of 78% obtained where the second step was 
carried whithout purifying the product obtained in the first step.
(61)
 Therefore, it is important 
for future researchers to omit the purification of the product after the first step.  
The 
1
H NMR spectrum of TU-011 (L-7) 43 (Figure 35) has the peaks corresponding to the 
protons of the ethyl substituent at 1.39 ppm (2’-CH3) and 4.41 ppm (1’-CH2-). The peaks of 
the methoxy groups are at 3.83 ppm and 3.92 ppm while the peaks of the protons of the 
aromatic ring substituted with the methoxy groups are at 6.29 ppm and 6.47 ppm. They are 
doublets because of meta-coupling which is confirmed by the coupling constant (J = 2.34 
Hz). The peak at 6.88 ppm represent the proton of the isoxazole ring and the peaks at 6.99 
ppm and 8.16 ppm represent the two sets of equivalent protons of the nitro-substituted ring.  
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Figure 35: 
1
H NMR spectrum of TU-011 (L-7) 43 in CDCl3 
 
The 
13
C NMR spectrum (Figure 36) has signals corresponding to the carbon nuclei of the 
ethyl group at 14.2 ppm (2’-CH3) and 62.1 ppm (1’-CH2-) whereas the peaks of the carbon 
nuclei of the methoxy groups are at 55.8 ppm and 56.2 ppm. The peaks of the carbon nuclei 
of the aromatic rings (both of the phenyl rings and the isoxazole ring) are in the interval 
spanning 90 ppm – 170 ppm.  
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Figure 36: 
13
C NMR spectrum of TU-011 (L-7) 43 in CDCl3 
 
HRMS (ESI) of TU-011 (L-7) 43 indicates that the mass of [M+H]
+
 is m/z = 415.1141 as 
compared to the experimentally obtained value m/z = 415.1156 (Figure 37).   
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Figure 37: HRMS (ESI) spectrum of TU-011 (L-7) 43 
 
2.2.5. Amidation of carboxylic acids and carboxylic esters 
There are various methods of preparation of amides. Some of the common methods include 
preparation of amides by acylation of amines with acyl halides, carboxylic anhydrides, 
carboxylic esters or carboxylic acids, the acyl halides being the most reactive of these 
reagents (Scheme 9, page 63).
(83,105)
 The amidation of acyl halides is very exothermic and the 
temperature is usually controlled either by dilution or cooling.
(83)
  
 
 
Scheme 9: Traditional methods of preparation of amides
(105) 
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In some cases, amides can be prepared from esters by simply heating the amine and the ester 
resulting in yields above 90%.
(61) 
Amides can be also prepared by reacting an ester with an 
amine in the presence of a Lewis acid such as BBr3,
(106)
 MgCl2
(107)
  and MgBr2
(107)
 and yields 
obtained in these reactions using MgBr2 or MgCl2 are generally above 90%. Amides have 
been also prepared by heating carboxylic acids and amines in the presence of dehydrating 
agents such as POCl3 and SOCl2.
(108)
 Other catalysts used to prepare amides from carboxylic 
acids include molecular sieves,
(109)
 transition metals such as ruthenium and copper,
(110)
 Lewis 
acids such as B(OCH2CF3)3
(111)
 and coupling reagents such as N,N,N’,N’-tetramethyl-O-
(benzotriazol-1-yl)uronium tetrafluoroborate (TBTU).
(61)
 Although amidation reactions 
catalysed with molecular sieves generally give very good yields, it requires high temperatures 
(> 140 °).
(109)
 However, reactions catalysed by TBTU give good yields at lower 
temperatures.
(61)
 As a result, we used this coupling reagent to synthesize many of our 
compounds (Scheme 10, page 76). However, we also synthesized another Boc-protected 
amide TU-012 (L-97) 49 using a different method
(61)
 and we obtained more amides by Boc-
deprotection followed by reductive amination (Scheme 4, page 40).  
TU-011 (L-7) 43 was reacted with 4-amino-1-Boc-piperidine at 90 °C for 36 hours and TU-
012 (L-97) 49 was obtained with a yield of 81%.  
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The 
1
H NMR spectrum of TU-012 (L-97) 49 (Figure 38) is quite complex and the protons of 
the piperidine ring cannot be easily assigned because of the different but very close chemical 
shift values of the axial and  equatorial hydrogen nuclei as well as their complex splitting 
patterns. The peak of the protons of the tert-butyl group are at 1.45 ppm, the peaks of the 
methoxy groups are at 3.82 ppm and 3.91 ppm and the protons (3’’-H and 5’’-H) of the ring 
substituted with methoxy groups are doublets at 6.27 ppm and 6.47 ppm with a meta-
coupling constant of J = 2.24 Hz. The peak of the amide proton is at 6.68 ppm and the peak 
of the proton of the isoxazole ring is at 6.92 ppm. The peaks of the protons (2’’’-H and 6’’’-
H, 3’’’-H and 5’’’-H) of the ring substituted with the nitro group are at 6.97 ppm and 8.18 
ppm. The peaks corresponding to the protons of the piperidine ring are at 1.39 ppm, 1.95 
ppm, 2.88 ppm and 4.06 ppm.  
 
 
Figure 38: 
1
H NMR spectrum of TU-012 (L-97) 49 in CDCl3 
 
The 
13
C NMR spectrum of TU-012 (L-97) 49 (Figure 39) is complex and some of the peaks 
could not be unambiguously assigned from the HSQC spectrum (Figure 40), for example in 
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the overlapping peaks of the carbon nuclei 2-C and 6-C at 42.9 ppm. Due to this overlap, the 
protons of the piperidine ring could also not be unambiguously assigned.  
 
 
Figure 39: 
13
C NMR spectrum of TU-012 (L-97) 49 in CDCl3 
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Figure 40: HSQC spectrum of TU-012 (L-97) 49 
 
The mass of TU-012 (L-97) 49 was confirmed by HRMS (ESI) analysis. The mass of 
[M+H]
+
  is m/z =569.2248) as compared to the experimental mass m/z = 569.2250 (Figure 
41).  
 
Figure 41: HRMS (ESI) spectrum of TU-012 (L-97) 49 
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The method used to prepare TU-012 (L-97) 49 did not work well for the preparation of TU-
013 (L-98) 57. When we tried to prepare TU-013 (L-98) 57 from TU-011 (L-7) 43 by heating 
the mixture at 90 °C with piperidine, we obtained a very low yield (9%) of TU-013 (L-98) 
57, and we had to change the method. We first prepared TU-014 (L-99) 58 from TU-011 (L-
7) 43 and from TU-014 (L-99) 58 we prepared TU-013 (L-98) 57.  
TU-014 (L-99) 58 was prepared by saponification of TU-011 (L-7) 43 followed by 
neutralization of the base by HCl, giving the desired product in a yield of 75%.  
 
 
  
The 
1
H NMR spectrum of TU-014 (L-99) 58 has two singlets corresponding to the protons of 
the methoxy groups at 3.87 ppm and 3.95 ppm, the signals of 3’-H and 5’-H of the ring 
substituted by the methoxy groups are doublets at 6.57 ppm and 6.77 ppm and the singlet at 
6.88 ppm represents the proton of the isoxazole ring. The doublets at 7.15 ppm and 8.25 ppm 
correspond to the protons ( 2’’-H and 6’’-H, 3’’-H and 5’’-H) of the nitro-substituted ring.  
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Figure 42: 1H NMR spectrum of TU-014 (L-99) 58 in DMSO-d6 (deuterated dimethyl 
sulfoxide) 
 
The 
13
C NMR spectrum of TU-014 (L-99) 58 (Figure 43) has peaks corresponding to the 
carbon nuclei of the methoxy groups at 57.0 ppm and 57.5 ppm. The remaining peaks 
between 90 ppm and 170 ppm correspond to the aromatic carbon nuclei and one of them 
correspond to the carbonyl carbon nucleus of the carboxylic acid group.  
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Figure 43: 
13
C NMR spectrum of TU-014 (L-99) 58 in DMSO-d6 
 
The mass of TU-014 (L-99) 58 was confirmed by HRMS (ESI) analysis. The calculated mass 
of [M+H]
+
 is m/z = 387.0828 as compared to the experimentally obtained mass m/z = 
387.0820 (Figure 44).  
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Figure 44: HRMS (ESI) spectrum of TU-014 (L-99) 58 
 
The preparation of TU-013 (L-98) 57 from TU-014 (L-99) 58 gave us a better yield (67%). It 
was prepared by reacting TU-014 (L-99) 58 with piperidine in the presence of the coupling 
agent N,N,N’,N’-tetramethyl-o-(benzotriazol-1-yl) uronium tetrafluoroborate (TBTU). The 
reaction was done in N,N-dimethylacetamide (DMA) and N,N-diisopropylethylamine 
(DIPEA) was used as the base.  
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In the 
1
H NMR spectrum of TU-013 (L-98) 57 (Figure 45), the singlets corresponding to the 
protons of the methoxy groups are at 3.82 ppm and 3.90 ppm. The peaks at 1.55 ppm, 1.65 
ppm, 3.61 ppm and 3.68 ppm represent the protons of the piperidine ring. The doublets at 
6.28 ppm and 6.47 ppm represent the protons 3’’-H and 5’’-H of the ring substituted by the 
methoxy groups. The singlet at 6.72 ppm represent the proton of the isoxazole ring whereas 
the multiplets at 7.00 ppm and 8.16 ppm represent the protons (2’’’-H and 6’’’-H, 3’’’-H and 
5’’’-H) of the nitro-substituted ring.  
 
71 
 
 
Figure 45: 
1
H NMR spectrum of TU-013 (L-98) 57 
 
The 
13
C NMR spectrum of TU-013 (L-98) 57 (Figure 46) has the peaks at 24.5 ppm, 25.6 
ppm, 26.6 ppm, 43.6 ppm and 48.1 ppm corresponding to the carbon nuclei of the piperidine 
ring. The peaks at 55.8 ppm and 56.2 ppm represent the carbon nuclei of the methoxy groups 
and the remaining peaks between 90 ppm and 170 ppm represent the carbon nuclei of the 
aromatic rings and the carbon nucleus of the amide group.  
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Figure 46: 
13
C NMR spectrum of TU-013 (L-98) 57 
 
The mass of TU-013 (L-98) 57 was confirmed by HRMS (ESI). The calculated mass of 
[M+H]
+
 is m/z = 454.1614) and the experimentally obtained mass is m/z = 454.1624 (Figure 
47).  
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Figure 47: HRMS (ESI) spectrum of TU-013 (L-98) 57  
 
TU-015 (L-100) 59, TU-016 (L-14) 60 and TU-017 (L-102) 61 were all prepared following 
the same method as the one used to prepare TU-013 (L-98) 57 from TU-014 (L-99) 58 
(Scheme 10, page 76). The only difference is that for each of these compounds a different 
amine  was used.  
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Scheme 10: Synthesis of analogues of NMS-E973 (L-1) 38 with the use of a coupling agent 
(TBTU) 
 
TU-015 (L-100) 59 was prepared using TU-014 (L-99) 58 and 2-(4-methylpiperazin-1-yl) 
ethanamine. A yield of 65% for the desired product was obtained.  
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In the 
1
H NMR spectrum (Figure 48) of TU-015 (L-100) 59, the peak of the protons of the 
methyl group attached to the piperazine ring is at 2.29 ppm. The peaks of the protons of the 
piperazine ring are at 2.55 ppm and they partially overlap with a triplet corresponding to the 
protons of the methylene group attached to the piperazine ring. The peak of the second 
methylene group (1’-CH2-) is a quartet at 3.50 ppm due to coupling with the protons of the 
other methylene (2’-CH2-) group and to the proton of the amide group. This is supported by 
the COSY spectrum (Figure 50). The peaks of the protons of the two methoxy groups are at 
3.82 ppm and 3.91 ppm. The doublets at 6.27 ppm and 6.47 ppm represent the protons of the 
aromatic ring substituted by the methoxy groups and the peak at 6.91 ppm represents the 
proton of the isoxazole ring. The signal of the amide proton is at 7.23 ppm. The doublets at 
7.01 ppm and 8.18 ppm represent the protons of the nitro-substituted aromatic ring.  
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Figure 48: 1H NMR spectrum of TU-015 (L-100) 59 
 
The 
13
C NMR spectrum (Figure 49) of TU-015 (L-100) 59 is complex and peaks cannot 
easily be assigned without using the HSQC spectrum (Figure 51).  
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Figure 49: 
13
C NMR spectrum of TU-015 (L-100) 59 
 
 
Figure 50: COSY spectrum of TU-015 (L-100) 59 
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The DEPT-135 spectrum was used on the F1 axis in place of the 
13
C spectrum (Figure 49) on 
the HSQC spectrum (Figure 51) in order to better differentiate between the carbon nuclei of 
the methoxy groups and those of the methylene group that overlaps with them in the 
13
C 
spectrum. The cross peak (2.55 ppm, 56.72 ppm) correlates the protons of the methylene (2’-
CH2-) with the carbon nucleus that they are attached to and differentiate it from the carbon 
nuclei of the methoxy groups with cross-peaks at (3.82 ppm, 56.11 ppm) and (3.91 ppm, 
56.56 ppm).  
 
 
Figure 51: HSQC spectrum of TU-015 (L-100) 59 
 
The results of HRMS (ESI) indicate that the calculated mass of [M+H]
+
 is m/z = 512.2145 as 
compared to the experimentally obtained mass m/z = 512.2152 (Figure 52).  
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Figure 52: HRMS (ESI) spectrum of TU-015 (L-100) 59 
 
TU-016 60 was prepared from TU-014 (L-99) 58 and 1-methyl-4-piperidinamine and a yield 
of 57% was obtained.  
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The 
1
H NMR spectrum of TU-016 60 (Figure 53) has a peak at 2.28 ppm corresponding to 
the methyl group (1’-CH3) connected to the piperidine ring. The peaks of the methoxy groups 
are at 3.82 ppm and 3.90 ppm and the peaks of the protons of the piperidine ring are at 1.57 
ppm, 1.98 ppm, 2.12 ppm, 2.79 ppm and 3.90 ppm. The peak at 3.90 ppm overlaps with the 
peak of one of the methoxy groups. The doublets at 6.27 ppm and 6.47 ppm represent the 
protons of the ring substituted with methoxy groups whereas the doublet at 6.68 ppm 
represents the amide proton. The singlet at 6.91 ppm represents the proton of the isoxazole 
ring and the two sets of doublets at 6.99 ppm and 8.17 ppm represent the two sets of 
equivalent protons of the aromatic ring with the nitro group.  
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Figure 53: 
1
H NMR spectrum of TU-016 (L-14) 60 
 
The peaks of the carbon nuclei of the piperidine ring in the 
13
C NMR spectrum (Figure 54) 
are at 31.9 ppm, 46.1 ppm and 54.3 ppm whereas those of the methoxy groups are at 55.8 
ppm and 56.2 ppm. The peaks of the aromatic and the amide carbon nuclei are in the range of 
90 ppm – 170 ppm.  
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Figure 54: 
13
C NMR spectrum of TU-016 (L-14) 60 
 
HRMS (ESI) of TU-016 (L-14) 60 indicates that the calculated mass of [M+H]
+
 is m/z = 
483.1880 as compared to the experimentally obtained mass m/z = 483.1879 (Figure 55). 
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Figure 55: HRMS (ESI) NMR spectrum of TU-016 (L-14) 60 
 
TU-017 (L-102) 61 was prepared from TU-014 (L-99) 58 and 4-amino-1, 2, 2, 6, 6-
pentamethylpiperidine with a yield of 57%.  
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The 
1
H NMR spectrum of TU-017 (L-102) 61 (Figure 56) has a singlet at 2.27 ppm that 
represents the protons of the methyl group (1’-CH3) connected to the nitrogen atom of the 
piperidine ring. The multiplet at 1.14 ppm with an integral of 12 protons represents the 
remaining four methyl (2’-(CH3)2 and 6’-(CH3)2) substituents of the piperidine ring.  
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Figure 56: 
1
H NMR spectrum of TU-017 (L-102) 61 
 
The multiplets at 1.39 ppm, 1.85 ppm and 4.29 ppm represent the protons of the piperidine 
ring. The singlets at 3.83 ppm and 3.91 ppm represent the protons of the methoxy groups. 
The signals of the protons attached to the same aromatic ring as the methoxy groups are 
doublets at 6.28 ppm and 6.47 ppm. The doublet at 6.58 ppm represents the proton (CONH) 
of the amide group. It is coupled to the neighbouring proton (4’-H) of the piperidine ring. The 
singlet at 6.89 ppm corresponds to the proton of the isoxazole ring whereas the multiplets at 
6.99 ppm and 8.17 ppm represent the protons of the aromatic ring with the nitro substituent.   
The interpretation of the 
13
C NMR of TU-017 (L-102) 61 (Figure 57) is complicated by the 
low intensity of the signals of the carbon nuclei of the piperidine ring. The signals of the 
carbon nuclei of methoxy groups at 55.8 ppm and 56.2 ppm have clear cross peaks with their 
corresponding protons on the HSQC (Figure 58). The peak at 55.2 ppm which represents the 
tetra-substituted carbon nuclei of the piperidine ring is practically invisible in the 
13
C NMR. 
Their presence was confirmed by cross peaks between the proton signals of the protons of the 
methyl group (1’-CH3) attached to the nitrogen atom of the piperidine ring and the 
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overlapping signals of the carbon nuclei of the piperidine ring on  the HMBC spectrum 
(Figure 59).  
 
 
Figure 57: 
13
C NMR spectrum of TU-017 (L-102) 61 
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Figure 58: HSQC spectrum of TU-017 (L-102) 61 
 
 
Figure 59: HMBC spectrum of TU-017 (L-102) 61 
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HRMS (ESI) analysis of TU-017 (L-102) 61 indicates that the calculated mass of [M+H]
+
 is 
m/z = 539.2506 as compared to the experimentally obtained mass m/z =539.2520 (Figure 
60). 
 
 
Figure 60: HRMS (ESI) spectrum of TU-017 (L-102) 61 
 
TU-018 (L-103) 50 was prepared by Boc-deprotection of TU-012 (L-97) 49 with HCl in 
dioxane (Scheme 4) with a yield of 89%.  
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The 
1
H NMR spectrum of TU-018 (L-103) 50 (Figure 61) has peaks representing the protons 
of the piepridine ring at 1.40 ppm, 1.98 ppm, 2.71 ppm, 3.08 ppm and 4.02 ppm. The peaks at 
3.82 ppm and 3.91 ppm represent the protons of the methoxy groups. The peaks of the 
aromatic protons of the ring substituted by the methoxy groups are doublets at 6.27 ppm and 
6.47 ppm and the peak of the amide proton is a doublet at 6.70 ppm because it couples the 
neighbouring proton of the piperidine ring. The singlet at 6.92 ppm represents the proton of 
the isoxazole ring and the multiplets at 6.99 ppm and 8.17 ppm represent the protons of the 
nitro-substituted aromatic ring.   
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Figure 61: 1H NMR spectrum of TU-018 (L-103) 50 
 
The 
13
C NMR spectrum of TU-018 (L-103) 50 (Figure 62) has the peaks  representing the 
carbon nuclei of the methoxy groups at 55.8 ppm and 56.2 ppm. The peaks at 33.2 ppm, 45.3 
ppm and 47.0 ppm represent the carbon nuclei of the piperidine ring. The peak of the carbon 
nucelus of the amide functional group is identified by analysis of the HMBC spectrum 
(Figure 63). In the HMCB spectrum, a cross-peak (6.70 ppm, 158.20 ppm) is observed 
between the signal of the amide proton and the nucleus of the carbonyl carbon. Another cross 
peak (6.92 ppm, 158.27 ppm) shows the coupling of the proton of the isoxazole ring with one 
of the neighbouring carbon nuclei (3-C). The rest of the peaks between 90 ppm and 170 ppm 
represent the carbon nuclei of the different aromatic rings(including the isoxazole).  
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Figure 62: 
13
C NMR spectrum of TU-018 (L-103) 50 
 
 
Figure 63: HMBC spectrum of TU-018 (L-103) 50 
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HRMS (ESI) analysis of TU-018 (L-103) 50 indicates that the calculated mass of [M+H]
+
  
m/z = 469.1723 as compared to the experimentally obtained mass m/z = 469.1732 (Figure 
64).  
 
 
Figure 64: HRMS (ESI) spectrum of TU-018 (L-103) 50 
 
TU-019 (L-104) 51 was prepared with a 5% yield by reductive amination of TU-018 (L-103) 
50 with acetone in the presence of sodium triacetoxyborohydride. The reaction was not 
optimized due to time constraints.  
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The peaks of the protons of the methoxy groups of TU-019 (L-104) 51 are at 3.82 ppm and 
3.90 ppm and the protons of the two equivalent methyl groups of the isopropyl substituent of 
the piperidine ring are represented by a doublet at 1.27 ppm because they couple with the 
neighbouring proton (1’’-H). The signal of proton 1’’-H is distinguished from the signal of 
proton 4’-H by the relevant cross peaks on the COSY spectrum (Figure 66). The signal of 
proton 4’-H at 4.08 ppm has a cross peak with the signal of the amide proton (CONH) and 
the signal of proton 1’’-H at 3.24 ppm has a cross peak with the signal of the methyl groups 
of the isopropyl substituent. The peaks at 2.12 ppm, 2.67 ppm and 3.24 ppm also represent 
the protons of the piperidine ring.  
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Figure 65: 1H NMR spectrum of TU-019 (L-104) 51 
 
Figure 66: COSY spectrum of TU-019 (L-104) 51 
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The doublets at 6.26 ppm and 6.46 ppm represent the protons of the methoxy substituted 
aromatic ring and the doublet at 7.03 ppm represents the proton of the amide group coupled 
with H-4’ of the piperidine ring. The singlet at 6.88 ppm represents the proton of the 
isoxazole ring. The doublets at 6.99 ppm and 8.17 ppm represent the two sets of equivalent 
protons of the aromatic ring with the nitro substituent.  
 
Figure 67: 
13
C NMR spectrum of TU-019 (L-104) 51 
 
The 
13
C NMR spectrum of TU-019 (L-104) 51 (Figure 66) has the peaks representing the 
carbon nuclei of the methoxy groups at 55.8 ppm and 56.2 ppm. The peaks at 17.2 ppm and 
56.4 ppm represent the carbon nuclei of the methyl groups (2’’-C and 3’’-C) and the tri-
substituted carbon nucleus (1’’-C) of the isopropyl substituent respectively. The signals of the 
aromatic ring carbon nuclei and the carbonyl carbon nucleus (158.8 ppm) are in the interval 
spanning 90 ppm to 170 ppm. 
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The HRMS (ESI) analysis of TU-019 (L-104) 51 indicates that the calculated mass of 
[M+H]
+
  (m/z = 511.2193) is similar to the experimentally obtained mass (m/z = 511.2191) 
(Figure 68).  
 
 
Figure 68: HRMS (ESI) spectrum of TU-019 (L-104) 51 
 
NOESY experiments of a number of the compounds in this study yielded information with 
regards to the spatial orientation of the methoxy groups attached to the aromatic ring. Nuclei 
that are within a certain distance from each other in space have cross peaks on a NOESY 
spectrum. For example, the signal of the aromatic proton 3’’’-H of TU-019 (L-104) 51 has a 
cross-peak with the signal of the protons of the methoxy group 2’’’-OCH3. Likewise, the 
signal of the aromatic proton 5’’’-H has a cross peak with the signal of the protons of the 
methoxy group 4’’’-OCH3. 
The preparation of different dimethyl ether resorcinol analogues of NMS-E973 (L-1) 38 from 
their precursor TU-014 (L-99) 58 has been a straightforward process and afforded higher 
yields than preparing them through reductive amination because reductive amination has an 
additional step and this results in a lower overal yield.  
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2.2.6. Demethylation of aryl methyl ethers  
The methyl group is widely considered an excellent protecting group for phenols in organic 
synthesis.
(112)
  This is mainly due to the stability of the resulting ether bond.
(112)
 The 
disadvantage is that in the past harsh conditions such as the use of concentrated HBr at high 
temperatures were required in order to liberate phenol
(83)
. The yields obtained using the 
system HBr/acetic acid varied between 49% and 90%.
(113)
   Hydriodic acid or hydroiodic acid 
(HI) in acetic acid in the presence of red phosphorous has been also reported to demethylate 
aryl methyl ethers by refluxing the mixture but the yield obtained was low (49 %).
(114)
 
However, a milder method using hydroiodic acid produced in situ from iodocyclohexane in 
DMF under argon and at reflux gave generally high yields (88 % - 95 %) with relatively short 
reaction times (2.5 – 14 h).(115)  However, HBr is usually preferred to HI due to the fact that 
HBr is less prone to producing side reactions.
(83)
 Many other methods which use less severe 
conditions have been reported but have various disadvantages. Although less harsh, the use of 
BBr3 requires long reaction times,  and the yields (29 % - 70 %) are low due to incomplete 
reactions and  the laborious reaction work-up.(61,72,116) BCl3 has also been used for the 
selective deprotection of the less hindered methoxy when two methoxy groups are 
present.
(116) 
However, this reaction has a very long reaction time (10 days).
(116)
 
Dimethylboron bromide (Me2BBr) is another Lewis acid used to cleave aryl methyl ethers 
and it is a versatile reagent which can also cleave even aliphatic and cyclic ethers.
(117)
 BF3, 
AlCl3 and AlBr3 alone or in combination with NaI also constitute good aryl methyl ether 
demethylating agents.
(118)
 In the case of Lewis acids, the departure of the methoxy or alkoxy 
in general is supported by complex formation with the Lewis acid.
(83)
  
 
 
Scheme 11: Ether cleavage with Me2BBr
(117)
 
Apart from Lewis acids, lithium salts have also been used in ether cleavage. Lithium iodide 
(LiI) refluxed with collidine was reported to cleave aryl alkyl ethers in general
(119-121)
 while 
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lithium chloride (LiCl) in boilig DMF has been used to selectively cleave alkyl aryl ethers 
activated with electron-withdrawing groups such as nitro, halogens, aldehydic and ester 
carbonyl groups in ortho- or para- positions with respect to the alkoxy group.
(120)
  In both 
cases the reactions tended to be slow and required high temperatures.
(119,120)
  
Another method
 
 which uses sodium ethanethiolate (EtSNa) in DMF at reflux temperatures 
give excellent yields (94 % and higher) in a relatively short time (3 hours) when compared to 
other methods found in the literature and is widely used.
(122)
 Aryl alkyl ethers have also been 
cleaved by alkali metal thiophenoxide (PheS
-
) at 190 °C giving good yields (70 % - 90 %) in 
a short time (10 min – 30 min).(122) In spite of the stated benefits of this method, it has a 
disadvantage that N-methyl-2-pyrrolidone and hexamethylphosphoramide which are the best 
solvents used in this method have been reported to be teratogenic and carcinogenic 
respectively,
(123-125)
 although other authors argue that N-methyl-2-pyrrolidone is no different 
from other solvents, that its toxicity is acute and that the benefits obtained from using it as a 
solvent outweigh its perceived toxicity.
(126,127)
 Although thiolates in general are popular 
amongst the methods used to cleave aryl methyl ethers, if the compound contains other 
functionalities, the choice of the thiolate and the solvent to use must be carefully considered. 
Thiolates can displace the nitro group  and halogen substituents.
(128,129)
 In addition, thiolates 
also reduce nitro groups to the corresponding amines.
(128)
 However, it was observed that 
catalytic potassium thiophenoxide (PheSK) generated in situ from PheSH and K2CO3 could 
selectively cleave the aryl methyl ether bond without affecting other functionalities present in 
the compound.
(122)
 Sodium trimethylsilanethiolate (Me3SiSNa) and hexamethyldisilathiane 
(Me3SiSSiMe3) were found to be good demethylating agents for the removal of two methoxy 
groups from aryl methyl ethers under alkaline conditions. Me3SiSNa gave yields of 86 % – 
92 % while Me3SiSSiMe3 gave yields of 72 % – 75 %. 
(130) 
 
 
Scheme 12:  Ester cleavage with nucleophiles 
(131)
  
 
In our study, we sought to demethylate TU-011 (L-7) 43 with PhSK
(122)
 generated in situ 
from PhSOH and K2CO3 as this method
(122)
 appeared to be the quickest and most promising 
in terms of yield. Unfortunately, the reaction did not yield the desired product. We then tried 
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to demethylate TU-012 (L-97) 49 using HBr in acetic acid (6.5% weight/volume)
(113)
. 
However instead of obtaining the desired product, we rather obtained the compound TU-018 
(L-103) 50 which resulted from Boc-deprotection of TU-012 (L-97) 49 instead of 
demethylation. Taking into consideration that demethylated analogues of NMS-E973 (L-1) 
38 would share the antiplasmodial pharmacophore with their dimethyl ether resorcinol 
analogues, we rather pursued the dimethyl ether resorcinol analogues  due to their ease of 
synthesis, the constraint of time and the inadequate quantities of starting materials for the 
demethylation studies.  We expected both the dimethyl ether resorcinol analogues and the 
demethylated analogues to possess the antiplasmodial activity, and for this reason we first 
sought to demonstrate that the dimethyl ether resorcinol analogues possessed that activity so 
that future researchers can further optimize these molecules by demethylation. Therefore, we 
synthesized the dimethyl ether resorcinol analogues and tested them for their biological 
activity.  
 
2.3. Cell-based assays  
After synthesis of the NMS-E973 (L-1) 38 analogues, they were sent for bioassays in the 
Biossay, Parasite and Tissue Culture Laboratory at Rhodes University. They were assayed for 
their antiplasmodial activity and their cytotoxicity. 
 
2.3.1. PLDH (Plasmodium lactate dehydrogenase) (Malaria) assay 
The compounds were incubated with P. falciparum (strain 3D7) cells for 48 hours in a 37 °C 
CO2 incubator. Afterwards, the % cell viability of the parasite was assessed in relation to the 
varying concentrations of each compound. (Table 5) Chloroquine 12 was used as a standard 
drug and its IC50 value was expected in the range 0.01 M – 0.05 M.  
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Table 5: Percentage (%) cell viability relative to the varying concentrations of the test 
compounds (PLDH assay) 
  TU-007 (L-96) 
55 
TU-011 (L-7) 
43 
TU-012 (L-97) 
49 
TU-013 (L-98) 
57 
Conc 
(µM) 
Log(Conc) %Viab SD %Viab SD %Viab SD %Viab SD 
100 2 94.58 9.23 97.66 7.83 99.50 1.63 90.81 7.62 
25 1.39 105.69 0.15 95.14 2.80 105.65 0.75 93.48 9.54 
6.25 0.79 107.05 8.07 113.05 13.16 117.77 7.25 114.25 2.16 
1.56 0.19 122.55 2.63 116.58 10.15 125.51 1.23 122.12 8.68 
0.39 -0.408 109.58 10.1 115.76 5.97 116.43 1.55 108.86 1.39 
0.097 -1.01 105.42 7.57 110.02 8.97 113.73 10.65 113.05 5.06 
0.024 -1.6 103.57 0.62 109.03 15.04 119.08 16.49 117.85 5.00 
0.0061 -2.21 104.60 7.25 107.40 12.80 118.03 8.79 118.81 15.98 
 
 
Table 5 (continued): Percentage (%) cell viability relative to the varying concentrations 
of the test compounds (PLDH assay) 
  TU-014 (L-
99) 58 
TU-015 (L-100) 
59 
TU-016 (L-14) 
60 
TU-017 (L-
102) 61 
Conc 
(µM) 
Log(Conc) %Viab SD %Viab SD %Viab SD %Viab SD 
100 2 84.79 11.20 15.52 1.00 79.39 3.59 36.80 7.08 
25 1.39 113.69 3.35 19.45 2.88 111.14 2.37 32.67 0.40 
6.25 0.79 114.66 7.92 98.94 3.62 120.25 5.71 44.44 1.30 
1.56 0.19 108.59 6.40 112.27 6.02 115.22 8.97 121.25 8.29 
0.39 -0.408 106.47 8.38 111.09 5.51 119.76 14.46 123.77 9.56 
0.097 -1.01 107.04 0.06 126.24 6.10 124.06 22.25 137.91 4.59 
0.024 -1.6 114.52 12.36 137.57 23.26 131.36 22.36 134.01 6.79 
0.0061 -2.21 106.22 0.21 145.11 4.17 128.49 22.81 130.11 12.83 
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Table 5 (continued): Percentage (%) cell viability relative to the varying concentrations 
of the test compounds (PLDH assay) 
  TU-018 (L-
103) 50 
TU-019 (L-104) 
51 
Chloroquine 12 
Conc 
(µM) 
Log(Conc) %Viab SD %Viab SD %Viab 
100 2 48.75 1.79 43.61 5.63 -5.160526 
25 1.39 37.51 1.58 49.72 9.29 -3.759966 
6.25 0.79 34.46 2.70 81.77 16.16 0.3770739 
1.56 0.19 116.98 12.78 120.35 11.91 -6.60418 
0.39 -0.408 118.15 6.29 119.52 16.05 54.374057 
0.097 -1.01 124.73 11.86 122.31 16.00 97.080371 
0.024 -1.6 137.93 13.94 134.36 19.85 107.07822 
0.0061 -2.21 136.14 11.19 152.56 15.78 100.1616 
 
The IC50 values (Table 6) were deduced from the dose-response plots (Figure 69 and Figure 
70) of the % viability of the parasites versus the logarithm of the concentrations of the 
compounds used.  
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Figure 69: Dose-response plot of the % viability of P. falciparum (3D7) in the presence 
of TU-007 (L-96) 55, TU-011 (L-7) 43, TU-012 (L-97) 49, TU-013 (L-98) 57, TU-014 (L-
99) 58 and chloroquine 12 
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Figure 70: Dose-response plot of the % viability of P. falciparum (3D7) in the presence 
of TU-015 (L-100) 59, TU-016 (L-14) 60, TU-017 (L-102) 61, TU-018 (L-103) 50, TU-019 
(L-104) 51 and chloroquine 12 
 
The IC50 values obtained show that the compounds TU-015 (L-100) 59, TU-017 (L-102) 61, 
TU-018 (L-103) 50 and TU-019 (L-104) 51 have IC50 values in the range of 1 M to 10 M. 
The rest of the compounds are not toxic to the parasite at 100 M. The most active compound 
is TU-018 (L-103) 50 which has an IC50 value of approximately 1.830 M. This IC50 value is 
172 times higher than the one (IC50 = 0.01062 M) obtained from the standard drug 
chloroquine.  
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Table 6: IC50 of the compounds tested by the PLDH assay 
Compound IC50 
(µM) 
TU-007 (L-96) 55 Not toxic at 100 M 
TU-011 (L-7) 43 Not toxic at 100 M 
TU-012 (L-97) 49 Not toxic at 100 M 
TU-013 (L-98) 57 Not toxic at 100 M 
TU-014 (L-99) 58 Not toxic at 100 M 
TU-015 (L-100) 59 9.343 M 
TU-016 (L-14) 60 Not toxic at 100 M 
TU-017 (L-102) 61 3.089 M 
TU-018 (L-103) 50 ~ 1.830 M 
TU-019 (L-104) 51 6.189 M 
Chloroquine 12 0.01062 
 
IC50 values were not calculated for compounds which were not toxic to  the parasite at 100 
M since no curve could be drawn.  
 
2.3.2. Cell cytotoxicity assay  
The compounds were incubated with HeLa cells for 48 hours and then the percentage cell 
viability was determined using the resazurin reagent and reading the fluorescence. Emetine 
62, the apoptosis inducer drug,
(132,133)
 was used as the standard drug and its IC50 value was 
expected in the range 0.01 M – 0.05 M.  
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Table 7: Percentage (%) cell viability relative to the varying concentrations of the test 
compounds (cell cytotoxicity assay) 
  TU-007 (L-
96) 55 
TU-011 (L-7) 
43 
TU-012 (L-97) 49 TU-013 (L-
98) 57 
Conc 
(µM) 
Log(Conc) %Viab SD %Viab SD %Viab SD %Viab SD 
100 2 110.26 9.69 100.33 8.70 108.88 0.70 106.36 12.36 
25 1.39 125.23 8.33 102.77 4.56 102.64 7.59 110.64 5.41 
6.25 0.79 123.42 3.92 103.63 14.48 96.59 2.33 114.92 31.98 
1.56 0.19 117.97 5.27 98.88 1.81 104.17 7.27 99.46 1.61 
0.39 -0.408 114.44 8.07 100.43 0.42 97.98 8.51 99.71 5.14 
0.097 -1.01 105.06 5.21 103.31 0.29 97.19 2.98 99.14 8.85 
0.024 -1.6 102.81 2.97 91.26 9.97 100.49 22.02 99.16 10.28 
0.0061 -2.21 114.81 4.72 108.14 0.00 106.99 3.07 101.92 2.85 
 
Table 7 (continued): Percentage (%) cell viability relative to the varying concentrations 
of the test compounds (cell cytotoxicity assay) 
  TU-014 (L-
99) 58 
TU-015 (L-
100) 59 
TU-016 (L-14) 60 TU-017 (L-
102) 61 
Conc 
(µM) 
Log(Conc) %Viab SD %Viab SD %Viab SD %Viab SD 
100 2 69.25 2.41 78.18 7.66 107.62 6.08 27.08 0.41 
25 1.39 95.14 6.71 110.12 5.30 98.82 11.82 84.86 9.78 
6.25 0.79 92.59 1.31 126.77 2.92 111.52 19.56 110.66 7.96 
1.56 0.19 97.56 0.70 125.39 14.27 117.28 10.39 97.74 2.45 
0.39 -0.408 104.21 4.91 121.88 17.27 107.03 21.48 88.99 3.52 
0.097 -1.01 97.86 0.50 128.35 7.41 123.57 19.73 98.13 4.83 
0.024 -1.6 102.03 10.74 139.57 4.21 125.75 18.62 105.28 11.04 
0.0061 -2.21 97.38 3.55 130.81 15.68 106.94 2.49 106.71 0.80 
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Table 7 (continued): Percentage (%) cell viability relative to the varying concentrations 
of the test compounds (cell cytotoxicity assay) 
  TU-018 (L-
103) 50 
TU-019 (L-104) 
51 
Emetine 62 
Conc 
(µM) 
Log(Conc) %Viab SD %Viab SD %Viab SD 
100 2 -0.44 0.62 6.47 5.86 2.278003 0.890768 
25 1.39 45.92 51.67 109.32 0.23 8.670643 1.188506 
6.25 0.79 102.17 2.76 111.90 9.75 21.09511 2.892763 
1.56 0.19 96.71 6.64 104.00 12.90 62.16879 6.409259 
0.39 -0.408 100.28 21.64 109.99 7.95 123.1905 33.12945 
0.097 -1.01 100.03 4.96 112.69 6.08 125.8574 11.37702 
0.024 -1.6 98.34 0.56 106.98 4.90 112.3763 20.28484 
0.0061 -2.21 99.01 6.61 95.60 0.87 113.67 5.664351 
 
The results of the percentage (%) cell viability  were plotted against the logarithm of the 
concentrations of the compounds tested for cell cytotoxicity and the IC50 values of those 
compounds were deduced from the resulting dose-response graphs.  
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Figure 71: Dose-response plot of the % viability of HeLa cells in the presence of TU-007 
(L-96) 55, TU-011 (L-7) 43, TU-012 (L-97) 49, TU-013 (L-98) 57, TU-014 (L-99) 58 and 
emetine 62 
 
 
 
Figure 72: Dose-response plot of the % viability of HeLa cells (3D7) in the presence of 
TU-015 (L-100) 59, TU-016 (L-14) 60, TU-017 (L-102) 61, TU-018 (L-103) 50, TU-019 
(L-104) 51 and emetine 62. 
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The analysis of the IC50 values obtained shows that most of our compounds were not 
cytotoxic at 100 M and that only compounds TU-014 (L-99) 58, TU-017 (L-102) 61, TU-
018 (L-103) 50 and TU-019 (L-104) 51 were toxic at concentrations of 25 M and higher. 
This means that the IC50 values of our compounds for cell cytotoxicity are at least 251 times 
higher than the IC50 value of emetine 62.  
 
Table 8: IC50 of the compounds tested for cell cytotoxicity 
Compound IC50 
(µM) 
TU-007 (L-96) 55 Not Cytotoxic at 100 µM 
TU-011 (L-7) 43 Not Cytotoxic at 100 µM 
TU-012 (L-97) 49 Not Cytotoxic at 100 µM 
TU-013 (L-98) 57 Not Cytotoxic at 100 µM 
TU-014 (L-99) 58 Cytotoxic at 25 µM and higher 
TU-015 (L-100) 59 Not Cytotoxic at 100 µM 
TU-016 (L-14) 60 Not Cytotoxic at 100 µM 
TU-017 (L-102) 61 ~ 28.49 
TU-018 (L-103) 50 ~ 24.78 
TU-019 (L-104) 51 Cytotoxic above 25 µM 
Emetine 62 0.09948  
 
2.4. Conclusion and recommendations   
Our results show that the compounds TU-015 (L-100) 59, TU-017 (L-102) 61, TU-018 (L-
103) 50 and TU-019 (L-104) 51 are active against the P. falciparum strain 3D7. Their activity 
is not related to their general toxicity since they are cytotoxic to HeLa cells only at 
concentration above 25 M whereas their IC50 values for the anti-plasmodial activity vary 
between 1 and 10 M. Although, these compounds are not as active as the standard drug 
chloroquine 12, they are worth further optimization since our preliminary results suggest that 
they would be generally safe, which also corroborates the previous findings.
(61)
 Moreover, 
these compounds are important because they represent novel scaffolds in the anti-malarial 
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area. PfHsp90 is also a novel anti-plasmodial target and more research is needed in order to 
confirm it as a drug target. 
Our docking results suggest that demethylated analogues of our compounds will be more 
active than their dimethyl ether resorcinol analogue counterparts. In addition, the 
demethylated compounds will more likely selectively bind to PfHsp90 in the presence of 
Hsp90. However, results obtained by docking studies are approximations and should not be 
interpreted as if they corresponded exactly to the experimental values.  It is also important for 
future researchers to assess whether the anti-plasmodial activity of these compounds was 
specifically mediated by PfHsp90 inhibition since in our case we only tested the growth 
inhibitory anti-plasmodial activity and not specifically the PfHsp90 inhibition.  
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Chapter Three: Experimental 
3.1. Organic synthesis  
The reagents used during our synthesis were of reagent grade while the solvents used for 
column chromatography were of technical grade and both were purchased from Sigma-
Aldrich unless stated otherwise. We collected NMR data of our compounds using either the 
Bruker 300 MHz Nuclear Magnetic Resonance Spectrometer or the Bruker 400 MHz Nuclear 
Magnetic Resonance Spectrometer or a Bruker Avance III 600 MHz Nuclear Magnetic 
Resonance Spectrometer. Mass Spectrometry data were collected using a Waters Synapt G2 
instrument with ESI ionisation method.  
 
3.1.1. Synthesis of 1,3-dimethyl-5-(4-nitrophenoxy)benzene TU-001 46 
 
 
3,5-dimethylphenol (M.W.: 122.16 g.mol
-1
; 0.13 g; 1.06 mmol), 1-fluoro-4-nitrobenzene 
(M.W.: 141.10 g.mol
-1
; 0.15 g; 1.06 mmol), K2CO3 (M.W.: 138.21 g.mol
-1
; 0.22 g; 1.59 
mmol) and dimethyl sulfoxide (5 mL) were added to a 50 mL round-bottomed flask and 
stirred at 110 °C for 4 hours. After cooling down, the reaction mixture was diluted with ethyl 
acetate (20 mL) and then washed with brine (3  10 mL), dried with MgSO4, filtered and 
finally concentrated under reduced pressure to give a crude product. The crude was purified 
by column chromatography (hexane: ethyl acetate 98:2; L = 5 cm; D = 1.90 cm; silica gel 
0.040 – 0.063 mm) to obtain TU-001 46 as an amorphous white solid (0.25 g, 96%). Melting 
point = 68 °C - 70 C. The retention factor (Rf) of TU-001 46 in hexane/ethyl acetate 9:1 is 
0.44. 
1
H-NMR (400.13 MHz; 30.160 C; CDCl3)  ppm 2.33 (s, 6 H (1-CH3 and 3-CH3)), 
6.71 (s, 2 H (4-H and 6-H)), 6.89 (s, 1 H (2-H)), 7.00 (d, J = 9.09 Hz, 2 H (2’-H and 6’-H)), 
8.17 (d, J = 9.09 Hz, 2 H (3’-H and 5’-H)). 13C-NMR (100.61 MHz; 30.160 C; CDCl3)  
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ppm 21.2 (1-CH3 and 3-CH3), 117.0 (2’-C and 6’-C), 118.1 (4-C and 6-C), 125.8 (3’-C and 
5’-C), 127.1 (2-C), 140.3 (1-C and 3-C), 142.5 (4’-C), 154.7 (5-C), 163.6 (1’-C).  
 
3.1.2. Synthesis of 1-(4-(3,5-dimethylphenoxy)phenyl)ethanone TU-002 47 
 
 
 
3,5-dimethylphenol (M.W.: 122.16 g.mol
-1
; 0.13 g; 1.06 mmol), 1-(4-fluorophenyl)ethanone 
(M.W.: 138.14 g.mol
-1
; 0.15 g, 1.09 mmol) and K2CO3 (M.W.: 138.21 g.mol
-1
; 0.22 g; 1.59 
mmol) were dissolved in  dimethyl sulfoxide (5 mL) and stirred at 110
 C for 48 hours. After 
cooling down, the mixture was diluted with ethyl acetate (20 mL), washed with brine (10 mL 
 3) and dried over MgSO4. After filtration, the mixture was concentrated under reduced 
pressure to give a crude product. Purification of the crude was done by column flash 
chromatography (hexane: ethyl acetate 98: 2, L=15 cm; D = 2.0 cm, silica gel: 0.040 – 0.063 
mm) to give TU-002 47 as an amorphous white solid (0.15 g, 60%). Melting point = 67 °C – 
68
 C. The retention factor of TU-002 47 in hexane: ethyl acetate 9:1 is 0.26. 1H-NMR 
(600.03 MHz; 25.000 °C; CDCl3)  ppm 2.31 (s, 6 H (3’’-CH3 and 5’’-CH3)), 2.57 (s, 3 H (2-
CH3)), 6.68 (s, 2 H (2’’-H and 6’’-H)), 6.83 (s, 1 H (4’’-H)), 6.99 (m, 2 H (3’-H and 5’-H)), 
7.93 (m, 2 H (2’-H and 6’-H)). 13C-NMR (150.88 MHz; 25.000 °C; CDCl3)  ppm 21.3 (3’’-
CH3 and 5’’-CH3), 26.4 (2-C), 117.2 (3’-CH and 5’-CH), 117.8 (2’’-C and 6’’-C), 126.3 (4’’-
C), 130.5 (2’-C and 6’-C), 131.7 (1’-C), 140.0 (3’’-C), 155.4 (1’’-C), 162.2 (4’-C-O), 196.8 
(1-C=O). 
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3.1.3. Synthesis of 1-(2,4-dimethoxy-6-(4-nitrophenoxy)phenyl)ethanone TU-003 41 
 
 
1-(2-hydroxy-4,6-dimethoxyphenyl)ethanone (M.W.: 196.20 g.mol
-1
; 0.60 g; 3.06 mmol), 1-
fluoro-4-nitrobenzene (M.W.: 141.10 g.mol
-1
; 0.45 g; 3.19 mmol) and K2CO3 (M.W.: 138.21 
g.mol
-1
; 0.53 g; 3.83 mmol) were dissolved in dimethyl sulfoxide (10 mL) and stirred at 45
 
°C for 4 hours. After cooling down, the mixture was diluted with ethyl acetate (50 mL) and 
washed with brine (20 mL  3). The mixture was then dried with MgSO4, filtered and then 
concentrated under reduced pressure to give a crude product. The crude was purified by 
column chromatography (hexane/ethyl acetate 4: 1) to give TU-003 41 as a white solid (0.86 
g, 88%). The retention factor of TU-003 41 in hexane: ethyl acetate 1:1 is 0.50. Melting point 
= 64 °C - 66 °C. 
1
H-NMR (300.19 MHz; 20.500 °C; CDCl3)  ppm 2.43 (s, 3 H (2-CH3)), 
3.78 (s, 3 H (4’-OCH3)), 3.86 (s, 3 H (2’-OCH3)), 6.14 (d, J = 2.05 Hz, 1 H (5’-H)), 6.38 (d, J 
= 2.05 Hz, 1 H (3’-H)), 7.00 (m, 2 H (2’’-H and 6’’-H)), 8.19 (m, 2 H (3’’-H and 5’’-H)). 
13
C-NMR (75.48 MHz; 20.500 °C; CDCl3)  ppm 32.3 (2-C), 55.7 (4’-OCH3), 56.0 (2’-
OCH3), 96.0 (3’-C), 98.4 (5’-C), 117.0 (2’’-C and 6’’-C), 117.7 (1’-C), 125.9 (3’’-C and 5’’-
C), 142.8 (4’’-C), 153.0 (6’-C), 159.2 (2’-C), 162.6 (4’-C), 163.1 (1’’-C), 199.4 (1-C=O). 
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3.1.4. The synthesis of 1-(2-hydroxy-4,6-dimethoxyphenyl)-2-(4-nitrophenyl)ethanone 
TU-004 52 
 
 
 
1-(2-hydroxy-4,6-dimethoxyphenyl)ethanone (M.W.: 196.20 g.mol
-1
; 0.20 g; 1.02 mmol), 1-
fluoro-4-nitrobenzene (M.W.: 141.10 g.mol
-1
; 0.15 g; 1.06 mmol) and K2CO3 (M.W.: 138.21 
g.mol
-1
; 0.22 g; 1.59 mmol) were dissolved in dimethyl sulfoxide (5 mL) and stirred at 55
 
°C 
for 4 hours. After cooling down, the mixture was diluted with ethyl acetate (20 mL) and 
washed with brine (10 mL  3). The mixture was then dried with MgSO4, filtered and then 
concentrated under reduced pressure to give a crude product. The crude product was purified 
by column chromatography (hexane/ethyl acetate 4:1) to give TU-004 52 as a white solid 
(0.023 g, 7%). Melting point = 124 °C - 126 °C. 
1
H-NMR (300.19 MHz; 21.4 °C; CDCl3)  
ppm 3.83 (s, 3 H (4’-OCH3)), 3.86 (s, 3 H (6’-OCH3)), 4.43 (s, 2 H (2-H)), 5.94 (d, J = 2.35 
Hz, 1 H (5’-H)), 6.09 (d, J = 2.35 Hz, 1 H (3’-H)), 7.37 (m, 2 H (2’’-H and 6’’-H)), 8.19 (m, 
2 H (3’’-H and 5’’-H)), 13.65 (s, 1 H (2’-OH)). 13C-NMR (75.48 MHz; 20.500 °C; CDCl3)  
ppm 50.0 (2-C), 55.7 (4’-OCH3 and 6’-OCH3 ), 91.1 (5’-C), 93.8 (3’-C), 105.5 (1’-C), 123.5 
(3’’-C and 5’’-C), 130.5 (2’’-C and 6’’-C), 143.3 (1’’-C), 146.8 (4’’-C), 162.5 (6’-C), 166.7 
(4’-C), 168.0 (2’-C), 200.8 (1-C=O). 
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3.1.5. Synthesis of 1-(2,4-dimethoxy-6-((4-nitrobenzyl)oxy)phenyl)ethanone TU-005 54 
 
 
 
1-(2-hydroxy-4,6-dimethoxyphenyl)ethanone (M.W.: 196.20 g.mol
-1
; 0.49 g; 2.50 mmol) and 
1-(bromomethyl)-4-nitrobenzene (M.W.: 216.03 g.mol
-1
; 0.66 g; 3.06 mmol) were added to a 
25 mL round-bottomed flask. Then, K2CO3 (M.W.: 138.21 g.mol
-1
; 0.59 g; 4.27 mmol) was 
also added and the mixture was dissolved in acetonitrile (10 mL) and afterwards refluxed for 
6 hours. Then, it was cooled down, diluted with ethyl acetate (50 mL), washed with deionised 
water (10 mL  3) and then with brine (10 mL  2). The extract was further dried with 
MgSO4, and afterwards concentrated under reduced pressure to give a residue. After 
purification of the mixture by column flash chromatography (first hexane/ethyl acetate 4:1; L 
= 12 cm; D = 2.5 cm, then hexane/ethyl acetate1:1), the collected fractions were concentrated 
to give TU-005 54 as a white solid (0.23 g, 28%). Melting point = 133 °C – 135 °C.1H-NMR 
(300.19 MHz; 17.50 °C; CDCl3)  ppm 2.49 (s, 3 H (2-CH3)), 3.80 (s, 3 H (4’-OCH3)), 3.81 
(s, 3 H (2’-OCH3)), 5.15 (s, 2 H (1’’-CH2-O-)), 6.08 (d, J = 2.02 Hz, 1 H (5’-H)), 6.14 (d, J = 
2.02 Hz, 1 H (3’-H)), 7.56 (m, 2 H (2’’-H and 6’’-H)), 8.23 (m, 2 H (3’’-H and 5’’-H)). 13C-
NMR (75.48 MHz; 17.50 °C; CDCl3)  ppm 32.7 (2-C), 55.5 (4’-OCH3 or 2’-OCH3), 55.9 
(4’-OCH3 or  2’-OCH3), 69.2 (1’’-CH2-O-), 91.1 (3’-C), 92.1 (5’-C), 114.2 (1’-C), 123.9 (3’’-
C and 5’’-C), 127.4 (2’’-C and 6’’-C), 143.9 (1’’-C), 147.5 (4’’-C), 156.5 (6’-C), 158.6 (2’-
C), 162.3 (4’-C), 201.6 (1-C=O).  
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3.1.6. Preparation of ethyl 2-hydroxy-4,6-dimethoxybenzoate TU-006 53 
 
 
Na (M.W.: 22.99 g.mol
-1
; 0.03 g; 1.30 mmol) was added to ethanol (3 mL) and dissolved 
completely. After completion of the reaction, we waited for 30 minutes to add 1-(2,4-
dimethoxy-6-(4-nitrophenoxy)phenyl)ethanone (41, M.W.: 317.29 g.mol
-1
; 0.20 g; 0.63 
mmol) and then diethyl oxalate (M.W.: 146.14 g.mol
-1
; 0.18 g; 1.23 mmol). After heating at 
90 °C for overnight, we could not obtain any product. More sodium (M.W.: 22.99 g.mol
-1
; 
0.1 g; 4.35 mmol) was dissolved in ethanol (2 mL) and added to the reaction mixture. Within 
5 minutes, a new product had formed. After stirring at room temperature for more 30 
minutes, the mixture was quenched by 1M HCl (10 mL), put on a rotavapor to remove 
ethanol, and then extracted with dichloromethane. The extract was concentrated on a 
rotavapor. Purification was done by column chromatography (hexane: ethyl acetate 9: 1; L = 
12 cm; D = 1.5 cm and then hexane: ethyl acetate 1:1). After concentration of the fractions on 
the rotavapor, the solvent was removed to give TU-006 53 as a white solid (0.06 g, 43%). 
Melting point = 64. °C- 65 °C. 
1
H-NMR (300.19 MHz; 19.30 °C; CDCl3)  ppm 1.39 (t, J = 
7.09 Hz, 3 H (2’-CH3)), 3.80 (s, 3 H (4-OCH3/6-OCH3)), 3.81(s, 3 H (6-OCH3/4-OCH3)), 
4.37 (q, J = 7.09 Hz, 2 H (1’-CH2)), 5.95 (d, J = 2.37 Hz, 1 H (5-H)), 6.10 (d, J = 2.37 Hz, 1 
H (3-H)), 12.09 (s, 1 H (OH)). 
13
C-NMR (75.48 MHz; 19.40 °C; CDCl3)  ppm 14.2 (2’-
CH3), 55.4 (4-OCH3/6-OCH3 ), 56.0 (6-OCH3/4-OCH3), 61.2 (1’-CH2), 91.6 (5-C), 93.4 (3-
C), 96.8 (6-C), 162.2 (4-C), 165.2 (1-C), 165.9 (2-C), 171.2 (COOEt)).  
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3.1.7. Preparation of 4,6-dimethoxy-3-methyl-2-(4-nitrophenyl)benzofuran TU-007 (L-
96) 55  
 
 
 
1-(2,4-dimethoxy-6-((4-nitrobenzyl)oxy)phenyl)ethanone (54, M.W.: 331.32 g.mol
-1
;. 0.10 g; 
0.30 mmol) was dissolved in ethanol (3 mL) and the mixture brought at 90 °C. Then, Na 
(M.W.: 22.99 g.mol
-1
; 0.10 g; 4.35 mmol) was dissolved in ethanol (3 mL) and added to the 
mixture at 90 °C. The mixture was stirred at 90 °C for 1 hour. Then, after cooling down, 1 M 
HCl (10 mL) was added. The mixture was concentrated and extracted with dichloromethane. 
The extract was concentrated on a rotavapor to give a crude product. Purification was done 
by gradient column chromatography (hexane: ethyl acetate 9: 1; L = 12 cm; D = 1.5 cm, then 
increased to hexane: ethyl acetate 1: 1 and finally to ethyl acetate: methanol 96: 4). Removal 
of volatiles resulted in recovery of TU-007 (L-96) 55 as an orange solid (0.06 g, 66%). 
Melting point = 160 °C – 162 °C. 1H-NMR (300.19 MHz; 19.20 °C; CDCl3)  ppm 2.65 (s, 3 
H (3-CH3)), 3.86 (s, 3 H (7-OCH3)), 3.90 (s, 3 H (5-OCH3)), 6.29 (d, J = 1.92 Hz, 1 H (8-H)), 
6.61 (d, J = 1.92 Hz, 1 H (6-H)), 7.85 (m, 2 H (3’-H and 5’-H)), 8.27 (m, 2 H (2’-H and 6’-
H)). 
13
C-NMR (75.48 MHz; 19.20 °C; CDCl3)  ppm 11.6 (3-CH3), 55.5 (5-OCH3), 55.8 (7-
OCH3), 87.7 (6-C), 94.4 (8-C), 114.0 (4-C), 116.7 (3-C) 124.0 (2’-C and 6’-C), 125.7 (3’-C 
and 5’-C), 137.7 (2-C), 145.7 (1’-C), 146.1 (4’-C), 155.8 (5-C), 156.3 (9-C), 160.2 (7-C). 
HRMS (ESI): m/z calculated for C17H15NO5+H
+
 314.1028, found 314.1039.  
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3.1.8. Synthesis of 1-(2, 4, 6-trimethoxyphenyl)ethanone TU-009 56 
 
 
 
1-(2-hydroxy-4, 6-dimethoxyphenyl)ethanone (M.W. : 196.20 g.mol
-1
; 0.20 g; 1.02 mmol), 
iodomethane (M.W.: 141.94 g.mol
-1
; 0.16 g; 1.13 mmol) and K2CO3 (M.W. : 138.21 g.mol
-1
; 
0.18 g; 1.30 mmol) were dissolved in acetonitrile (10 mL) and refluxed for 12 hours. 
Thereafter, the reaction product was cooled down and acetonitrile was removed under 
reduced pressure. Water (20 mL) and dichloromethane (30 mL) were added to the mixture 
and the layers were separated. The aqueous layer was extracted further with dichloromethane 
(10 mL  2). The organic extracts were combined and washed with brine (15 mL), then dried 
over MgSO4, and afterwards concentrated under reduced pressure to give a crude product. 
The crude product was purified with column chromatography (hexane: ethyl acetate: 95: 5; L 
= 10 cm; D = 2 cm). After removing, the first spot, the column was washed with hexane: 
ethyl acetate 1:1. Removal of volatiles resulted in recovery of compound TU-009 56 as a 
white solid (0.09 g, 43 %). Melting point = 79 °C – 80 °C. 1H-NMR (600.03 MHz; 25 °C; 
CDCl3)  ppm 2.46 (s, 3 H (2-CH3)) 3.79 (s, 6 H (2’-OCH3 and 6’-OCH3)), 3.82 (s, 3 H (4’-
OCH3)), 6.10 (s, 2 H (3’-H and 5’-H)). 
13
C-NMR (150.89 MHz; 25 °C; CDCl3)  ppm 32.5 
(2-C), 55.4 (4’-OCH3), 55.8 (2’-OCH3 and 6’-OCH3), 90.6 (3’-C and 5’-C), 113.8 (1’-C), 
158.4 (2’-C and 6’-C), 162.3 (4’-C), 201.7 (1-C=O).   
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3.1.9. Synthesis of (Z)-ethyl 4-(2, 4-dimethoxy-6-(4-nitrophenoxy) phenyl)-2-hydroxy-4-
oxobut-2-enoate TU-010 48 
 
 
 
1-(2, 4-dimethoxy-6-(4-nitrophenoxy) phenyl) ethanone (41, M.W.: 317.29 g.mol
-1
; 2.15 g; 
6.78 mmol) was added to a two-neck flask. Then, dry tetrahydrofuran (15 mL) was added and 
the mixture was stirred at – 5 °C until all the starting material had dissolved. Afterwards, 1 M 
lithium bis (trimethylsilyl) amide in tetrahydrofuran (11.46 mL; 10.21 g; d = 0.891g/mL; 
61.02 mmol) was added and the mixture left to stir for 10 minutes. Then, diethyl oxalate 
(M.W.: 146.14; 1.98 g, 13.55 mmol) was added and the mixture was slowly warmed up while 
stirring from –5 °C to room temperature under argon atmosphere. After stirring for an 
overnight, excess base was neutralized with 1 M HCl (15 mL) and tetrahydrofuran was 
removed under reduced pressure. Afterwards, brine (40 mL) and ethyl acetate (80 mL) were 
added and layers separated. The aqueous layer was further extracted with ethyl acetate (20 
mL  3) and the organic extracts were combined, then dried with MgSO4, filtered and 
concentrated under reduced pressure to give a crude product. Purification was done by 
column chromatography (hexane: ethyl acetate 7: 3; L = 12 cm; D = 2 cm) to give TU-010 48 
as a white solid (1.84 g, 65 %). Melting point = 83 °C – 84 °C. 1H-NMR (600.03 MHz; 18.4 
°C; CDCl3)  ppm 1.34 (t, J = 7.12 Hz, 3 H (2’’’-CH3), 3.81 (s, 3 H (4’’-OCH3)), 3.88 (s, 3 H 
(2’’-OCH3)), 4.33 (q, J = 7.12 Hz, 2 H (1’’’-CH2)), 6.18 (d, J = 2.20 Hz, 1 H (5’’-H)), 6.40 
(d, J = 2.20 Hz, 1 H (3’’-H)), 6.69 (s, 1 H (3-H)), 7.00 (m, 2 H (2’-H and 6’-H)), 8.19 (m, 2 H 
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(3’-H and 5’-H)), 14.25 (s, 1 H (2-OH)). 13C-NMR (150.89 MHz; 18.7 °C; CDCl3)  ppm 
14.1 (2’’’-CH3), 55.8 (4’’-OCH3), 56.3 (2’’-OCH3), 62.5 (1’’’-CH2), 96.1 (3’’-C), 98.9 (5’’-
C), 105.8 (3-C), 114.1 (1’’-C), 117.0 (2’-C and 6’-C), 126.0 (3’-C and 5’-C), 142.9 (1’-C), 
154.6 (6’’-C), 160.1 (2’’-C), 162.3 (1-C=OO), 163.0 (4’-C), 163.8 (4’’-C), 164.4 (2-C), 192.2 
(4-C=O). 
 
3.1.10. Synthesis of ethyl 5-(2, 4-dimethoxy-6-(4-nitrophenoxy) phenyl) isoxazole-3-
carboxylate TU-011 (L-7) 43 
 
 
 
(Z)-Ethyl 4-(2, 4-dimethoxy-6-(4-nitrophenoxy) phenyl)-2-hydroxy-4-oxobut-2-enoate (48, 
M.W.: 417.37 g.mol
-1
; 1.85 g; 4.43 mmol) and hydroxylamine hydrochloride (M.W.: 69.49 
g.mol
-1
; 0.40 g; 5.76 mmol) were dissolved in ethanol (20 mL) and refluxed for 5 hours. 
Afterwards, the mixture was cooled down and ethanol concentrated under reduced pressure. 
The crude was purified by column chromatography (hexane: dichloromethane 6:4; L = 15 
cm; D = 2.5 cm, then changed to dichloromethane: ethyl acetate 99:1) and after concentration 
of the collected fractions, TU-011 (L-7) 43 was obtained as a white solid (1.42 g, 77 % 
yield). Melting point = 125 °C – 127 °C. 1H-NMR (600.03 MHz; 18.7 °C; CDCl3)  ppm 
1.39 (t, J = 7.16 Hz, 3 H (2’-CH3)), 3.83 (s, 3 H (4’’-OCH3)), 3.92 (s, 3 H (2’’-OCH3)), 4.41 
(q, J = 7.16 Hz, 2 H (1’-CH2-)), 6.29 (d, J = 2.34 Hz, 1 H (5’’-H)), 6.47 (d, J = 2.34 Hz, 1 H 
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(3’’-H)), 6.88 (s, 1 H (4-H)), 6.99 (m, 2 H (2’’’-H and 6’’’-H)), 8.16 (m, 2 H (3’’’-H and 5’’’-
H)). 
13
C-NMR (150.89 MHz; 19.4 °C; CDCl3)  ppm 14.2 (2’-CH3), 55.8 (4’’-OCH3), 56.2 
(2’’-OCH3), 62.1 (1’-CH2-), 96.2 (3’’-C), 99.2 (5’’-C), 103.1 (1’’-C), 105.6 (4-C), 116.8 
(2’’’-C and 6’’’-C), 126.0 (3’’’-C and 5’’’-C), 142.8 (1’’’-C), 154.2 (6’’-C), 156.0 (3-C), 
159.6 (2’’-C), 160.2 (3-C=OO), 162.8 (4’’’-C), 163.3 (4’’-C), 165.2 (5-C). HRMS (ESI): m/z 
calculated for C20H18N2O8+H
+
 415.1141, found 415.1156. 
 
3.1.11. Synthesis of tert-butyl 4-(5-(2,4-dimethoxy-6-(4-nitrophenoxy)phenyl)isoxazole-3-
carboxamido)piperidine-1-carboxylate TU-012 (L-97) 49 
 
 
Ethyl 5-(2,4-dimethoxy-6-(4-nitrophenoxy)phenyl)isoxazole-3-carboxylate (43, M.W.: 
414.37 g.mol
-1
, 0.88 g; 2.12 mmol) and 4-amino-1-Boc-piperidine (1.70 g; 8.49 mmol) were 
dissolved in dichloromethane (10 mL) and refluxed while stirring to obtain a homogeneous 
solution. Then, the solvent was removed and the mixture heated at 90 °C for 36 hours. After 
cooling down, the reaction product was concentrated under reduced pressure to a crude 
product, which was purified by column chromatography (dichloromethane: ethyl acetate 80: 
20; L = 12 cm; D = 2 cm) to give TU-012 (L-97) 49 as a white powder (0.98 g, 81%). 
Melting point = 65 °C – 68 °C. 1H -NMR (600.03 MHz; 16.9 °C; CDCl3)  ppm 1.39 (d, J = 
10.20 Hz, 2 H (3-H/5-H)), 1.45 (s, 9 H (1’’’’-(CH3)3), 1.95 (m, 2 H (5-H/ 3-H)), 2.88 (br s, 2 
H (2-H/6-H)), 3.82 (s, 3 H (4’’-OCH3)), 3.91 (s, 3 H (2’’-OCH3)), 4.06 (m, (3 H (4-H and 6-
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H/2-H)), 6.27 (d, J = 2.24 Hz, 1 H (5’’-H)), 6.47 (d, J = 2.24 Hz, 1 H (3’’-H)), 6.68 (d, J = 
8.08 Hz, 1 H (CONH)), 6.92 (s, 1 H (4’-H)), 6.99 (m, 2 H (2’’’-H and 6’’’-H)), 8.18 (m, 2 H 
(3’’’-H and 5’’’-H)). 13C-NMR (150.88 MHz; 16.9 °C; CDCl3)  ppm 28.4 (1’’’’-(CH3)3), 
31.8 (3-C and 5-C), 42.9 (2-C and 6-C), 46.9 (4-C), 55.8 (4’’-OCH3), 56.2 (2’’-OCH3), 79.9 
(1’’’’-C), 96.2 (3’’-C), 99.1 (5’’-C), 103.1 (1’’-C), 104.7 (4’-C), 116.8 (2’’’-C and 6’’’-C), 
126.0 (3’’’-C and 5’’’-C), 142.8 (1’’’-C), 154.2 (6’’-C), 154.7 (COO), 158.1 (3’-C), 158.4 
(CONH), 159.6 (2’’-C), 162.8 (4’’’-C), 163.3 (4’’-C), 165.3 (5’-C). HRMS (ESI): m/z 
calculated for C28H32N4O9+H
+ 
569.2248, found 569.2250. 
 
3.1.12. Synthesis of (5-(2,4-dimethoxy-6-(4-nitrophenoxy)phenyl)isoxazol-3-
yl)(piperidin-1-yl)methanone TU-013 (L-98) 57 
 
 
5-(2,4-dimethoxy-6-(4-nitrophenoxy)phenyl)isoxazole-3-carboxylic acid (58, M. W.: 386.31 
g.mol
-1
; 0.10 g; 0.26 mmol) was dissolved in N,N-dimethylacetamide (DMA) (3 mL) 
followed by addition of N,N,N’,N’-tetramethyl-o-(benzotriazol-1-yl) uronium 
tetrafluoroborate (TBTU) (M.W.: 321.08; 0.15 g; 0.47 mmol). After stirring for 15 minutes at 
room temperature, N,N-diisopropylethylamine (DIPEA) (M.W.: 129.24 g.mol
-1
; 0.10 g; 0.77 
mmol) was added, which was followed by the addition of piperidine (M.W.: 85.15 g.mol
-1
; 
0.03 g; 0.35 mmol). The mixture was left to stir at room temperature for 24 hours. Then, the 
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resultant reaction mixture was poured into a saturated solution of NaHCO3 (20 mL), which 
was extracted with ethyl acetate (20 mL  3), washed with brine (10 mL  3), dried with 
MgSO4 and finally concentrated to give a crude product. The crude was purified by column 
chromatography (dichloromethane: ethyl acetate 95: 5; L = 11 cm; D = 2 cm) and removal of 
volatiles resulted in recovery of TU-013 (L-98) 57 as a white solid (0.08 g, 67 %). Melting 
point = 132 °C – 134 °C. 1H -NMR (600.03 MHz; 24.9 °C; CDCl3)  ppm 1.55 (m, 2 H (3-
H/5-H)), 1.65 (m, 4 H (4-H and 5-H/3-H)), 3.61 (m, 2 H (2-H/6-H)), 3.68 (m, 2 H (6-H/2-
H)), 3.82 (s, 3 H (4’’-OCH3)), 3.90 (s, 3 H (2’’-OCH3)), 6.28 (d, J = 2.34 Hz, 1 H (5’’-H)), 
6.47 (d, J = 2.34 Hz, 1 H (3’’-H)), 6.72 (s, 1 H (4’-H)), 7.00 (m, 2 H (2’’’-H and 6’’’-H)), 
8.16 (m, 2 H (3’’’-H and 5’’’-H)). 13C-NMR (150.88 MHz; 19.0 °C; CDCl3)  ppm 24.5 (4-
C), 25.6 (5-C and 3-C), 26.6 (3-C/5-C), 43.6 (6-C/2-C), 48.1 (2-C/6-C), 55.8 (4’’-OCH3), 
56.2 (2’’-OCH3), 96.2 (3’’-C), 99.1 (5’’-C), 103.2 (1’’-C), 106.0 (4’-C), 116.9 (2’’’-C and 
6’’’-C), 125.9 (3’’’-C and 5’’’-C), 142.8 (1’’’-C), 154.2 (6’’-C), 158.4 (3’-C), 159.6 (2’’-C), 
159.7 (CON), 162.8 (4’’’-C), 163.1 (4’’-C), 163.6 (5’-C). HRMS (ESI): m/z calculated for 
C23H23N3O7+H
+
 454.1614, found 454.1624.  
 
3.1.13. 5-(2, 4-dimethoxy-6-(4-nitrophenoxy) phenyl) isoxazole-3-carboxylic acid TU-014 
(L-99) 58 
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Ethyl 5-(2, 4-dimethoxy-6-(4-nitrophenoxy) phenyl) isoxazole-3-carboxylate (43, M.W.: 
414.37 g.mol
-1
; 0.35 g; 0.84 mmol) was dissolved in deionised water (10 mL) and KOH 
(M.W.: 56.11; 0.24 g; 4.28 mmol) was added. The mixture was stirred at 80 °C for an 
overnight. After cooling down, 1 M HCl (10 mL) was added which was accompanied by 
precipitating of the desired compound TU-014 (L-99) 58. The aqueous layer was removed 
and the solid dried in the oven. The product was obtained as a brown solid (0.24 g, 75 %). 
Melting point = 153 °C – 155 °C. 1H -NMR (600.03 MHz; 19.0 °C; DMSO)  ppm 3.87 (s, 3 
H (4’-OCH3)), 3.95 (s, 3 H (2’-OCH3)), 6.57 (d, J = 2.01 Hz, 1 H (5’-H)), 6.77 (d, J = 2.01 
Hz, 1 H (3’-H)), 6.88 (s, 1 H (4-H)), 7.15 (d, J = 9.17 Hz, 2 H (2’’-H and 6’’-H), 8.25 (d, J = 
9.17 Hz, 2 H (3’’-H and 5’’-H)). 13C-NMR (150.88 MHz; 19.0 °C; CDCl3)  ppm 57.0 (4’-
OCH3), 57.5 (2’-OCH3), 97.6 (3’-C), 100.7 (5’-C), 102.9 (1’-C), 106.4 (4-C), 117.9 (2’’-C 
and 6’’-C), 127.1 (3’’-C and 5’’-C), 143.3 (1’’-C), 154.5 (6’-C), 157.7 (3-C), 160.4 (2’-C), 
161.8 (COOH), 163.4 (4’’-C), 164.3 (4’-C), 165.8 (5-C). HRMS (ESI): m/z calculated for 
C18H14N2O8+H
+
 387.0828, found 387.0820.  
 
3.1.14. 5-(2, 4-dimethoxy-6-(4-nitrophenoxy) phenyl)-N-(2-(4-methylpiperazin-1-yl) 
ethyl) isoxazole-3-carboxamide TU-015 (L-100) 59 
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5-(2, 4-dimethoxy-6-(4-nitrophenoxy) phenyl) isoxazole-3-carboxylic acid (58, M.W.: 386.31 
g.mol
-1
; 0.15 g; 0.39 mmol) was dissolved in DMA (3 ml) and TBTU (M.W.: 321.08 g.mol
-1
; 
0.15 g; 0.47 mmol) was added. After stirring for 15 minutes at room temperature, DIPEA 
(M.W.: 129.24 g.mol
-1
; 0.2 ml; 0.15 g; 1.16 mmol) was added. Afterwards, 2-(4-
methylpiperazin-1-yl) ethanamine (M.W.: 143.23 g.mol
-1
; 0.06 g; 0.42 mmol) was added and 
the reaction mixture left to stir at room temperature for 48 hours. The resultant mixture was 
then poured into a saturated solution of NaHCO3 (20 mL), extracted with ethyl acetate (20 
mL  3), washed with brine (10 mL  3), dried with MgSO4 and finally concentrated to 
obtain a crude product. The crude was purified with column chromatography (CHCl3: MeOH 
95: 5) and solvents removed to give a white powder (0.13 g, 65 %). Melting point = 144 °C – 
145 °C. 
1
H -NMR (600.03 MHz; 25.0 °C; CDCl3)  ppm 2.29 (s, 3 H (4’’-CH3)), 2.55 (m, 10 
H (2’-H and 2’’-H and 3’’-H and 5’’-H and 6’’-H)), 3.50 (q, J = 5.65 Hz, 2 H (1’-H)), 3.82 (s, 
3 H (4’’’-OCH3)), 3.91 (s, 3 H (2’’’-OCH3)), 6.27 (d, J = 2.04 Hz, 1 H (5’’’-H)), 6.47 (d, J = 
2.04 Hz, 1 H (3’’’-H)), 6.91 (s, 1 H (4-H)), 7.01 (d, J = 9.16 Hz, 2 H (2’’’’-H and 6’’’’-H)), 
7.23 (s, 1 H (CONH)), 8.18 (d, J = 9.16 Hz, 2 H (3’’’’-H and 5’’’’-H)). 13C-NMR (150.89 
MHz; 25.0 °C; CDCl3)  ppm 36.1 (1’-C), 45.9 (4’’-CH3), 52.8 (2’’-C and 6’’-C), 55.0 (3’’-C 
and 5’’-C), 55.8 (4’’’-OCH3), 56.2 (2’’’-OCH3), 56.3 (2’-C), 96.2 (3’’’-C), 99.0 (5’’’-C), 
103.2 (1’’’-C), 104.8 (4-C), 116.9 (2’’’’-C and 6’’’’-C), 126.0 (3’’’’-C and 5’’’’-C), 142.9 
(1’’’’-C), 154.3 (6’’’-C), 158.3 (3-C), 159.1 (CONH), 159.7 (2’’’-C), 162.7 (4’’’’-C), 163.2 
(4’’’-C), 165.0 (5-C). HRMS (ESI): m/z calculated for C25H29N5O7+H
+
 512.2145, found 
512.2152.  
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3.1.15. Synthesis of 5-(2,4-dimethoxy-6-(4-nitrophenoxy)phenyl)-N-(1-methylpiperidin-
4-yl)isoxazole-3-carboxamide TU-016 (L-14) 60 
 
 
5-(2, 4-dimethoxy-6-(4-nitrophenoxy) phenyl) isoxazole-3-carboxylic acid (58, M.W.: 386.31 
g.mol
-1
; 0.17 g; 0.44 mmol) was dissolved in DMA (3 mL) and TBTU (M.W.: 321.08 g.mol
-
1
; 0.17 g; 0.53 mmol) added. After stirring for 15 minutes, DIPEA (M.W.: 129.24 g.mol
-1
; 
0.17 g; 1.32 mmol) and 1-methyl-4-piperidinamine (M.W.: 114.19 g.mol
-1
; 0.05 g; 0.44 
mmol) were added and the mixture left to stir at room temperature for 24 hours. The resultant 
mixture was then poured into a saturated solution of NaHCO3 (20 mL), extracted with ethyl 
acetate (20 mL  3), washed with brine (10 mL  3), dried with MgSO4 and later filtered and 
concentrated to give a crude product. The crude was purified by column flash 
chromatography (CHCl3: MeOH 95: 5; L = 8 cm; D = 1.75 cm) to give an orange solid (0.12 
g, 57%). Melting point = 175 °C – 177 °C. 1H -NMR (600.03 MHz; 25.0 °C; CDCl3)  ppm 
1.57 (qd, 4  J = 3.65 Hz, 2 H (3’-H/5’-H)), 1.98 (m, 2 H (5’-H/3’-H)), 2.12 (t, J = 9.03 Hz, 2 
H (2’-H/6’-H)), 2.28 (s, 3 H (1’-CH3)), 2.79 (s, 2 H (6’-H/2’-H)), 3.82 (s, 3 H (4’’-OCH3)), 
3.90 (m, 4 H (4’-H and 2’’-OCH3)), 6.27 (d, J = 2.26 Hz, 1 H (5’’-H)), 6.47 (d, J = 2.26 Hz, 1 
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H (3’’-H)), 6.68 (d, J = 8.01 Hz, 1 H (CONH)), 6.91 (s, 1 H (4-H)), 6.99 (m, 2 H (2’’’-H and 
6’’’-H), 8.17 (m, 2 H (3’’’-H and 5’’’-H)). 13C-NMR (150.88 MHz; 25.0 °C; CDCl3)  ppm 
31.9 (3’-C and 5’-C), 46.1 (4’-C and 1’-CH3), 54.3 (2’-C and 6’-C), 55.8 (4’’-OCH3), 56.2 
(2’’-OCH3), 96.2 (3’’-C), 99.1 (5’’-C), 103.2 (1’’-C), 104.7 (4-C), 116.8 (2’’’-C and 6’’’-C), 
126.0 (3’’’-C and 5’’’-C), 142.8 (1’’’-C), 154.2 (6’’-C), 158.3 (3-C), 158.4 (CONH), 159.6 
(2’’-C), 162.8 (4’’’-C), 163.3 (4’’-C), 165.1 (5-C). HRMS (ESI): m/z calculated for 
C24H26N4O7+H
+
 483.1880, found 483.1879. 
 
3.1.16. Synthesis of 5-(2, 4-dimethoxy-6-(4-nitrophenoxy) phenyl)-N-(1, 2, 2, 6, 6-
pentamethylpiperidin-4-yl) isoxazole-3-carboxamide TU-017 (L-102) 61 
 
 
5-(2, 4-dimethoxy-6-(4-nitrophenoxy) phenyl) isoxazole-3-carboxylic acid (58, M. W.: 
386.31 g.mol
-1
; 0.15 g; 0.39 mmol) was dissolved in DMA (3 mL) and TBTU (M.W.: 386.31 
g.mol
-1
; 0.15 g; 0.47 mmol) was added. After stirring for 15 minutes, DIPEA (M.W.: 129.24 
g.mol
-1
; 0.15 g; 1.16 mmol) and 4-amino-1, 2, 2, 6, 6-pentamethylpiperidine (M.W.: 170.30 
g.mol
-1
; 0.07 g; 0.41 mmol) were added and the reaction mixture left to stir at room 
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temperature for 24 hours. The resultant mixture was poured into a saturated solution of 
NaHCO3, extracted with ethyl acetate (20 mL  3), washed with brine (10 mL  3), dried 
with MgSO4, filtered and concentrated to give a crude product. The crude was purified by 
column chromatography (dichloromethane: methanol 98: 2; L = 10 cm; D = 1.75 cm) and 
solvents removed to give a red solid (0.12 g, 57%). Melting point = 125 °C – 127 °C. 1H -
NMR (600.03 MHz; 25.0 °C; CDCl3)  ppm 1.14 (m, 12 H (2’-(CH3)2 and 6’-(CH3)2)), 1.39 
(m, 2 H (3’-H/5’-H)), 1.85 (dd, 2  J = 3.56 Hz, 2 H (5’-H/3’-H)), 2.27 (s, 3 H (1’-CH3)), 
3.83 (s, 3 H (4’’-OCH3)), 3.91 (s, 3 H (2’’-OCH3)), 4.29 (m, 1 H (4’-H)), 6.28 (d, J = 2.30 
Hz, 1 H (5’’-H), 6.47 (d, J = 2.30 Hz, 1 H (3’’-H), 6.58 (d, J = 6.53 Hz, 1 H (CONH)), 6.89 
(s, 1 H (4-H)), 6.99 (m, 2 H (2’’’-H and 6’’’-H)), 8.17 (m, 2 H (3’’’-H and 5’’’-H)). 13C-
NMR (150.88 MHz; 25.0 °C; CDCl3)  ppm 20.1 (2’-(CH3)2)/6’-(CH3)2), 28.2 (1’-CH3), 33.1 
((6’-CH3)2 or 2’-(CH3)2), 41.8 (4’-C), 46.8 (3’-C and 5’-C), 55.2 (2’-C and 6’-C), 55.8 (4’’-
OCH3), 56.2 (2’’-OCH3), 96.2 (3’’-C), 99.1 (5’’-C), 103.2 (1’’-C), 104.7 (4-C), 116.7 (2’’’-C 
and 6’’’-C), 126.0 (3’’’-C and 5’’’-C), 142.8 (1’’’-C), 154.1 (6’’-C), 158.3 (3-C), 158.3 
(CONH), 159.6 (2’’-C), 162.8 (4’’’-C), 163.2 (4’’-C), 165.1 (5-C). HRMS (ESI): m/z 
calculated for C28H34N4O7+H
+
 539.2506, found 539.2520. 
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3.1.17. Synthesis of 5-(2,4-dimethoxy-6-(4-nitrophenoxy)phenyl)-N-(piperidin-4-
yl)isoxazole-3-carboxamide TU-018 (L-103) 50 
 
 
Tert-butyl 4-(5-(2,4-dimethoxy-6-(4-nitrophenoxy)phenyl)isoxazole-3-
carboxamido)piperidine-1-carboxylate (49, M.W.: 568.58 g.mol
-1
; 0.60 g; 1.06 mmol) was 
dissolved  in 4.0 M HCl in dioxane (5 mL) and the mixture was left to stir overnight under 
argon. Then, HCl was neutralized with KOH and the mixture was poured into ice water (100 
mL) and extracted with chloroform (30 mL  3). The extracted organic layer was dried with 
MgSO4, filtered and concentrated to give a crude product. The crude was purified by column 
chromatography (dichloromethane: methanol 95: 5; L = 7 cm; D = 1.75 cm) and the solvents 
removed to give TU-018 (L-103) 50 as a yellow solid (0.44 g, 89%). Melting point = 70 °C – 
72 °C. 
1
H -NMR (600.03 MHz; 25.0 °C; CDCl3)  ppm 1.40 (m, 2 H (3’-H/5’-H), 1.98 (m, 2 
H (5’-H/3’-H)), 2.71 (td, 3  J = 2.58 Hz, 2 H (2’-H/6’-H)), 3.09 (dt, 2  J = 3.64 Hz, 2 H 
(6’-H/2’-H)), 3.82 (s, 3 H (4’’-OCH3)), 3.91 (s, 3 H (2’’-OCH3)), 4.01 (m, 1 H (4’-H)), 6.27 
(d, J = 2.28 Hz, 1 H (5’’-H)), 6.47 (d, J = 2.28 Hz, 1 H(3’’-H)), 6.70 (d, J = 8.26 Hz 1 H 
(CONH)), 6.92 (s, 1 H (4-H)), 7.00 (m, 2 H (2’’’-H and 6’’’-H)), 8.18 (m, 2 H (3’’’-H and 
5’’’-H)). 13C-NMR (150.88 MHz; 25.0 °C; CDCl3)  ppm 33.2 (3’-C and 5’-C), 45.3 (2’-C 
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and 6’-C), 47.1 (4’-C), 55.8 (4’’-OCH3), 56.2 (2’’-OCH3), 96.2 (3’’-C), 99.1 (5’’-C), 103.2 
(1’’-C), 104.8 (4-C), 116.8 (2’’’-C and 6’’’-C), 126.0 (3’’’-C and 5’’’-C), 142.8 (1’’’-C), 
154.2 (6’’-C), 158.2 (CONH), 158.3 (3-C), 159.6 (2’’-C), 162.8 (4’’’-C), 163.3 (4’’-C), 165.1 
(5-C). HRMS (ESI): m/z calculated for C23H24N4O7+H
+
 469.1723, found 469.1732.  
 
3.1.18. Synthesis 5-(2,4-dimethoxy-6-(4-nitrophenoxy)phenyl)-N-(1-isopropylpiperidin-
4-yl)isoxazole-3-carboxamide TU-019 (L-104) 51 
 
 
 
5-(2, 4-dimethoxy-6-(4-nitrophenoxy) phenyl)-N-(piperidin-4-yl) isoxazole-3-carboxamide 
hydrochloride (50, M.W.: 504.92 g.mol
-1
; 0.19 g; 0.38 mmol) was dissolved in DMA (3 ml) 
and acetone (M.W.: 58.08 g.mol
-1
; 0.10 g; 4.65 mmol) was added. After stirring for a few 
minutes, sodium triacetoxyborohydride (M.W.: 211.94 g.mol
-1
; 0.36 g; 1.70 mmol) was 
added and the reaction mixture was left to stir at room temperature for 24 hours. The resultant 
mixture was then dissolved in ethyl acetate (40 mL), washed with brine (15 mL  3), dried 
with MgSO4, filtered and concentrated to give a crude product. The crude was purified with 
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column chromatography (dichloromethane: methanol 95: 5; L = 7 cm; D = 1.75 cm), and 
after concentration of the solvents TU-019 (L-104) 51 was isolated as a yellow solid (0.01 g, 
5%). Melting point = 80 °C – 82 °C. 1H -NMR (600.03 MHz; 25.0 °C; CDCl3)  ppm 1.27 
(d, J = 6.66 Hz, 6 H (2’’-CH3 and 3’’-CH3)), 2.12 (br s, 4 H (3’-CH2 and 5’-CH2)), 2.67 (br s, 
2 H (2’-CH2/6’-CH2)), 3.24 (m, 3 H (1’’-H and 6’-CH2/2’-CH2)), 3.82 (s, 3 H (4’’’-OCH3)), 
3.90 (s, 3 H (2’’’-OCH3)), 4.08 (m, 1 H (4’-H)), 6.26 (d, J = 2.25 Hz, (1 H (5’’’-H)), 6.46 (d, 
J = 2.25 Hz, 1 H (3’’’-H)), 6.88 (s, 1 H (4-H)), 6.99 (m, 2 H (2’’’’-H and 6’’’’-H)), 7.03 (d, J 
= 7.57 Hz, 1 H (CONH)), 8.17 (m, 2 H (3’’’’-H and 5’’’’-H)). 13C-NMR (150.88 MHz; 25.0 
°C; CDCl3)  ppm 17.2 (2’’-C and 3’’-C), 29.4 (3’-C and 5’-C), 45.3 (4’-C), 47.1 (2’-C and 
6’-C), 55.8 (4’’’-OCH3), 56.2 (2’’’-OCH3), 56.4 (1’’-C), 96.2 (3’’’-C), 99.1 (5’’’-C), 103.1 
(1’’’-C), 104.6 (4-C), 116.8 (2’’’’-C and 6’’’’-C), 126.0 (3’’’’-C and 5’’’’-C), 142.9 (1’’’’-
C), 154.2 (6’’’-C), 157.9 (3-C), 158.8 (C=O), 159.6 (2’’’-C), 162.7 (4’’’’-C), 163.3 (4’’’-C), 
165.2 (5-C). HRMS (ESI): m/z calculated for C26H30N4O7+H
+
 511.2193, found 511.2191.  
 
3.2. PLDH (malaria) assay 
Plasmodium falciparum (strain 3D7) cells were maintained in RPMI (Roswell Park Memorial 
Institute) 1640 medium containing 2 mM L-glutamine and 25 mM Hepes (Lonza). The 
medium was further supplemented with 5% Albumax II, 20 mM glucose, 0.65 mM 
hypoxanthine, 60 g/ml gentamycin and 2-4% hematocrit human red blood cells. The 
parasites were then cultured at 37 °C under an atmosphere of 5% CO2, 5% O2, and 90% N2 in 
sealed T75 culture flasks. The compounds to be screened (in a range of 100 M to 0.0061 
M) were then added in duplicate to the parasite cultures in 96-well plates and incubated for 
48 hours in a 37 °C CO2 incubator. After 48 hours, the plates were removed from the 
incubator, and then 20 L of culture removed from each well and mixed with 125 L of a 
mixture of Malstat solution and NBT/PES (nitro blue tetra-zolium + phenazine ethosulphate) 
solution in a fresh 96-well plate in order to measure the activity of the parasite lactate 
dehydrogenase (PLDH) enzyme in the cultures. Absorbance readings at 620 nm were 
recorded for each well, the number of parasites in that well deduced, and then the % parasite 
viability in comparison to the untreated controls was calculated. The anti-malarial drug 
chloroquine was used as a drug standard.  
 
131 
 
3.3. Cell cytotoxicity assay  
The compounds to be screened (in concentrations ranging from 100 M to 0.0061 M) were 
incubated in two replicates in 96-well plates containing human cervix adenocarcinoma 
(HeLa) cells for 48 hours. The number of cells surviving the drug was then determined using 
the resazurin reagent (TOX8-Kit (Sigma)) and then reading the fluorescence in the multi-well 
plate reader. The percentage cell viability for each compound concentration was determined 
by comparing the fluorescence of the treated wells with the untreated wells. The cell 
apoptosis inducer drug, emetine was used as a drug standard.  
 
3.4. Virtual screening  
Virtual screening of the candidate compounds was done using Autodock vina. First, the 
energy of each ligand molecule was minimized with Vegazz, and then the ligand and the 
target protein (PfHsp90 (PDB code: 3K60) or human Hsp90 (PDB code: 1BYQ)) were 
prepared with Autodock tools for docking with Autodock vina. Compounds  whose estimate 
maximum length was less than 15 Å, they were docked in a 25 Å × 25 Å × 25 Å box and 
those with an estimated maximum length equal to or larger than 15 Å were docked in a 30 Å 
× 30 Å × 30 Å box. The intention was to increase the docking speed, thus minimizing the 
docking time while preserving the accuracy of predictions of the binding modes of the 
candidate compounds. Then, the ratio between the inhibition constants of the best binding 
modes of each ligand for human Hsp90 and PfHsp90 was determined and used to decide 
which compounds would selectively bind to PfHsp90 in the presence of human Hsp90. The 
approximate dimensions of the ligand compounds were determined using Vegazz.  
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Appendices 
Appendix I: Calculated binding energies (in kcal/mol) of different ligands bound to 
human Hsp90 (1BYQ) 
 
Code 
of 
ligand 
Experiment no 
Mean S.D. Ki(M) 
1 2 3 4 5 6 7 8 9 10 
L-1 -9.3 -9.4 -9.4 -9.4 -9.4 -9.4 -9.4 -9.4 -9.4 -9.4 -9.4 0.0 0.1 
L-2 -8.4 -8.4 -8.3 -8.4 -8.4 -8.3 -8.4 -8.3 -8.3 -8.4 -8.4 0.1 0.7 
L-3 -6.7 -6.7 -6.7 -6.7 -6.7 -6.7 -6.7 -6.7 -6.7 -6.7 -6.7 0.0 12.3 
L-4 -8.3 -8.3 -8.3 -8.4 -8.3 -8.4 -8.4 -8.1 -8.4 -8.4 -8.3 0.1 0.8 
L-5 -6.9 -7.0 -7.0 -7.0 -7.0 -7.0 -7.0 -7.0 -7.0 -6.9 -7.0 0.0 7.6 
L-6 -6.9 -6.9 -6.9 -6.9 -6.9 -6.9 -6.9 -6.9 -6.9 -6.8 -6.9 0.0 8.9 
L-7 -7.7 -7.8 -7.7 -7.7 -7.7 -7.7 -7.7 -7.7 -7.7 -7.7 -7.7 0.0 2.2 
L-8 -7.8 -7.7 -7.7 -7.7 -7.7 -7.8 -7.8 -7.8 -7.6 -7.7 -7.7 0.1 2.2 
L-9 -7.5 -7.4 -7.6 -7.4 -7.4 -7.5 -7.5 -7.5 -7.5 -7.5 -7.5 0.1 3.3 
L-10 -7.7 -7.7 -7.7 -7.7 -7.7 -7.8 -7.8 -7.7 -7.7 -7.7 -7.7 0.0 2.2 
L-11 -8.0 -8.2 -8.0 -7.9 -8.0 -8.0 -8.2 -8.0 -7.9 -7.9 -8.0 0.1 1.3 
L-12 -6.9 -6.8 -6.8 -6.9 -7.0 -7.0 -6.9 -6.9 -6.9 -6.7 -6.9 0.1 9.1 
L-13 -6.7 -6.8 -6.7 -6.7 -6.9 -7.0 -6.6 -6.8 -6.7 -6.7 -6.8 0.1 11.1 
L-14 -8.4 -8.4 -8.4 -8.4 -8.6 -8.4 -8.4 -8.4 -8.4 -8.4 -8.4 0.1 0.7 
L-15 -7.3 -7.3 -7.4 -7.4 -7.3 -7.3 -7.3 -7.3 -7.3 -7.3 -7.3 0.0 4.3 
L-16 -7.4 -7.5 -7.5 -7.5 -7.4 -7.5 -7.3 -7.5 -7.5 -7.4 -7.5 0.1 3.5 
L-17 -7.9 -7.9 -8.0 -7.8 -7.8 -7.9 -7.9 -7.9 -7.9 -8.0 -7.9 0.1 1.6 
L-18 -6.9 -6.9 -6.9 -6.8 -6.9 -6.9 -6.9 -6.9 -6.9 -6.9 -6.9 0.0 8.9 
L-19 -7.4 -7.5 -7.4 -7.4 -7.4 -7.4 -7.4 -7.4 -7.4 -7.4 -7.4 0.0 3.7 
L-20 -8.6 -8.5 -8.6 -8.6 -8.6 -8.6 -8.6 -8.5 -8.5 -8.5 -8.6 0.1 0.5 
L-21 -8.4 -8.4 -8.4 -8.4 -8.4 -8.4 -8.5 -8.4 -8.4 -8.4 -8.4 0.0 0.7 
L-22 -6.5 -6.5 -6.5 -6.5 -6.5 -6.5 -6.5 -6.5 -6.5 -6.5 -6.5 0.0 17.2 
L-23 -6.6 -6.6 -6.6 -6.6 -6.6 -6.6 -6.6 -6.6 -6.5 -6.6 -6.6 0.0 14.8 
L-24 -6.6 -6.7 -6.6 -6.5 -6.5 -6.6 -6.6 -6.5 -6.5 -7.0 -6.6 0.2 14.3 
L-25 -7.8 -7.7 -7.7 -7.7 -7.7 -7.7 -7.7 -7.8 -7.7 -7.7 -7.7 0.0 2.2 
L-26 -8.7 -8.6 -8.6 -8.6 -8.6 -8.5 -8.6 -8.6 -8.5 -8.6 -8.6 0.1 0.5 
L-27 -8.6 -7.6 -7.6 -8.6 -8.6 -8.6 -8.6 -8.6 -7.6 -8.6 -8.3 0.5 0.8 
L-28 -8.1 -8.1 -8.1 -8.1 -8.1 -8.1 -8.1 -8.1 -8.1 -8.1 -8.1 0.0 1.2 
L-29 -9.0 -9.0 -9.0 -9.0 -9.0 -9.0 -9.0 -9.0 -8.9 -9.0 -9.0 0.0 0.3 
L-30 -8.4 -8.3 -8.3 -8.4 -8.4 -8.3 -8.3 -8.4 -8.4 -8.4 -8.4 0.1 0.7 
L-31 -8.1 -8.1 -8.2 -8.1 -8.1 -8.1 -8.1 -8.1 -8.1 -8.2 -8.1 0.0 1.1 
L-32 -7.7 -7.7 -7.7 -7.7 -7.7 -7.7 -7.7 -7.7 -7.7 -7.7 -7.7 0.0 2.3 
L-33 -7.5 -7.5 -7.7 -7.4 -7.5 -7.5 -7.4 -7.5 -7.5 -7.4 -7.5 0.1 3.2 
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L-34 -8.0 -8.0 -8.1 -8.1 -8.0 -8.1 -8.1 -8.0 -8.0 -8.0 -8.0 0.1 1.3 
L-35 -7.9 -7.8 -7.8 -7.8 -7.8 -7.8 -7.8 -7.8 -7.8 -7.9 -7.8 0.0 1.9 
L-36 -8.0 -7.9 -7.7 -8.0 -8.0 -7.9 -8.0 -8.0 -7.7 -8.0 -7.9 0.1 1.6 
L-37 -8.0 -8.0 -8.0 -8.1 -8.0 -8.0 -8.0 -8.0 -8.0 -8.1 -8.0 0.0 1.3 
L-38 -7.8 -7.8 -7.8 -7.8 -7.8 -7.8 -7.8 -7.8 -7.8 -7.8 -7.8 0.0 1.9 
L-39 -7.7 -7.7 -7.7 -7.6 -7.7 -7.7 -7.7 -7.7 -7.7 -7.7 -7.7 0.0 2.3 
L-40 -7.8 -7.7 -7.9 -7.8 -7.8 -7.9 -7.8 -7.8 -7.8 -7.8 -7.8 0.1 1.9 
L-41 -7.5 -7.5 -7.5 -7.5 -7.5 -7.5 -7.5 -7.5 -7.5 -7.5 -7.5 0.0 3.2 
L-42 -7.5 -7.5 -7.5 -7.5 -7.5 -7.5 -7.5 -7.6 -7.5 -7.5 -7.5 0.0 3.1 
L-43 -7.4 -7.5 -7.4 -7.4 -7.3 -7.4 -7.4 -7.4 -7.4 -7.5 -7.4 0.1 3.7 
L-44 -7.5 -7.6 -7.5 -7.6 -7.6 -7.6 -7.5 -7.5 -7.5 -7.5 -7.5 0.1 3.0 
L-45 -7.5 -7.5 -7.5 -7.5 -7.6 -7.6 -7.5 -7.5 -7.5 -7.6 -7.5 0.0 3.0 
L-46 -6.8 -6.7 -6.7 -6.7 -6.7 -6.7 -6.8 -6.7 -6.8 -6.7 -6.7 0.0 11.7 
L-47 -7.0 -7.2 -6.9 -6.9 -6.9 -7.3 -6.9 -6.9 -7.0 -7.2 -7.0 0.2 7.1 
L-48 -7.9 -7.9 -7.8 -7.9 -7.9 -7.9 -7.9 -7.9 -7.9 -7.8 -7.9 0.0 1.7 
L-49 -7.9 -7.9 -8.0 -7.6 -8.0 -7.9 -7.9 -7.9 -7.9 -7.8 -7.9 0.1 1.7 
L-50 -7.9 -7.9 -7.8 -7.9 -7.9 -7.9 -7.8 -7.9 -7.9 -8.2 -7.9 0.1 1.6 
L-51 -7.8 -7.8 -7.9 -7.9 -7.9 -7.6 -7.8 -7.8 -7.9 -7.7 -7.8 0.1 1.9 
L-52 -8.2 -8.2 -8.2 -8.2 -8.2 -8.2 -8.2 -8.2 -8.2 -8.1 -8.2 0.0 1.0 
L-53 -8.0 -7.6 -7.6 -7.8 -8.1 -7.6 -7.9 -7.8 -7.6 -8.0 -7.8 0.2 1.9 
L-54 -8.2 -8.2 -8.2 -8.2 -8.2 -8.2 -8.2 -8.2 -8.2 -8.2 -8.2 0.0 1.0 
L-55 -8.3 -7.9 -8.3 -8.3 -8.2 -8.3 -8.2 -8.1 -8.3 -8.3 -8.2 0.1 0.9 
L-56 -8.0 -7.7 -7.7 -7.7 -7.9 -8.0 -7.8 -8.0 -7.7 -8.0 -7.9 0.1 1.8 
L-57 -9.0 -8.4 -8.7 -8.6 -9.0 -8.7 -8.7 -8.6 -8.7 -8.6 -8.7 0.2 0.4 
L-58 -8.6 -8.6 -8.5 -8.6 -8.5 -8.6 -8.6 -8.6 -8.6 -8.6 -8.6 0.0 0.5 
L-59 -8.4 -8.3 -8.3 -8.3 -8.6 -8.9 -8.8 -8.2 -8.3 -8.3 -8.4 0.2 0.7 
L-60 -8.8 -8.8 -8.8 -8.8 -8.8 -8.9 -8.8 -8.8 -8.8 -8.8 -8.8 0.0 0.3 
L-61 -8.8 -8.7 -8.7 -8.7 -8.7 -8.8 -8.8 -8.7 -8.7 -8.7 -8.7 0.0 0.4 
L-62 -8.3 -8.3 -8.3 -8.3 -8.3 -8.3 -8.3 -8.3 -8.3 -8.3 -8.3 0.0 0.8 
L-63 -8.4 -8.4 -8.3 -8.4 -8.4 -8.3 -8.4 -8.3 -8.4 -8.0 -8.3 0.1 0.8 
L-64 -8.8 -8.9 -8.8 -8.9 -9.0 -8.8 -8.9 -8.8 -8.9 -8.8 -8.9 0.1 0.3 
L-65 -8.6 -8.6 -8.6 -8.6 -8.5 -8.6 -8.6 -8.6 -8.6 -8.6 -8.6 0.0 0.5 
L-66 -8.7 -8.7 -8.7 -8.7 -8.8 -8.7 -8.6 -8.7 -8.7 -8.7 -8.7 0.0 0.4 
L-67 -8.2 -8.2 -7.8 -8.0 -8.1 -7.9 -8.2 -7.9 -8.2 -8.0 -8.1 0.2 1.3 
L-68 -8.2 -8.3 -8.2 -8.2 -8.2 -8.2 -8.2 -8.2 -8.2 -8.2 -8.2 0.0 1.0 
L-69 -7.9 -8.1 -7.7 -7.7 -8.5 -8.1 -8.4 -7.7 -7.8 -7.7 -8.0 0.3 1.5 
L-70 -8.7 -8.7 -8.7 -8.7 -8.7 -8.7 -8.7 -8.7 -8.7 -8.7 -8.7 0.0 0.4 
L-71 -8.5 -8.3 -8.5 -8.2 -8.3 -8.5 -8.4 -8.4 -8.5 -8.4 -8.4 0.1 0.7 
L-72 -8.0 -8.2 -8.0 -8.0 -8.0 -8.2 -8.0 -8.1 -8.1 -8.2 -8.1 0.1 1.2 
L-73 -8.6 -8.6 -8.6 -8.5 -8.5 -8.5 -8.6 -8.5 -8.4 -8.4 -8.5 0.1 0.6 
L-74 -8.3 -8.8 -8.9 -8.5 -8.7 -8.7 -8.3 -8.6 -8.7 -8.5 -8.6 0.2 0.5 
L-75 -8.9 -8.8 -8.8 -8.9 -8.7 -8.8 -8.8 -8.7 -8.8 -8.8 -8.8 0.1 0.4 
L-76 -7.9 -7.9 -7.9 -7.9 -7.9 -7.9 -8.2 -7.8 -8.4 -8.4 -8.0 0.2 1.3 
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L-77 -8.8 -9.1 -9.1 -9.1 -8.6 -9.0 -8.8 -9.0 -9.2 -9.2 -9.0 0.2 0.3 
L-78 -8.6 -8.5 -8.5 -8.4 -8.6 -8.4 -8.3 -8.4 -8.6 -8.4 -8.5 0.1 0.6 
L-79 -9.7 -9.7 -9.2 -9.7 -9.6 -8.6 -9.1 -9.6 -9.6 -8.0 -9.3 0.6 0.2 
L-80 -8.8 -9.0 -8.9 -8.8 -8.9 -8.8 -8.9 -9.0 -9.0 -8.9 -8.9 0.1 0.3 
L-81 -9.1 -8.8 -8.6 -8.9 -9.1 -9.0 -8.9 -8.8 -8.7 -8.9 -8.9 0.2 0.3 
L-82 -7.8 -7.8 -7.9 -7.8 -7.7 -7.7 -7.7 -7.7 -7.8 -7.7 -7.8 0.1 2.1 
L-83 -7.4 -7.4 -7.8 -7.4 -7.4 -7.4 -7.4 -7.4 -7.7 -7.8 -7.5 0.2 3.1 
L-84 -9.4 -9.4 -9.4 -9.4 -9.3 -9.4 -9.2 -9.5 -9.3 -9.3 -9.4 0.1 0.1 
L-85 -9.1 -9.1 -9.1 -9.2 -9.1 -8.9 -9.5 -9.2 -9.5 -9.1 -9.2 0.2 0.2 
L-86 -9.3 -9.5 -9.2 -9.5 -9.3 -9.5 -9.5 -9.5 -9.4 -9.5 -9.4 0.1 0.1 
L-87 -8.1 -8.1 -8.1 -8.1 -8.1 -8.1 -8.1 -8.2 -8.1 -8.1 -8.1 0.0 1.1 
L-88 -9.5 -9.6 -9.6 -9.6 -9.6 -9.5 -9.6 -9.6 -9.7 -9.4 -9.6 0.1 0.1 
L-89 -9.8 -9.7 -9.8 -9.8 -9.4 -9.8 -9.8 -9.8 -9.8 -9.7 -9.7 0.1 0.1 
L-90 -7.7 -7.6 -7.6 -7.7 -7.7 -7.7 -7.8 -7.6 -7.7 -7.8 -7.7 0.1 2.3 
L-91 -8.9 -8.8 -7.9 -8.6 -8.5 -8.8 -7.9 -7.9 -8.8 -8.9 -8.5 0.4 0.6 
L-92 -7.2 -7.7 -7.7 -7.8 -8.0 -7.8 -7.4 -7.8 -7.8 -7.7 -7.7 0.2 2.3 
L-93 -8.4 -8.4 -8.4 -8.4 -8.4 -8.4 -8.4 -8.4 -8.4 -8.4 -8.4 0.0 0.7 
L-94 -8.5 -8.6 -8.5 -8.5 -8.5 -8.6 -8.5 -8.5 -8.5 -8.5 -8.5 0.0 0.6 
L-95 -9.1 -9.1 -9.1 -9.1 -9.1 -9.1 -9.1 -9.1 -9.1 -9.1 -9.1 0.0 0.2 
L-96 -7.0 -7.0 -7.0 -6.9 -7.0 -7.1 -7.0 -7.0 -7.0 -7.0 -7.0 0.0 7.4 
L-97 -8.3 -8.3 -8.4 -8.4 -8.2 -8.3 -8.3 -8.4 -8.5 -8.4 -8.4 0.1 0.8 
L-98 -8.6 -8.5 -8.5 -8.6 -8.5 -8.5 -8.5 -8.5 -8.6 -8.5 -8.5 0.0 0.6 
L-99 -7.9 -7.9 -7.8 -7.9 -7.8 -7.8 -7.8 -7.8 -7.8 -7.9 -7.8 0.1 1.8 
L-100 -8.3 -8.0 -8.2 -8.2 -8.2 -8.3 -8.2 -8.2 -8.3 -8.2 -8.2 0.1 1.0 
L-102 -8.7 -8.5 -8.8 -8.6 -8.7 -8.5 -8.6 -8.6 -8.6 -8.6 -8.6 0.1 0.5 
L-103 -7.9 -7.7 -7.9 -7.7 -8.2 -7.8 -7.9 -7.8 -7.8 -7.7 -7.8 0.2 1.8 
L-104 -8.5 -8.3 -8.2 -8.5 -8.3 -8.2 -8.3 -8.3 -8.2 -8.5 -8.3 0.1 0.8 
 
Appendix II: Calculated binding energies (in kcal/mol) of different ligands bound to 
PfHsp90 (3K60) 
Code 
of 
ligand 
Experiment no 
Mean S.D. Ki (M) 
1 2 3 4 5 6 7 8 9 10 
L-1 -9.0 -9.0 -8.9 -9.0 -9.0 -9.0 -9.0 -9.0 -9.0 -9.0 -9.0 0.0 0.3 
L-2 -8.1 -8.3 -8.6 -7.8 -8.5 -7.9 -7.8 -7.9 -7.8 -7.9 -8.1 0.3 1.2 
L-3 -6.9 -6.9 -6.9 -6.9 -6.9 -6.9 -6.9 -6.9 -6.9 -6.9 -6.9 0.0 8.8 
L-4 -8.3 -7.8 -8.0 -7.8 -8.0 -7.9 -7.9 -7.9 -7.9 -7.9 -7.9 0.1 1.5 
L-5 -6.8 -6.8 -6.8 -6.5 -6.8 -6.8 -6.8 -6.5 -6.8 -6.8 -6.7 0.1 11.5 
L-6 -6.5 -6.5 -6.5 -6.5 -6.5 -6.5 -6.5 -6.5 -6.5 -6.5 -6.5 0.0 17.2 
L-7 -7.6 -7.6 -7.3 -7.5 -7.6 -7.6 -7.6 -7.6 -7.6 -7.5 -7.6 0.1 2.9 
L-8 -7.9 -7.8 -7.8 -7.9 -7.8 -7.8 -7.9 -7.8 -7.9 -7.8 -7.8 0.1 1.8 
L-9 -7.5 -7.6 -7.6 -7.7 -7.6 -7.6 -7.5 -7.6 -7.4 -7.5 -7.6 0.1 2.9 
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L-10 -7.5 -7.5 -7.5 -7.5 -7.7 -7.5 -7.7 -7.5 -7.5 -7.6 -7.6 0.1 2.9 
L-11 -8.1 -8.0 -8.1 -8.1 -8.0 -8.1 -8.1 -8.1 -8.1 -8.0 -8.1 0.0 1.2 
L-12 -6.6 -6.6 -6.6 -6.6 -6.6 -6.6 -6.6 -6.6 -6.6 -6.6 -6.6 0.0 14.5 
L-13 -6.6 -6.7 -6.7 -6.7 -6.6 -6.7 -6.6 -6.7 -6.6 -6.6 -6.7 0.1 13.4 
L-14 -8.1 -8.3 -8.6 -8.3 -8.7 -8.7 -8.7 -8.5 -8.6 -8.7 -8.5 0.2 0.6 
L-15 -7.4 -7.4 -7.4 -7.3 -7.3 -7.5 -7.5 -7.4 -7.3 -7.2 -7.4 0.1 4.0 
L-16 -7.4 -7.2 -7.3 -7.4 -7.4 -7.3 -7.3 -7.4 -7.3 -7.5 -7.4 0.1 4.1 
L-17 -7.5 -7.5 -7.7 -7.6 -7.6 -7.5 -7.6 -7.7 -7.6 -7.6 -7.6 0.1 2.7 
L-18 -7.3 -7.3 -7.3 -7.3 -7.3 -7.2 -7.3 -7.3 -7.3 -7.3 -7.3 0.0 4.5 
L-19 -7.2 -7.2 -7.3 -7.3 -7.3 -7.3 -7.3 -7.2 -7.2 -7.2 -7.3 0.1 4.8 
L-20 -8.4 -8.1 -8.4 -8.4 -8.4 -8.4 -8.1 -8.4 -8.4 -8.4 -8.3 0.1 0.8 
L-21 -8.3 -8.3 -8.3 -8.3 -8.3 -8.3 -8.3 -8.3 -8.3 -8.3 -8.3 0.0 0.8 
L-22 -6.4 -6.4 -6.4 -6.4 -6.5 -6.4 -6.5 -6.4 -6.4 -6.4 -6.4 0.0 19.7 
L-23 -6.6 -6.6 -6.6 -6.6 -6.6 -6.6 -6.6 -6.6 -6.6 -6.6 -6.6 0.0 14.5 
L-24 -6.5 -6.5 -6.5 -6.5 -6.5 -6.5 -6.5 -6.5 -6.5 -6.5 -6.5 0.0 17.2 
L-25 -7.8 -7.9 -7.8 -7.8 -7.8 -7.9 -7.9 -7.8 -7.8 -7.8 -7.8 0.0 1.8 
L-26 -8.8 -8.8 -8.8 -8.8 -8.8 -8.8 -8.8 -8.8 -8.8 -8.7 -8.8 0.0 0.4 
L-27 -8.6 -8.6 -8.5 -8.6 -8.6 -8.5 -8.6 -8.6 -8.5 -8.6 -8.6 0.0 0.5 
L-28 -8.1 -8.2 -8.1 -8.1 -8.1 -8.2 -8.2 -8.2 -8.1 -8.2 -8.2 0.1 1.1 
L-29 -8.8 -8.8 -8.8 -8.8 -8.9 -8.9 -8.8 -8.9 -8.9 -8.8 -8.8 0.1 0.3 
L-30 -8.5 -8.5 -8.5 -8.5 -8.5 -8.5 -8.5 -8.5 -8.5 -8.5 -8.5 0.0 0.6 
L-31 -9.3 -9.3 -9.3 -9.3 -9.2 -9.3 -9.3 -9.3 -9.3 -9.3 -9.3 0.0 0.2 
L-32 -7.8 -7.8 -7.8 -7.9 -7.9 -7.8 -7.8 -7.9 -7.9 -7.9 -7.9 0.1 1.8 
L-33 -8.0 -7.8 -8.0 -7.7 -7.8 -7.8 -7.8 -8.0 -7.8 -8.0 -7.9 0.1 1.7 
L-34 -7.4 -7.4 -7.6 -7.4 -7.5 -7.5 -7.5 -7.5 -7.5 -7.5 -7.5 0.1 3.3 
L-35 -7.8 -8.0 -8.0 -7.8 -7.7 -7.8 -7.9 -7.7 -7.9 -8.0 -7.9 0.1 1.7 
L-36 -8.0 -7.9 -7.9 -8.0 -8.0 -7.9 -7.9 -8.0 -7.9 -8.0 -8.0 0.1 1.5 
L-37 -8.1 -8.1 -8.1 -8.1 -8.1 -8.2 -8.1 -8.1 -8.1 -8.2 -8.1 0.0 1.1 
L-38 -7.8 -7.4 -7.4 -7.4 -7.3 -7.8 -7.9 -7.9 -7.4 -7.9 -7.6 0.3 2.6 
L-39 -7.7 -7.7 -7.7 -7.7 -7.8 -7.7 -7.7 -7.7 -7.7 -7.7 -7.7 0.0 2.2 
L-40 -7.3 -7.3 -7.3 -7.9 -7.3 -7.9 -7.3 -7.9 -7.2 -7.3 -7.5 0.3 3.3 
L-41 -7.3 -7.2 -7.3 -7.3 -7.3 -7.3 -7.3 -7.3 -7.3 -7.3 -7.3 0.0 4.5 
L-42 -7.6 -7.6 -7.6 -7.6 -7.6 -7.6 -7.6 -7.6 -7.6 -7.6 -7.6 0.0 2.7 
L-43 -7.1 -7.1 -7.1 -6.9 -7.1 -7.1 -7.1 -7.1 -7.1 -7.1 -7.1 0.1 6.5 
L-44 -7.4 -7.4 -7.3 -7.1 -7.4 -7.3 -7.3 -7.3 -7.4 -7.3 -7.3 0.1 4.3 
L-45 -7.4 -7.4 -7.4 -7.4 -7.4 -7.4 -7.4 -7.4 -7.4 -7.4 -7.4 0.0 3.8 
L-46 -7.2 -7.2 -7.2 -7.2 -7.2 -7.0 -7.2 -7.1 -7.2 -7.2 -7.2 0.1 5.6 
L-47 -7.2 -7.2 -7.2 -7.0 -7.0 -7.2 -7.2 -7.3 -7.0 -7.2 -7.2 0.1 5.7 
L-48 -7.9 -7.9 -7.8 -7.8 -7.8 -7.7 -7.7 -7.7 -7.7 -7.9 -7.8 0.1 1.9 
L-49 -7.4 -7.9 -7.8 -7.7 -7.7 -7.6 -7.6 -7.4 -7.5 -7.9 -7.7 0.2 2.5 
L-50 -8.4 -8.4 -8.4 -8.4 -8.4 -8.4 -8.4 -8.4 -8.4 -8.4 -8.4 0.0 0.7 
L-51 -7.8 -7.5 -7.8 -7.8 -7.8 -7.8 -7.8 -7.8 -7.8 -7.8 -7.8 0.1 2.0 
L-52 -8.1 -8.1 -8.1 -8.1 -8.0 -8.0 -8.1 -8.1 -8.1 -8.1 -8.1 0.0 1.2 
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L-53 -7.8 -7.8 -7.8 -7.8 -7.8 -7.8 -7.8 -7.8 -7.8 -7.7 -7.8 0.0 1.9 
L-54 -8.4 -8.4 -8.4 -8.4 -8.2 -8.3 -8.3 -8.4 -8.4 -8.2 -8.3 0.1 0.8 
L-55 -8.4 -7.6 -8.3 -8.4 -8.3 -8.4 -8.3 -8.0 -8.4 -8.3 -8.2 0.3 0.9 
L-56 -8.3 -8.3 -8.2 -8.0 -8.3 -8.2 -8.2 -8.2 -8.1 -8.1 -8.2 0.1 1.0 
L-57 -8.6 -9.0 -8.9 -9.1 -8.9 -9.0 -9.0 -9.0 -9.0 -9.0 -9.0 0.1 0.3 
L-58 -9.0 -9.2 -9.1 -9.2 -9.3 -9.1 -9.2 -9.2 -9.2 -9.2 -9.2 0.1 0.2 
L-59 -9.1 -8.8 -9.2 -9.1 -9.1 -9.1 -9.1 -8.9 -9.1 -9.0 -9.1 0.1 0.2 
L-60 -9.0 -9.6 -9.0 -8.9 -9.0 -8.9 -9.5 -9.0 -8.9 -9.0 -9.1 0.3 0.2 
L-61 -8.9 -8.9 -8.9 -9.4 -9.5 -8.9 -8.8 -8.9 -8.9 -8.9 -9.0 0.2 0.3 
L-62 -9.2 -9.2 -9.2 -9.2 -9.2 -9.2 -9.2 -9.2 -9.3 -9.2 -9.2 0.0 0.2 
L-63 -9.4 -9.5 -9.4 -9.5 -9.5 -9.5 -9.4 -9.5 -9.5 -9.5 -9.5 0.0 0.1 
L-64 -9.3 -9.2 -8.9 -9.3 -9.2 -9.4 -9.4 -8.4 -9.3 -9.2 -9.2 0.3 0.2 
L-65 -8.9 -8.9 -8.9 -8.8 -8.9 -9.0 -8.8 -8.7 -8.7 -8.8 -8.8 0.1 0.3 
L-66 -8.5 -8.5 -8.5 -8.5 -8.4 -8.5 -8.5 -8.3 -8.5 -8.5 -8.5 0.1 0.6 
L-67 -7.5 -7.9 -8.1 -8.0 -7.2 -7.3 -7.1 -7.9 -7.4 -7.9 -7.6 0.4 2.6 
L-68 -8.1 -8.1 -8.1 -8.1 -8.1 -8.0 -8.1 -8.1 -8.1 -8.1 -8.1 0.0 1.2 
L-69 -8.9 -8.6 -8.6 -8.1 -9.0 -9.2 -7.9 -8.6 -8.1 -8.0 -8.5 0.5 0.6 
L-70 -8.4 -8.4 -8.2 -8.4 -8.3 -8.3 -8.4 -8.4 -8.4 -8.4 -8.4 0.1 0.7 
L-71 -8.9 -8.8 -8.9 -8.9 -9.0 -8.9 -8.8 -8.9 -8.9 -8.9 -8.9 0.1 0.3 
L-72 -9.1 -9.1 -9.1 -9.1 -9.1 -9.1 -9.1 -9.1 -9.1 -9.1 -9.1 0.0 0.2 
L-73 -9.0 -9.0 -9.0 -9.0 -9.0 -9.0 -8.9 -9.0 -9.0 -9.0 -9.0 0.0 0.3 
L-74 -8.3 -9.0 -8.5 -9.2 -8.4 -8.4 -9.0 -8.2 -8.7 -8.5 -8.6 0.3 0.5 
L-75 -9.3 -9.3 -9.4 -9.4 -9.4 -9.5 -9.3 -9.4 -9.5 -9.4 -9.4 0.1 0.1 
L-76 -9.2 -8.9 -8.7 -8.6 -8.5 -9.1 -8.6 -8.8 -8.7 -8.7 -8.8 0.2 0.4 
L-77 -8.8 -8.8 -8.9 -8.8 -8.7 -8.6 -8.6 -9.1 -8.8 -8.7 -8.8 0.1 0.4 
L-78 -8.3 -7.9 -8.3 -8.3 -8.9 -8.3 -8.4 -8.3 -8.8 -8.4 -8.4 0.3 0.7 
L-79 -9.1 -9.3 -8.9 -9.1 -9.9 -10 -9.9 -10 -9.7 -10 -9.6 0.4 0.1 
L-80 -8.5 -8.7 -8.5 -8.1 -8.7 -8.7 -8.6 -8.6 -8.7 -8.6 -8.6 0.2 0.5 
L-81 -9.6 -9.6 -9.6 -9.8 -9.7 -10.1 -9.8 -9.6 -10 -9.8 -9.8 0.2 0.1 
L-82 -8.7 -8.5 -8.4 -8.4 -8.5 -8.9 -9.1 -8.9 -8.7 -9.1 -8.7 0.3 0.4 
L-83 -8.5 -8.4 -8.4 -8.4 -8.5 -8.5 -8.3 -8.5 -8.4 -8.4 -8.4 0.1 0.7 
L-84 -8.7 -8.7 -8.8 -8.7 -8.7 -8.7 -8.7 -8.7 -8.8 -8.7 -8.7 0.0 0.4 
L-85 -9.1 -8.8 -8.7 -8.8 -8.9 -8.7 -8.8 -8.9 -8.8 -8.7 -8.8 0.1 0.3 
L-86 -8.8 -9.0 -9.7 -9.5 -9.3 -9.5 -9.6 -9.1 -9.0 -9.1 -9.3 0.3 0.2 
L-87 -9.2 -9.2 -9.3 -9.1 -9.2 -9.3 -9.2 -9.2 -9.3 -9.2 -9.2 0.1 0.2 
L-88 -9.9 -9.9 -9.8 -9.8 -10.0 -9.8 -10.0 -10.0 -9.9 -9.8 -9.9 0.1 0.1 
L-89 -9.4 -9.4 -9.4 -8.9 -9.4 -9.4 -9.4 -9.3 -9.3 -9.3 -9.3 0.2 0.1 
L-90 -7.1 -7.6 -7.6 -7.6 -7.6 -7.6 -7.0 -7.6 -7.6 -7.7 -7.5 0.2 3.2 
L-91 -7.3 -8.3 -8.1 -8.4 -8.5 -8.2 -8.2 -8.3 -8.5 -8.2 -8.2 0.3 1.0 
L-92 -7.9 -7.9 -7.9 -7.8 -8.0 -7.8 -8.0 -8.0 -8.0 -7.8 -7.9 0.1 1.6 
L-93 -8.2 -8.9 -8.9 -8.4 -8.4 -9.2 -9.1 -8.3 -9.1 -9.2 -8.8 0.4 0.4 
L-94 -8.6 -8.3 -8.4 -8.6 -8.4 -8.6 -8.6 -8.5 -8.6 -8.4 -8.5 0.1 0.6 
L-95 -9.4 -9.4 -9.3 -9.4 -8.5 -9.2 -9.3 -9.2 -8.4 -8.8 -9.1 0.4 0.2 
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L-96 -7.4 -7.3 -7.3 -7.3 -7.3 -7.3 -7.3 -7.1 -7.3 -7.3 -7.3 0.1 4.5 
L-97 -8.7 -8.6 -8.7 -8.5 -8.6 -8.6 -8.5 -8.5 -8.5 -8.6 -8.6 0.1 0.5 
L-98 -8.0 -8.5 -8.0 -8.2 -8.5 -8.1 -8.1 -8.1 -8.2 -8.5 -8.2 0.2 0.9 
L-99 -7.4 -7.2 -7.5 -7.4 -7.4 -7.4 -7.4 -7.5 -7.4 -7.3 -7.4 0.1 3.8 
L-100 -8.7 -7.7 -7.6 -8.4 -7.8 -8.5 -7.7 -8.4 -8.6 -7.6 -8.1 0.5 1.2 
L-102 -8.5 -8.7 -8.7 -8.7 -8.6 -8.5 -8.6 -8.6 -8.5 -8.5 -8.6 0.1 0.5 
L-103 -8.0 -7.5 -8.0 -7.4 -7.6 -7.6 -7.6 -8.3 -8.2 -7.8 -7.8 0.3 1.9 
L-104 -9.2 -8.7 -7.8 -8.0 -8.9 -7.9 -8.6 -7.8 -8.6 -7.9 -8.3 0.5 0.8 
 
Appendix III: List of the molecules screened by molecular docking  
Code Formula Smiles M.W. Maximum 
Approximate  
length (Å) 
L-1 
 
O=C(C1=NOC(C2=C(
OC3=CC=C([N+]([O-
])=O)C=C3)C=C(O)C=
C2O)=C1)NC4CCN(C)
CC4 
454.43 16 
L-2 
 
OC1=CC(OC2=CC=C(
[N+]([O-
])=O)C=C2)=C(C3=CC
(C(NCC)=O)=NO3)C(
O)=C1 
385.33 17 
L-3 
 
 
OC1=CC(O)=CC(OC2
=CC(Cl)=C(Cl)C=C2)=
C1 
271.10 11 
L-4 
 
ClC1=CC=C(OC2=C(C
3=CC(C(NCC)=O)=NO
3)C(O)=CC(O)=C2)C=
C1 
374.78 16 
149 
 
L-5 
 
 
CC(C1=C(OC2=CC=C(
[N+]([O-
])=O)C=C2)C=C(OC)C
=C1OC)=O 
317.29 11 
L-6 
 
 
CC(C1=C(OC2=CC=C(
Cl)C=C2)C=C(OC)C=
C1OC)=O 
306.74 11 
TU-011 
(L-7) 43 
 
COC1=CC(OC2=CC=
C([N+]([O-
])=O)C=C2)=C(C3=CC
(C(OCC)=O)=NO3)C(
OC)=C1 
414.37 15 
L-8 
 
COC1=CC(OC2=CC=
C([N+]([O-
])=O)C=C2)=C(C3=CC
(C(NCC)=O)=NO3)C(
OC)=C1 
413.38 16 
L-9 
 
ClC1=CC=C(OC2=C(C
3=CC(C(NCC)=O)=NO
3)C(OC)=CC(OC)=C2)
C=C1 
402.83 16 
150 
 
L-10 
 
COC1=CC=CC(OC2=
CC=C([N+]([O-
])=O)C=C2)=C1C3=C
C(C(NCC)=O)=NO3 
383.35 13 
L-11 
 
COC1=CC(OC2=CC=
C([N+]([O-
])=O)C=C2)=C(C3=CC
(C(NCC)=O)=NO3)C=
C1 
383.35 15 
L-12 
 
CC(C1=C(OC2=CC=C(
[N+]([O-
])=O)C=C2)C=CC=C1
OC)=O 
287.27 13 
L-13 
 
CC(C1=C(OC2=CC=C(
[N+]([O-
])=O)C=C2)C=C(OC)C
=C1)=O 
287.27 12 
TU-016 
(L-14) 60 
 
O=C(C1=NOC(C2=C(
OC3=CC=C([N+]([O-
])=O)C=C3)C=C(OC)C
=C2OC)=C1)NC4CCN(
C)CC4 
482.49 20 
151 
 
L-15 
 
 
ClC1=CC=C(OC2=C(C
3=CC(C(OCC)=O)=NO
3)C(OC)=CC(OC)=C2)
C=C1 
403.81 14 
L-16 
 
COC1=CC=CC(OC2=
CC=C([N+]([O-
])=O)C=C2)=C1C3=C
C(C(OCC)=O)=NO3 
384.34 12 
L-17 
 
 
COC1=CC(OC2=CC=
C([N+]([O-
])=O)C=C2)=C(C3=CC
(C(OCC)=O)=NO3)C=
C1 
384.34 17 
L-18 
 
 
ClC1=CC=C(OC2=C(C
3=CC=NO3)C(OC)=C
C(OC)=C2)C=C1 
331.75 13 
L-19 
 
ClC1=CC=C(OC2=C(C
3=CC=NO3)C(O)=CC(
O)=C2)C=C1 
303.70 12 
152 
 
L-20 
 
 
OC1=CC=CC(OC2=C
C=C([N+]([O-
])=O)C=C2)=C1C3=C
C(C(NCC)=O)=NO3 
369.33 14 
L-21 
 
OC1=CC(OC2=CC=C(
[N+]([O-
])=O)C=C2)=C(C3=CC
(C(NCC)=O)=NO3)C=
C1 
369.33 15 
 
L-22 
 
CC(C1=C(OC2=CC=C(
N)C=C2)C=C(OC)C=C
1OC)=O 
287.31 12 
L-23 
 
CC(C1=C(OC2=CC=C(
N)C=C2)C=CC=C1OC
)=O 
257.28 11 
L-24 
 
CC(C1=C(OC2=CC=C(
N)C=C2)C=C(OC)C=C
1)=O 
257.28 
 
 
12 
L-25 
 
OC1=CC(OCC2=CC=
C([N+]([O-
])=O)C=C2)=C(C3=CC
(C(NCC)=O)=NO3)C(
O)=C1 
399.35 16 
153 
 
L-26 
 
OC1=CC(OC2=CC=C(
[N+]([O-
])=O)C=C2)=C(C3=CC
(C(NC4CCCCC4)=O)=
NO3)C(O)=C1 
439.42 17 
L-27 
 
 
OC1=CC(OC2=CC=C(
[N+]([O-
])=O)C=C2)=C(C3=CC
(C(NC4=CC=CC=C4)=
O)=NO3)C(O)=C1 
433.37 14 
L-28 
 
 
OC1=CC(OC2=CC=C(
[N+]([O-
])=O)C=C2)=C(C3=CC
(C(NC(C)C)=O)=NO3)
C(O)=C1 
399.35 15 
L-29 
 
OC1=CC(OC2=CC=C(
[N+]([O-
])=O)C=C2)=C(C3=CC
(C(NCC4CCCCC4)=O)
=NO3)C(O)=C1 
453.44 14 
L-30 
 
 
O=C(C1=NOC(C2=C(
OC3=CC=C([N+]([O-
])=O)C=C3)C=C(O)C=
C2O)=C1)NC4CCNCC
4 
440.41 15 
154 
 
L-31 
 
 
O=C(C1=NOC(C2=C(
OC3=CC=C([N+]([O-
])=O)C=C3)C=C(O)C=
C2O)=C1)NC4CCN(C(
C)C)CC4 
482.49 18 
L-32 
 
ClC1=CC=C(OC2=C(C
3=CC(C(OCC)=O)=NO
3)C(O)=CC(O)=C2)C=
C1 
375.76 12 
L-33 
 
ClC1=CC=C(OC2=C(C
3=CC(C(OCC)=O)=NO
3)C=CC(O)=C2)C=C1 
359.76 12 
L-34 
 
ClC1=CC=C(OC2=C(C
3=CC(C(OCC)=O)=NO
3)C(O)=CC=C2)C=C1 
359.76 12 
L-35 
 
OC1=CC(OC2=CC=C(
[N+]([O-
])=O)C=C2)=C(C3=CC
(C(OCC)=O)=NO3)C(
O)=C1 
386.31 16 
155 
 
L-36 
 
OC1=CC(OC2=CC=C(
[N+]([O-
])=O)C=C2)=C(C3=CC
(C(OCC)=O)=NO3)C=
C1 
370.31 13 
L-37 
 
OC1=CC=CC(OC2=C
C=C([N+]([O-
])=O)C=C2)=C1C3=C
C(C(OCC)=O)=NO3 
370.31 12 
L-38 
 
OC1=CC(OC2=CC=C(
[N+]([O-
])=O)C=C2)=C(C3=CC
=NO3)C(O)=C1 
314.25 12 
L-39 
 
OC1=CC(OC2=CC=C(
[N+]([O-
])=O)C=C2)=C(C3=CC
=NO3)C=C1 
298.25 12 
L-40 
 
OC1=CC=CC(OC2=C
C=C([N+]([O-
])=O)C=C2)=C1C3=C
C=NO3 
298.25 13 
L-41 
 
ClC1=CC=C(OC2=C(C
3=CC=NO3)C(O)=CC=
C2)C=C1 
287.70 12 
156 
 
L-42 
 
ClC1=CC=C(OC2=C(C
3=CC=NO3)C=CC(O)=
C2)C=C1 
287.70 12 
L-43 
 
O=[N+]([O-
])C1=CC=C(OC2=C(C
3=CC=NO3)C(OC)=C
C(OC)=C2)C=C1 
342.30 14 
L-44 
 
O=[N+]([O-
])C1=CC=C(OC2=C(C
3=CC=NO3)C=CC(OC
)=C2)C=C1 
312.28 13 
L-45 
 
O=[N+]([O-
])C1=CC=C(OC2=C(C
3=CC=NO3)C(OC)=C
C=C2)C=C1 
312.28 12 
L-46 
 
ClC1=CC=C(OC2=C(C
3=CC=NO3)C(OC)=C
C=C2)C=C1 
301.72 13 
L-47 
 
ClC1=CC=C(OC2=C(C
3=CC=NO3)C=CC(OC
)=C2)C=C1 
301.72 12 
157 
 
L-48 
 
OC1=CC(OC2=CC=C(
[N+]([O-
])=O)C=C2)=C(C3=CC
(C(OC)=O)=NO3)C(O)
=C1 
372.29 15 
L-49 
 
ClC1=CC=C(OC2=C(C
3=CC(C(OC)=O)=NO3
)C(O)=CC(O)=C2)C=C
1 
361.73 14 
L-50 
 
 
OC1=CC(OC2=CC=C(
[N+]([O-
])=O)C=C2)=C(C3=CC
(C(O)=O)=NO3)C(O)=
C1 
358.26 13 
L-51 
 
ClC1=CC=C(OC2=C(C
3=CC(C(O)=O)=NO3)
C(O)=CC(O)=C2)C=C
1 
347.71 12 
L-52 
 
 
OC1=CC(OC2=CC=C(
[N+]([O-
])=O)C=C2)=C(C3=CC
(C(N(C)C)=O)=NO3)C
(O)=C1 
385.33 15 
158 
 
L-53 
 
OC1=CC(OC2=CC=C(
[N+]([O-
])=O)C=C2)=C(C3=CC
(C(NCCF)=O)=NO3)C(
O)=C1 
403.32 14 
L-54 
 
 
OC1=CC(OC2=CC=C(
[N+]([O-
])=O)C=C2)=C(C3=CC
(C(NCCOC)=O)=NO3)
C(O)=C1 
415.35 17 
L-55 
 
 
OC1=CC(OC2=CC=C(
[N+]([O-
])=O)C=C2)=C(C3=CC
(C(NCCO)=O)=NO3)C
(O)=C1 
401.33 17 
L-56 
 
 
O=C(C1=NOC(C2=C(
OC3=CC=C([N+]([O-
])=O)C=C3)C=C(O)C=
C2O)=C1)NCCCN(C)C 
442.42 13 
L-57 
 
 
OC1=CC(OC2=CC=C(
[N+]([O-
])=O)C=C2)=C(C3=CC
(C(NCC4=CC=CC=C4)
=O)=NO3)C(O)=C1 
447.40 17 
159 
 
L-58 
 
OC1=CC(OC2=CC=C(
[N+]([O-
])=O)C=C2)=C(C3=CC
(C(NCC4CCCNC4)=O)
=NO3)C(O)=C1 
454.43 18 
L-59 
 
 
OC1=CC(OC2=CC=C(
[N+]([O-
])=O)C=C2)=C(C3=CC
(C(NCC4CCNCC4)=O)
=NO3)C(O)=C1 
454.43 17 
L-60 
 
OC1=CC(OC2=CC=C(
[N+]([O-
])=O)C=C2)=C(C3=CC
(C(NCC4CCCN(C)C4)
=O)=NO3)C(O)=C1 
468.46 14 
L-61 
 
 
OC1=CC(OC2=CC=C(
[N+]([O-
])=O)C=C2)=C(C3=CC
(C(NCC4CCN(C)CC4)
=O)=NO3)C(O)=C1 
468.46 17 
L-62 
 
 
OC1=CC(OC2=CC=C(
[N+]([O-
])=O)C=C2)=C(C3=CC
(C(NC4CC(C)(C)N(C)
C(C)(C)C4)=O)=NO3)
C(O)=C1 
510.54 17 
160 
 
L-63 
 
 
OC1=CC(OC2=CC=C(
[N+]([O-
])=O)C=C2)=C(C3=CC
(C(NC4CCN(C(C)=O)
CC4)=O)=NO3)C(O)=
C1 
482.44 19 
L-64 
 
 
OC1=CC(OC2=CC=C(
[N+]([O-
])=O)C=C2)=C(C3=CC
(C(NC4CCN(CCCC(F)
(F)F)CC4)=O)=NO3)C(
O)=C1 
550.48 20 
L-65 
 
OC1=CC(OC2=CC=C(
[N+]([O-
])=O)C=C2)=C(C3=CC
(C(NC4CCN(C5CCCC
C5)CC4)=O)=NO3)C(
O)=C1 
522.55 17 
L-66 
 
OC1=CC(OCC2=CC=
C([N+]([O-
])=O)C=C2)=C(C3=CC
(C(NC4CCN(C)CC4)=
O)=NO3)C(O)=C1 
468.46 16 
161 
 
L-67 
 
OC1=CC(OCC2=CC=
C(C=C2)[N+]([O-
])=O)=C(C=C1)C3=CC
(C(NCC)=O)=NO3 
383.35 13 
L-68 
 
[O-
][N+](C(C=C1)=CC=C
1COC(C=CC=C2O)=C
2C3=CC(C(NCC)=O)=
NO3)=O 
383.35 13 
L-69  
 
OC1=CC(OCC2=CC=
C(C=C2)[N+]([O-
])=O)=C(C=C1)C3=CC
(C(NC4CCN(CC4)C)=
O)=NO3 
452.46 16 
L-70 
 
[O-
][N+](C(C=C1)=CC=C
1COC(C=CC=C2O)=C
2C3=CC(C(NC4CCN(
CC4)C)=O)=NO3)=O 
452.46 16 
L-71 
 
O=C(NC1CCN(CC1)C(
C)C)C2=NOC(C3=C(C
=C(C=C3)O)OC4=CC=
C(C=C4)[N+]([O-
])=O)=C2 
466.49 19 
162 
 
L-72 
 
O=C(NC1CCN(CC1)C(
C)C)C2=NOC(C3=C(C
=CC=C3O)OC4=CC=C
(C=C4)[N+]([O-
])=O)=C2 
466.49 21 
L-73 
 
OC1=CC(OC2=CC=C(
C=C2)[N+]([O-
])=O)=C(C(O)=C1)C3=
CC(C(NCC4CC(C)(C)
N(C)C(C)(C)C4)=O)=N
O3 
524.57 15 
L-74  
 
O=C(NCC1CCN(C(C)
C)CC1)C2=NOC(C3=C
(C=C(C=C3O)O)OC4=
CC=C(C=C4)[N+]([O-
])=O)=C2 
496.51 14 
L-75 
 
OC1=CC(OC2=CC=C(
C=C2)[N+]([O-
])=O)=C(C(O)=C1)C3=
CC(C(NCC4CCN(C(C)
=O)CC4)=O)=NO3 
496.47 14 
163 
 
L-76 
 
OC1=CC(OC2=CC=C(
C=C2)[N+]([O-
])=O)=C(C(O)=C1)C3=
CC(C(NC4CCN(C5CC
CC5)CC4)=O)=NO3 
508.52 13 
L-77 
 
OC1=CC(OC2=CC=C(
C=C2)[N+]([O-
])=O)=C(C(O)=C1)C3=
CC(C(NC4CCN(C5CC
CCCC5)CC4)=O)=NO3 
536.58 15 
L-78 
 
OC1=CC(OC2=CC=C(
C=C2)[N+]([O-
])=O)=C(C(O)=C1)C3=
CC(C(NC4CCN(C5CC
N(C)CC5)CC4)=O)=N
O3 
537.56 19 
 
L-79 
 
OC1=CC(OC2=CC=C(
C=C2)[N+]([O-
])=O)=C(C(O)=C1)C3=
CC(C(NC4CCN(C5CC
C6(OCCO6)CC5)CC4)
=O)=NO3 
580.59 21 
 
 
L-80 
 
OC1=CC(OC2=CC=C(
C=C2)[N+]([O-
])=O)=C(C(O)=C1)C3=
CC(C(NC4CCN(CC5C
CCCC5)CC4)=O)=NO3 
536.58 18 
164 
 
L-81 
 
OC1=CC(OC2=CC=C(
C=C2)[N+]([O-
])=O)=C(C(O)=C1)C3=
CC(C(NC4CCN(CC5=
CC=CC=C5)CC4)=O)=
NO3 
530.53 14 
L-82 
 
OC1=CC(OC2=CC=C(
C=C2)N(C)C)=C(C(O)
=C1)C3=CC(C(NC4CC
N(C)CC4)=O)=NO3 
452.50 14 
 
 
L-83 
 
OC1=CC(OC2=CC=C(
C=C2)N(C)C)=C(C(O)
=C1)C3=CC(C(NC4CC
NCC4)=O)=NO3 
438.48 18 
L-84 
 
OC1=CC(OC2=CC=C(
C=C2)N(C)C)=C(C(O)
=C1)C3=CC(C(NC4CC
N(C5CCCCC5)CC4)=
O)=NO3 
520.62 19 
L-85 
 
OC1=CC(OC2=CC=C(
C=C2)N(C)C)=C(C(O)
=C1)C3=CC(C(NC4CC
N(C5CCC6(OCCO6)C
C5)CC4)=O)=NO3 
578.66 17 
165 
 
L-86 
 
OC1=CC(OC2=CC=C(
C=C2)NC(C)C)=C(C(O
)=C1)C3=CC(C(NC4C
CN(C)CC4)=O)=NO3 
466.53 18 
L-87 
 
OC1=CC(OC2=CC=C(
C=C2)N3CCCC3)=C(C
(O)=C1)C4=CC(C(NC5
CCN(C)CC5)=O)=NO4 
478.54 17 
L-88 
 
OC1=CC(OC2=CC=C(
C=C2)NC3CCC3)=C(C
(O)=C1)C4=CC(C(NC5
CCN(C)CC5)=O)=NO4 
478.54 20 
L-89 
 
OC1=CC(OC2=CC=C(
C=C2)NC3CCOCC3)=
C(C(O)=C1)C4=CC(C(
NC5CCN(C)CC5)=O)=
NO4 
508.57 14 
166 
 
L-90 or  
VER-
50589 
 
OC1=C(Cl)C=C(C(O)=
C1)C2=C(C3=CC=C(O
C)C=C3)C(C(NCC)=O)
=NO2 
388.80 15 
L-91 or  
NVP-
AUY922 
 
OC1=C(C(C)C)C=C(C(
O)=C1)C2=C(C3=CC=
C(CN4CCOCC4)C=C3
)C(C(NCC)=O)=NO2 
465.54 15 
L-92 
or 
SST0116
CL1 
 
CC(C)C1=C(O)C=C(O)
C(C2=C(N(C(CCN3CC
OCC3)=O)[H])C(C(N([
H])CC)=O)=NO2)=C1 
446.50 16 
L-93 
 
O=C(C1=NOC(C2=C(
OC3=CC=C([N+]([O-
])=O)C=C3)C=C(O)C=
C2O)=C1)N4CCCCC4 
425.39 17 
L-94 
 
O=C(C1=NOC(C2=C(
OC3=CC=C([N+]([O-
])=O)C=C3)C=C(O)C=
C2O)=C1)NCCN4CCN
(C)CC4 
483.47 15 
 
167 
 
L-95 
 
OC1=CC(OC2=CC=C(
C=C2)[N+]([O-
])=O)=C(C(O)=C1)C3=
CC(C(NC4CCN(CC4)C
C)=O)=NO3 
468.46 18 
TU-007 
(L-96) 55 
 
COC1=CC(OC)=CC2=
C1C(C)=C(C3=CC=C([
N+]([O-])=O)C=C3)O2 
313.30 13 
TU-012 
(L-97) 49 
 
COC1=CC(OC2=CC=
C([N+]([O-
])=O)C=C2)=C(C3=CC
(C(N([H])C4CCN(C(O
C(C)(C)C)=O)CC4)=O)
=NO3)C(OC)=C1 
568.58 17 
TU-013 
(L-98) 57 
 
COC1=CC(OC)=CC(O
C2=CC=C([N+]([O-
])=O)C=C2)=C1C3=C
C(C(N4CCCCC4)=O)=
NO3 
453.44 15 
168 
 
TU-014 
(L-99) 58 
 
COC1=CC(OC)=CC(O
C2=CC=C([N+]([O-
])=O)C=C2)=C1C3=C
C(C(O)=O)=NO3 
386.31 
 
 
14 
TU-015 
(L-100) 
59 
 
 
COC1=CC(OC2=CC=
C([N+]([O-
])=O)C=C2)=C(C3=CC
(C(N([H])CCN4CCN(C
)CC4)=O)=NO3)C(OC)
=C1 
511.53 13 
TU-017 
(L-102) 
61 
 
COC1=CC(OC2=CC=
C([N+]([O-
])=O)C=C2)=C(C3=CC
(C(N([H])C4CC(C)(C)
N(C)C(C)(C)C4)=O)=N
O3)C(OC)=C1 
538.59 18 
TU-018 
(L-103) 
50 
 
COC1=CC(OC2=CC=
C([N+]([O-
])=O)C=C2)=C(C3=CC
(C(N([H])C4CCN([H])
CC4)=O)=NO3)C(OC)
=C1 
468.46 
 
16 
169 
 
TU-019 
(L-104) 
51 
 
 
COC1=CC(OC2=CC=
C([N+]([O-
])=O)C=C2)=C(C3=CC
(C(N([H])C4CCN(C(C)
C)CC4)=O)=NO3)C(O
C)=C1 
510.54 17 
 
 
 
 
 
